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Summary
1. A brief overview of the adenosine and opioid systems and their role in 
analgesia has been presented. However, the evidence available until now 
concerning the nature and mechanism of the interaction between opioids and 
adenosine has been broadly reviewed and discussed with reference to 
contemporary and current literature. There is a large body of evidence 
indicating a role of adenosine in opioid-mediated antinociception as well as in 
the development of opioid tolerance, dependence and withdrawal. In order to 
investigate the possible interaction between the opioid and adenosine systems 
in the CNS, mice deficient in p opioid receptors, enkephalin peptides or A2 A 
adenosine receptors were employed. Manipulation of the opioid system by 
chronic naltrexone treatment was also carried out.
2. Quantitative autoradiographic mapping of Ai and A2 A adenosine receptors and 
nitrobenzylthioinosine (NBTI) sensitive adenosine transporters in the brains 
and spinal cords of wild type, heterozygous and homozygous p opioid receptor 
knockout mice revealed a small but significant reduction in Ai and NBTI- 
sensitive adenosine transporter binding in mutant mice brains but not in spinal 
cords. Regions of greatest decrease in Ai receptor binding correlated with 
regions of high p receptor expression. No significant change in A2A receptor 
binding was detected in homozygous p opioid receptor knockout mice brains 
whereas no A2A receptors were detected in the spinal cord. In contrast, 
quantitative autoradiographic mapping of Ai adenosine receptors and NBTI- 
sensitive adenosine transporters in the brains of wild type and homozygous
v ii
enlephalin knockout mice revealed a small but significant increase in Ai and 
NBTI-sensitive adenosine transporter binding in mutant mice. Regions of 
greatest increase in Ai receptor binding correlated with regions of greatest 
upregulation of p receptor expression in enkephalin knockout mice. Again, no 
significant change in A2 A receptor binding was detected in enkephalin 
knockout brains. The results suggest that there may be functional interactions 
between p receptors and Ai receptors as well as p receptors and NBTI- 
sensitive adenosine transporters in the brain but not in the spinal cord.
3. In order to investigate whether the manipulation of the opioid system by 
chronic administration of an opioid antagonist could lead to changes in 
adenosine receptor expression, quantitative autoradiographic maping of p, A% 
and A2A receptors was carried out in the brains of chronic naltrexone-treated 
mice. The significant increase of p receptor binding was followed by a 
significant upregulation of Ai receptors, especially in regions of high p 
receptor expression. Again, no change in A2 A receptor binding was observed 
in chronic naltrexone-treated mice. The results suggest that there may be 
functional interactions between p receptors and Ai receptors in the brain.
4. To investigate if there are any compensatory alterations in opioid systems in 
A2 A receptor knockout mice, quantitative autoradiographic mapping of p, ô, k  
and ORLl opioid receptors was carried out in the brains and spinal cords of 
wild-type and homozygous A2A receptor knockout mice. In addition, p-, ô - 
and K-mediated antinociception using the tail immersion test was tested in 
wild-type and homozygous A2A receptor knockout mice. A significant
reduction in 6  receptor binding and a significant increase in k  receptor binding 
were detected in the spinal cords but not in the brains of the knockout mice, p 
and ORLl receptor expression were not significantly altered. Moreover, a 
significant reduction in 6 -mediated antinociception and a significant increase 
in K-mediated antinociception were detected in mutant mice whilst p-mediated 
antinociception was unaffected. Comparison of basal nociceptive latencies 
showed a significant hypoalgesia in knockout mice when tested at 55°C but 
not at 52°C. The results suggest a functional interaction between the spinal 6  
and K opioid and the peripheral adenosine system in the control of pain 
pathways.
5. The role of Aia adenosine receptors in the expression of morphine withdrawal 
was investigated by examining naloxone-precipitated morphine withdrawal 
signs in wild type and A%A receptor knockout mice. To further investigate if 
the opioid system is altered in the absence of the A%A receptor gene under 
conditions of morphine withdrawal, quantitative autoradiography of p opioid 
receptors and p opioid receptor stimulated guanylyl 5’-[y-[^^S]thio]- 
triphosphate ([^^H]GTPyS) autoradiography were carried out in brain sections 
of morphine-withdrawn wild type and A2A receptor knockout mice. Moreover, 
to investigate the involvement of D2 dopamine receptors in modulating A2A 
receptor effects, quantitative autoradiography of D2 dopamine receptors was 
carried out in brain sections of morphine-withdrawn wild type and A2A 
receptor knockout mice. A significant enhancement of withdrawal jumping, 
paw tremor and writhing were observed in A2 A receptor knockout mice. 
Moreover, no significant changes in D2 dopamine and p opioid receptor
binding were observed in any of the brain regions of the naloxone-precipitated 
morphine-withdrawn A2A receptor knockout mice analysed. However, a 
significant increase in the level of p receptor stimulated [^^SJGTPyS binding 
was observed in the nucleus accumbens of morphine-withdrawn A2 A receptor 
knockout mice compared to wild type. The data indicate that adenosine, via its 
action on A2A receptors, exerts an important control on the expression of 
opioid withdrawal. Several mechanisms may be involved in the adenosinergic 
control of morphine withdrawal including possible inhibitory effects of A2A 
receptor stimulation on p receptor G protein activation.
6 . Despite the limitations associated with the technology of homologous 
recombination in the production of knockout mice, these animals have proved 
to be an important tool for the study of the interaction of the opioid with the 
adenosine system. However, these studies have prompted more questions than 
they have actually answered.
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CHAPTER 1
GENERAL INTRODUCTION
1. General Introduction
1.1. Introduction
Classically, neurotransmitters are known to exert their biological effects by binding to 
specific receptors that would trigger the signalling or activation of particular pathways 
in the CNS. However, as far as G-protein coupled receptors are concerned, there is 
increasing evidence to suggest that “cross talk” occurs between receptors and between 
their intracellular second messenger pathways. Cross talk between different pathways 
may occur at the level of receptors, G-proteins, effectors or second messengers 
(Cordeaux & Hill, 2002). Indeed, it is clear from ligand binding, co- 
immunoprecipitation, immunodetection and fluorescent or bioluminescent energy 
transfer studies, that some G-protein coupled receptors can form homodimers and/or 
heterodimers either between subtypes of the same receptor family or between 
receptors of different families (Bouvier, 2001; Marshall, 2001). More traditionally 
though, receptor interactions have been observed at the level of effector activation and 
second messenger production where both stimulatory and inhibitory cross talk take 
place. Examples of cross-talk between distinct neurotransmitter systems in the CNS 
include p opioid-5 opioid (Gomes et al, 2000; Qiu et al, 2000), Ai adenosine-Di 
dopamine (Ferre et al, 1992), D% dopamine-sst] somatostatin (Rocheville et a l, 2000) 
and Al adenosine-mGluia glutamate (Ciruela et al, 2001) receptor-receptor 
interactions.
Understanding the mechanisms of cross talk between different neurotransmitter 
systems seems to be the key to the design and application of future therapeutics.
Indeed A2 A adenosine receptor antagonists have been suggested to be used in the 
treatment of Parkinson’s disease. The most important feature of Parkinson’s disease is 
hypokinesia, which is due to dopamine denervation in the basal ganglia (Albin et a l, 
1989; DeLong, 1990). A2A receptor agonists have been shown to have an inhibitory 
effect and A2A receptor antagonists to have a stimulatory effect on D2 dopamine 
receptor activation, binding and function in the striatum of the brain (Ferre et a l,
1992). Thus, selective A2A receptor antagonists could be used in Parkinson’s disease, 
as they would increase the effect of endogenous dopamine or D2 receptor agonists.
Adenosine and opioids are two important systems that are thought to interact with 
each other. Although there is a large body of evidence suggesting their interaction, 
there are still many questions unanswered and many issues unclear. As this thesis 
deals with interactions between opioids and adenosine in the CNS, and as opioids are 
classically involved in the regulation of pain, an overview on the role of adenosine 
and opioids in regulating nociception will be provided in this chapter. The evidence 
available concerning the nature and manifestation of the interaction between opioids 
and adenosine in the CNS will be, however, the focus of the general introduction.
1.2. The role of the adenosine system in nociception
The physiological importance of adenosine has been widely reported since 1929 when 
Drury and Szent-Gyorygi (1929) showed that adenosine exerted a large number of 
biological effects, including bradycardia and vasodilation. The biological effects of 
adenosine include among others inhibition of locomotor activity and motor 
coordination, antinociception, sedation, depression of cardiovascular and respiratory
function, immunosupression, inhibition of acid secretion, antidiuresis, stimulation of 
glucose uptake, stimulation of glyconeogenesis and inhibition of lipolysis (Collis & 
Hourani, 1993). It is now accepted that the majority of these effects are mediated via 
an interaction of the purine with cell surface receptors (Ai, A2A, A2 B, A3 adenosine 
receptors). The pharmacology of adenosine receptor subtypes is outside the scope of 
this thesis and will not be discussed in detail. The reader is recommended reviews on 
this subject by Collis and Hourani (1993), Fredholm et al (1994) and Ralevic and 
Bumstock (1998). A summary containing information on the characteristics and 
distribution of each receptor subtype, as well as on the pharmacological tools 
available to characterise them, is presented in Table 1.1.
Neurons have the ability to secrete adenosine under physiological conditions (Meghji,
1993). There are several sources of extracellular adenosine. Adenosine is produced by 
extracellular degradation of ATP sequentially: ATP, ADP, AMP, adenosine by 
ectonucleotidases. Another pathway involves the intracellular formation of adenosine 
from ATP, followed by export of adenosine via nucleoside transporters to the 
extracellular space (Meghji, 1993). Adenosine is metabolised either intracellularily by 
phosphorylation by adenosine kinase or by deamination by adenosine deaminase 
(Meghji, 1993). Deamination can also take place extracellularily by adenosine 
deaminase bound to a membrane adenosine deaminase-binding protein (Andy & 
Komfeld, 1982; Schrader et al, 1983; Schrader et a l, 1984). Inhibitors of adenosine 
metabolism have been used in order to increase extracellular adenosine concentration. 
For instance 5-amino-5’deoxyadenosine (5 ’-NH2 dAdo) is used as an
Table. 1.1. Summary of classification of adenosine receptors
Name A, ^2A ^28 A3
G-coupling Gi(i-3) Gs.Goif Gs Gi/o
Effectors 4 cyclic AMP T cyclic AMP T cycHc AMP 4 cyclic AMP
T IP3 t  Ca^ T Ca'^
t  K"
i  Ca^
Agonists High: (0.3-3 nM) High: (1-20 nM) High: (0.5-5 pM) High: (1-2 nM)
CPA, CHA, R-PIA NECA, CGS 21680 NECA 2-CI-IB-MECA
CCPA, S-ENBA Ado IB-MECA
Intermediate: (3-30 nM) Intermediate:(20-200 nM) Intermediate: (5-20 pM) Intermediate: (10-30 nM)
NECA, CADO, Ado CADO, CV 1808 CADO, Ado NECA, R-PIA
R-PIA R-PIA
Low: (30-350 nM) Low: (200-500 nM) Low: (20-100 pM) Low: (lOO-lOOOnM)
S-PIA CPA, CHA, S-PIA S-PIA CGS 21680
Very low: (>350 nM) Very low: (>100 pM)
CV 1808, CGS 21680 CGS 21680, CV 1808
Antagonists High: (0.5-2 nM) High: (0.3-3 nM) High: (20-10 nM) High: (1-20 nM)
DPCPX,XAC SCH 58261, ZM 241385 DPCPX MRS1220
MRS1523
MRS1191
Low: (1-20 pM) Low: (0.2-20 pM) Low: (10-20 pM)
Theophylline, DPCPX, DMPX, Theophylline DMPX
Theophylline
Very low (>20pM) Very low: (>30pM) Veiy low: (>30pM)
Caffeine, DMPX Caffeine Caffeine, KF 17837
Radioligands [^H]CHA [^HjCGS 21680 [^HjDPCPX [^^T]AB-MECA
[^HJDPCPX [^H]ZM 241385 [^H]ZM 241385
[^H]CCPA [^H]SCH 58261
Distribution Brain (high in cortex. Brain (strictly localised in Brain Brain
in the CNS hippocampus, cerebellum). nucleus accumbens.
Spinal cord (high in caudate putamen.
dorsal horns) olfactory tubercle)
Table 1.1. Summary of classification of adenosine receptors. Table modified from 
Fredholm (1994) and updated according to the adenosine receptor section of the 
Trends in Pharmacological Sciences 2001 nomenclature supplement (Alexander et al, 
2001a). The table consists only of compounds of high selectivity and of any ligands 
mentioned in the general introduction. The full name of the abbreviations cited can be 
found in the list of abbreviations. The agonists and antagonists have been grouped 
into four categories according to their affinity: high, intermediate, low and very low. 
Most of the affinity figures are from binding data on brain membranes.
adenosine kinase inhibitor and erythro-9-(2-hydroxy3nonyl) adenine as an adenosine 
deaminase inhibitor. Moreover, nitrobenzylthioinosine (NBTI), dipyridamole and 
dilazep have been used as nucleoside transporter inhibitors which can inhibit 
adenosine uptake or release (Meghji, 1993). More information about adenosine 
transporters is provided in section 1.4.2.2. A schematic representation of adenosine 
metabolism is presented in Figure 1.1.
The first demonstration of the antinociceptive effects of adenosine and its analogues 
was carried out by Vapaatalo et al. (1975) who reported that systemic injection of N^- 
(R-phenylisopropyl)-adenosine (R-PIA), an adenosine receptor agonist, caused 
antinociception in rats. Since then, a large body of studies demonstrated that many 
adenosine receptor agonists and inhibitors of adenosine metabolism produced 
antinociception in a variety of test systems, including thermal, inflammatory and 
neuropathic pain tests, when administered systemically or intrathecally (i.t.) (for 
reviews see Sawynok et al, 1989b; Sawynok, 1998). Antinociception was 
antagonised by adenosine receptor antagonists, suggesting involvement of adenosine 
receptors (Sawynok et al, 1989b; Sawynok, 1998). Local administration of Ai 
agonists to the rat hind paw produced antinociception in a pressure hyperalgesia and 
low concentration formalin model, whereas A2 A receptor agonists enhanced pain 
responses in both models (Taiwo & Levine, 1991; Karlsten gr al, 1992). An A3 
receptor agonist produced an intrinsic nociceptive as well as an augmenting response 
to a low concentration of formalin, when administered locally (Sawynok et a l, 1997). 
Studies examining adenosine agonists' and antagonists action in the
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spinal cord have indicated that the Ai adenosine receptor subtype is of greater 
importance compared to the A] and A3 receptors in spinal antinociception (Karlsten et 
al, 1991; Reeve & Dickenson, 1995; Lee & Yaksh, 1996). The selective A2 A receptor 
agonist, CGS 21680 exhibited efficacy in thermal (Suh et al, 1997), inflammatory 
(Poon & Sawynok, 1998) and neuropathic pain tests (Lee et al, 1996). However this 
occurred at high CGS 21680 doses, suggesting a possible activation of other receptors 
such as Al receptors. Although it is generally accepted that a great density of Ai 
receptors are present in the dorsal horns of the spinal cord, the presence of A2 
receptors is a matter of dispute as non-selective radioligands have been used in 
binding studies (Goodman & Synder, 1982; Geiger & Nagy, 1984b; Choca et al, 
1987). At the cellular level, A% adenosine receptors are localised primarily on neurons 
postsynaptic to primary afferents, and descending projections within the dorsal horn 
of the spinal cord (Geiger et al, 1984a; Choca et al, 1988), but some receptors are 
present on ventral terminals of primary afferent neurons. There is also evidence for 
presynaptic adenosine receptors on afferent terminals (Santicioli et a l, 1993). 
Supraspinal administration of adenosine and its analogues was shown to produce 
antinociception in the hot-plate, but not the tail-flick test in both rats and mice. This 
effect was blocked by adenosine receptor antagonists and potentiated by an adenosine 
uptake blocker and an adenosine deaminase inhibitor, both of which would increase 
extracellular adenosine levels (Yarbrough & McGuffin-Clineschmidt, 1981; 
Holmgren e / <3/., 1986).
A number of cellular mechanisms have been implicated in spinal antinociception 
caused by the binding of adenosine or its analogues to Ai adenosine receptors.
Inhibition of adenylate cyclase has been demonstrated in response to adenosine 
analogues in the dorsal and ventral spinal cord of rats (Choca et a l, 1987). I.t. pre­
treatment of rats with pertussis toxin reduced considerably the antinociceptive action 
of the adenosine receptor agonists R-PIA, N^-cyclohexyladenosine (CHA) and 5’-N- 
ethylcarboxamidoadenosine (NECA) in both the tail flick and hot plate tests, 
suggesting a G, involvement in adenosine-antinociception (Sawynok & Reid, 1988). 
The same group reported a reduction of the antinociceptive effect of both CHA and 
NECA after the administration of forskolin, and a reduction of the action of CHA 
after the administration of a phosphodiesterase inhibitor. This suggested inhibition of 
adenylate cyclase by Ai receptor activation as a mechanism of adenosine-induced 
antinociception (Sawynok et al, 1988). In other parts of the CNS, adenosine produces 
a pertussis toxin-sensitive hyperpolarization of neurons by activating a current 
through a mechanism independent of adenylate cyclase (Trussell & Jackson, 1987). 
Adenosine antinociception might also be mediated by G-proteins linked directly to a 
Ca"  ^ channel as has been demonstrated for opioids (Hescheler et a l, 1987). It has 
been reported that the inhibitory effects occurring after Ai receptor stimulation is 
most likely to cause inhibition of the postsynaptic actions of substance P and 
excitatory amino acids (Doi et al, 1987; DeLander & Wahl, 1991) and thus the 
inhibition of pain transmission.
There are problems in the use of pharmacological tools for the study of adenosine- 
mediated antinociception. Firstly, in many of the studies described above, 
administration of adenosine analogues at high doses produced sedation and reduced 
motor coordination in addition to antinociception, making it difficult to discriminate
between the antinociceptive and motor effects of the drugs (Crawley et a l, 1981; 
Holmgren et a l, 1986; Herrick-Davis et al, 1989). However, it is accepted that 
antinociception and motor effects are dissociated for some adenosine analogues 
(DeLander & Hopkins, 1987). Secondly, many of the adenosine receptor ligands used 
in the above studies have low selectivity, especially antagonists like theophylline and 
caffeine that act as phosphodiesterase inhibitors as well. The recent development of 
two very selective A2A receptor antagonists, ZM241385 and SCH58261, will help 
clarify various issues in the field and to help realize the potential for novel drugs 
acting via adenosine receptors.
1.3. The role of the opioid system in nociception
Opium, obtained by extraction of the juices from the unripe seed capsule of the poppy 
Papaver somniferum, has been used as a medication for more than 5,000 years. Some 
of its medicinal uses include relieving pain and diarrhoea. It also creates a feeling of 
contentment or well being (euphoria). Opium use does, however, have associated side 
effects including addiction, constipation, respiratory depression and vomiting. 
Morphine, which was isolated firom opium in 1803 by a German chemist, Friedrich 
Sertuner, still remains the most successful painkiller but the drive to make new 
compounds without the side effects of morphine continues. It is now accepted that 
opiates, referring to the products derived from the juices of the opium poppy, as well 
as some endogenous peptides, exercise their effects by acting on p, Ô and k  opioid 
receptors. Antagonism by naloxone, the prototypic opioid receptor antagonist, is used
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as a criterion in the screening of compounds for opioid activity. By the mid-1970s, the 
first endogenous peptide ligands for opioid receptors (enkephalins and p-endorphin) 
were isolated and sequenced (Hughes et al, 1975; Bradbury et al, 1976; Cox et al, 
1976; Li & Chung, 1976; Pasternak et al, 1976). The dynorphins, which are another 
group of peptides, were identified in the 1980s (Goldstein et al, 1981). All of the 
opioid peptides are part of larger precursor polypeptides. In mammals there are three 
such precursors: a) proenkephalin which yields four sequences of Met-enkephalin, 
one Leu-enkephalin, one Met-ehkephalin-Arg^-Gly^-Leu^ and one Met-enkephalin- 
Arg^-Phe^ (Noda et al, 1982); b) prodynorphin which gives rise to dynorphin A and 
B, and a- and P-neoendorphins (Kakidani et al, 1982); and c) proopiomelanocortin 
which is processed into p-endorphin along with several non-opioid hormones 
corticotropin, p-lipotropin and melanotropins (Nakanishi et al, 1979).
The detailed pharmacology of opioid receptor subtypes is outside the scope of this 
thesis. The reader is recommended a review in this subject by Corbett et a l (1993). A 
summary containing information on the characteristics and distribution of each 
receptor subtype, the endogenous ligands acting on them, as well as the 
pharmacological tools used to characterise them, is presented in Table 1.2. The 
opioid-related receptor (ORLl) is the most recent addition to the opioid receptor 
family and it displays a significant degree of homology with the other opioid receptors 
(Mollereau et al, 1994; Henderson & McKnight, 1997). Although ORLl has been 
accepted as a member of the “family” of opioid receptors based on structural 
homology, it has no corresponding pharmacological homology with the other opioid
12
Table. 1.2. Summary of classification of opioid receptors
Name P Ô K ORLl
G-protein
coupling
Gj/o Gi/o Gi/o G|/o
Effectors 4 cyclic AMP 4 cyclic AMP 4 cyclic AMP 4 cyclic AMP
t  K"- t
4 Ca^
4 Ca^ 
t  IP3
Î
t  IP3
Endogenous
ligands
(affinity
order)
P-end>dynA>met=leu P-end=leu=met>dynA dynA»P-end>leu>met N/OFQ»dynA
Selective Endomorphin-1 and 2, DPDPE, DSBTULET, U69,593, CI977, N/OFQ,N/OFQi.,3-NH2,
agonists DAMGO, sulfentanil, 
PL017
[DAla^jdehorphin I and II U50,488 Ro646198
Selective
antagonists
CTOP Naltrindole, TIPP Nor-binahorphine J113397, 
[Nphe*]nociceptin( 1 -13)NH
Radioligands [^H]DAMGO [^HjDPDPE, [^HJTIPP, 
[^HJnaltrindole, 
[^H]deltorphin I
[^H]CI-977, [^H]U69,593 [^H]N/OFQ,
[3H]Leu-nociceptin,
[i25i]Tyr^ LN/OFQ
Distribution Brain (high binding in Brain (high binding in Brain (highest binding Brain (highest binding in
in the CNS nucleus accumbens, external plexiform layers in claustrum. cortex, hippocampus.
habenula and thalamus of olfectory bulb. endopiriform nucleus amygdala, accessory
then diminishing in caudate putamen diminishing in olfactory bulbs
cortex, hypothalamus, diminishing in cortex. the nucleus accumbens. diminishing in thalamus
amygdala and superior basolateral amygdala. ventral pallidum, central and periaqueductal grey)
coUiculus) Spinal cord nucleus accumbens. grey and substantia Spinal cord
(superficial layers of tubercle and hippocampus) nigra) Spinal cord (superficial layers of
dorsal horns) Spinal cord 
(superficial layers o f 
dorsal horns)
(superficial layers o f  
dorsal horns)
dorsal horns)
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Table 1.2. Summary of classification of opioid receptors. The full name of the 
abbreviations cited can be found in the list of abbreviations. The table has been 
redrawn and modified from the opioid receptor section of the Trends in 
Pharmacological Sciences 2001 nomenclature supplement (Alexander et a l, 2001b). 
Receptor distribution information has been obtained from receptor autoradiography 
studies done by our group in the mouse brain (Kitchen et al, 1997; Clarke et al, 
2001).
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receptors. Classical selective and non-selective p ,  § or k  opioid ligands (including 
naloxone) have very low affinity for the ORLl receptor and only nociceptin, an 
endogenous peptide having very little affinity for p, ô and k  opioid receptors, was 
shown to have high affinity for the ORLl receptor. Nociceptin was shown to be part 
of a larger precursor protein, pro-nociceptin (Meunier et a l, 1995; Reinscheid et al, 
1995).
The most important pharmacological effect of opioids is antinociception. It is 
accepted that opioids relieve pain through actions upon the nervous system and may 
also act locally upon peripheral tissue under certain circumstances, for example in 
inflammation. There is a large body of studies demonstrating that direct action of 
opioids upon the brain, the spinal cord and/or peripheral tissues produces an 
antinociceptive effect. For an extensive review on this topic, the reader is 
recommended reviews from Porreca & Burks (1993), Stein, (1993) and Yaksh (1993). 
p opioid receptor selective ligands are more potent than ô and k  agonists in most of 
the analgesic tests when acting supraspinally, spinally as well as peripherally. For the 
ORLl receptor ligand, nociceptin, there are studies which demonstrate that it elicits 
antinociception and pain when administered supraspinally (Rossi et al, 1997), 
whereas it only relieves pain when administered spinally (Faber et al, 1996; Stanfa et 
a/., 1996; Xu e/û/., 1996).
In spite of the universally accepted role of p opioid receptors in supraspinal and spinal 
antinociception, the development of novel analgesics with actions exclusive at this
site has limited attraction due to their unwanted side-effects such as respiratory 
depression, nausea, vomiting, constipation and the development of physical 
dependence. As a result ô  and k  selective agonists have been considered for the 
development of novel analgesics that lacked the addictive properties of morphine.
1.4. Opioid-adenosine interaction
The independent action of adenosine (and its analogues) and opioids in producing 
analgesia has already been described briefly. Apart from the individual action of those 
compounds in creating antinociception, there are a large number of studies that 
provide evidence for interactions between adenosine and opioids in analgesia as well 
as in opioid tolerance, dependence and withdrawal. The rest of the introduction will 
be focused on the discussion of these studies as well as on the mechanisms by which 
opioid-adenosine interactions might take place.
1.4.1. In vivo evidence for opioid-adenosine interactions in antinociception
1,4.LI. Historical overview o f opioid-adenosine interactions in regulating spinal, 
supraspinal and peripheral pain
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The first demonstration of the involvement of adenosine in opioid-induced 
antinociception was reported in by Ho et a l (1973) who showed that subcutaneous 
(s.c) co-administration of theophylline, a non selective adenosine receptor antagonist, 
with morphine, inhibited the antinociception induced by morphine. Three years later, 
it was shown that theophylline blocked the inhibitory effects of morphine on 
electrically-induced contractions in the guinea pig ileum, which suggested the 
presence of an opioid-adenosine interaction in other pharmacological effects of 
morphine apart from antinociception (Sawynok & Jhamandas, 1976). It was also 
demonstrated that methyxanthines could block the inhibitory effects of morphine on 
acetylcholine release from ileum (Sawynok & Jhamandas, 1979), cortex (Jhamandas 
et al, 1978; Phillis et al, 1980a) and in neuronal firing from striatum (Stone & 
Perkins, 1979). However, definite conclusions on the interaction between opioids and 
adenosine from the above studies were difficult as methylxanthines could have acted 
as phosphodiesterase inhibitors in addition to adenosine receptor antagonists, thus 
interfering with opioid receptor effects at the second messenger level rather than the 
receptor level.
More evidence suggesting an opioid-adenosine interaction in supraspinal, spinal as 
well as peripheral antinociception was acquired later. DeLander et a l showed that i.t. 
injection of morphine, DAMGO, DPDPE and P-endorphin produced dose-dependent 
antinociceptive effects, which were inhibited by co-administration of theophylline in 
the tail flick assay in mice (DeLander & Wahl, 1988; DeLander & Wahl, 1989; 
DeLander et al, 1992). Similarly, theophylline, administered intrathecally, was shown 
to inhibit antinociception induced by all the above opioid agonists administered
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intracerebroventricularily (i.c.v.), as measured in the tail flick assay in mice 
(DeLander & Hopkins, 1986; DeLander et al, 1992). However, i.c.v. theophylline co­
administration failed to inhibit antinociception induced by i.c.v. opioid agonists, as 
measured in the tail flick assay (DeLander et al, 1992). This study, combined with 
the fact that naloxone did not block adenosine-induced antinociception (DeLander et 
al, 1986), not only suggests a local opioid-adenosine interaction at the level of the 
spinal cord, but also provides evidence for spinal adenosine interactions with 
supraspinal opioid-stimulated descending antinociceptive pathways (DeLander et al, 
1992). However, no significant interaction was observed at the supraspinal level. 
Similar effects of adenosine receptor antagonists on morphine-antinociception have 
been shown in rats. Systemic and i.t. administration of a non-selective adenosine 
receptor antagonist aminophylline, was shown to inhibit the antinociceptive action of 
both systemic and i.t. morphine in rats (Juma, 1981; Juma, 1984). Moreover, a non- 
selective adenosine receptor antagonist theophylline, administered i.t. at low 
concentrations (nM) inhibited i.c.v. morphine analgesia in the tail flick and hot plate 
test (Sweeney et a l, 1991). That study suggested that activation of spinal adenosine 
receptors is important in the antinociception produced by supraspinal administration 
of morphine in rats and that was thought to take place by morphine activation of 
descending antinociceptive pathways.
Additional evidence for adenosine involvement in opioid-induced antinociception was 
provided by Ahlijanian and Takemori (1985), who demonstrated that intraperitoneal 
(i.p.) administration of the adenosine analogue, R-PIA, at subanalgesic doses, 
induced, whereas caffeine, a weak adenosine receptor antagonist, antagonised the
analgesic action of morphine in the tail flick test in mice. It was shown that the 
analgesic effects of R-PIA and morphine were blocked by caffeine and naloxone 
respectively in a dose-dependent fashion (Ahlijanian et al, 1985). These observations 
suggest that R-PIA and morphine act only on their respective classes of receptors and 
that there is no cross-talk between them. The possibility that the enhancement of 
morphine-antinociception was due to R-PIA-mediated general depression of the 
spontaneous locomotor activity was reported by several investigators (Vapaatalo et 
al, 1975; Snyder et al, 1981; Dunwiddie & Worth, 1982). However, this might have 
not been the case in the above study as the doses were 1 0  fold less than those used by 
Vapaatalo gr al (1975) reporting R-PIA-mediated decrease of spontaneous locomotor 
activity. The possibility that the results of the Ahlijanian and Takemori study (1985) 
could have been explained as effects of R-PIA and caffeine on morphine metabolism 
was ruled out as there were no significant differences in the brain levels of morphine 
among the saline-, R-PIA- or caffeine-treated groups .
More recent evidence showed an opioid-adenosine interaction in neuropathic pain 
models in addition to the acute pain models aheady described. Lavand’homme and 
Eisenach (1999) demonstrated that i.t. adenosine greatly enhanced the spinal 
antiallodynic effects of i.t. morphine in a rat model of neuropathic pain in an additive 
manner. As morphine has much reduced efficacy in models of neuropathic pain 
compared to other acute pain studies such as the tail flick or hot plate tests, it has thus 
been suggested that this reduced effect of morphine in the neuropathic pain test could 
reflect a disruption of the spinal opioid-adenosine link (Lavand'homme et al, 1999). 
A marked enhancement of the anti-allodynic effect of morphine was observed by
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combined i.t. administration of R-PIA and morphine in a rat model of chronic central 
pain produced by photochemical induction of spinal cord injury (von Heijne et al, 
2000). This study provides additional evidence for the importance of adenosine-opioid 
interactions in neuropathic pain.
In spite of the large body of behavioural evidence suggesting that adenosine receptor 
agonists enhance, whereas antagonists inhibit morphine-induced analgesia, there are 
some reports that disagree with these general findings. For instance, Mantegazza 
reported that the adenosine analogues, 2-chloroadenosine (CADO), L-PIA and NECA 
given i.c.v., i.p. or subcutaneously (s.c.) inhibited s.c. morphine-antinociception in the 
tail-flick test in rats. That effect was reversed by caffeine (Mantegazza et a l, 1984). 
Misra (1985) also demonstrated that i.p. caffeine, potentiated antinociception induced 
by s.c. or i.p. morphine in the tail-flick test in rats. This potentiation was reversed by 
naloxone, implying an opioid involvement. These discrepancies could be due to 
different experimental conditions, to pharmacokinetic factors and to other effects of 
caffeine. Indeed, a significantly higher concentration of morphine was observed in the 
brain and plasma of caffeine-treated rats as compared to controls (Misra et al, 1985). 
Moreover, caffeine has many pharmacological effects in the CNS apart from being a 
weak non-selective adenosine receptor antagonist (Daly et a l, 1981). These include 
inhibition of phosphodiesterases with consequent increases in cAMP, increases in the 
rate of turnover of noradrenaline and dopamine (Waldeck, 1971; Bucher et al, 1992), 
increases in brain concentrations of 5-hydroxytryptamine (5HT) and tryptophan 
(Femstrom et al, 1984) and translocation of intracellular Ca"*^ .
Fewer studies have been carried out on the interaction between opioids and adenosine 
in regulating peripheral pain. Aley and Levine (1997) reported the use of a model for 
measuring peripheral antinociception in rats. Peripheral antinociception was 
determined by assessing the degree of inhibition of prostaglandin E2 -induced 
mechanical hyperalgesia by using the Raridall-Selitto paw-withdrawal test. In that 
study it was demonstrated that the a2 adrenergic receptor agonist clonidine induced 
antinociception which was blocked not only by the a 2 adrenergic receptor antagonist 
yohimbine but also by the Ai receptor antagonist l ,3 -dipropyl-8 -(2 -amino-4 - 
chlorophenyl)-xanthine (PACPX) and by the p receptor antagonist naloxone. 
Moreover, DAMGO and N-6 -cyclopentyl adenosine (CPA)-mediated antinociception 
were not only blocked by naloxone and PACPX respectively, but also by yohimbine. 
From these data, the presence of a p, Ai, c%2 receptor complex mediating 
antinociception in the periphery was suggested with interactions occurring between p 
and « 2  receptors and Ai and « 2  receptors but not between p and Ai receptors (Aley et 
a/., 1997).
1.4.1.2, Opioid subtype-adenosine subtype interaction in the CNS
The studies discussed in section 1.4.1.1 give evidence for the importance of opioid- 
adenosine interactions, especially in the CNS. However, none of them focused on the 
nature of interactions of each individual opioid receptor subtype (p, ô, k )  with each 
individual adenosine receptor subtype (Ai, A2 A). DeLander and Keil (1994) 
demonstrated by the use of isobolographic analysis that the nature of adenosine
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receptor selective agonists interacting with p, 6  and k  selective agonists was 
heterogeneous. I.t. co-administration of Ai or A2A receptor agonists CPA or CGS 
21680 respectively with agonists selective for p opioid receptors, DAMGO or PL017, 
produced additive interactions in the tail flick test in mice. An additive interaction was 
also observed for morphine and adenosine agonists. In contrast, i.t. co-administation 
of CPA or CGS 21680 with the ô selective agonists, deltorphin-I, DSLET, or the k  
selective agonist, U50,488H, was shown to produce synergistic interactions in the 
same model. These data suggest a common mechanism of action for p and adenosine 
(both Al, A2a) agonists to induce antinociception, whereas ô, k  and adenosine 
receptor agonists may induce antinociception by independent mechanisms (DeLander 
et al, 1994). However, the issue of whether CGS 21680 actually induced 
antinociception in this study by acting on A2 A receptors is debatable as significantly 
greater doses of CGS 21680, as compared to CPA were required to induce 
antinociception. Thus it is likely that the opioid-CGS 21680 interactions observed 
were due to interactions at A% receptors at which CGS 21680 has lower potency 
(DeLander 1994).
Another study suggested distinct functional roles for p and ô opioid receptors in 
opioid-induced antinociception at spinal and supraspinal levels. Antinociception 
produced by i.t. DPDPE was more effectively inhibited by theophylline than that 
produced by i.t. DAMGO when co-administered with theophylline. In contrast, 
antinociception produced by i.c.v. administration of DAMGO was more effectively 
inhibited by i.t. theophylline than that produced by i.c.v. DPDPE when administered 
with i.t. theophylline in the tail flick test in mice (DeLander et a l, 1992). These
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results suggest a greater importance of 5 receptors in spinal and p receptors in 
supraspinal opioid-induced adenosine-mediated antinociception.
In relation to defining subtypes of adenosine receptors involved in opioid-induced 
antinociception, no definite conclusions can be drawn as most studies already 
mentioned used ligands which could not clearly distinguish between Ai and A2 
adenosine receptor subtypes. It was shown that the administration of the Ai adenosine 
receptor antagonist PACPX and the A2 receptor antagonist l,3-dimethyl-7- 
propylxanthine (DMPX), attenuated the inhibition of the tail-flick response induced 
by i.c.v. morphine or P-endorphin in mice (Suh et al, 1997). However, as PACPX 
and DMPX have low affinity for Ai and A2 adenosine receptors respectively it may be 
worth repeating these experiments using more selective ligands for Ai (e.g. DPCPX) 
and for A2 A (e.g. ZM 241385 and SCH58261) receptors.
1.4.13. Effect o f manipulating extracellular adenosine concentration on opioid- 
mediated antinociception
All the studies mentioned above used exogenous adenosine, adenosine receptor 
agonists and antagonists as well as opioid ligands as_ pharmacological tools to 
investigate opioid-adenosine interactions. Further evidence for the involvement of 
adenosine in opioid-mediated antinociception has been provided from studies that 
increased extracellular endogenous adenosine by blocking its metabolism with the use 
of adenosine kinase and adenosine deaminase inhibitors and by blocking the
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nucleoside transporters. Keil and DeLander (1995) reported that i.t. pre-treatment with 
NBTI, dipyridamole and dilazep (nucleoside transporter inhibitors), inhibited, 
whereas i.t. post treatment enhanced antinociception induced by i.t. morphine and 
DAMGO in the tail flick test in mice. It was also shown that i.t. administration of the 
Ô selective agonist, deltorphin II, with the nucleoside transporter inhibitors, resulted in 
enhancement of antinociception, regardless of the nucleoside inhibitor administration 
protocol (Keil & DeLander, 1995). This study suggests that activation of p. opioid 
receptors stimulates adenosine release via nucleoside transporters. Adenosine would 
consequently act on adenosine receptors to induce antinociception. Nucleoside 
transporters are bi-directional (see section 1 .4.2.2 for more information), and can thus 
mediate both nucleoside release and reuptake from the cell. Pre-treatment with 
nucleoside transporter inhibitors would thus result in blocking adenosine release, 
causing a decrease of extracellular adenosine and DAMGO-mediated antinociception. 
Post-treatment, though, would result in blocking adenosine uptake, causing an 
increase of extracellular adenosine and DAMGO-mediated antinociception. The study 
also suggests that adenosine and ô opioid receptor-mediated antinociception occurs 
via distinct mechanisms.
Keil and DeLander (1994) demonstrated in another study that i.t. 5 ’-NH2dAdo, an 
adenosine kinase inhibitor, significantly increased i.t. DAMGO and deltorphin II 
antinociception in the tail-flick test in mice, whereas deoxycoformycin and erythro-9 - 
(2-hydroxy-3nonyl) adenine (adenosine deaminase inhibitors) had no significant 
effect. In addition, isobolographic analysis of antinociception following i.t. co­
administration of 5 ’-NH2dAdo with opioids revealed an additive interaction with p
and synergistic interactions with ô opioid agonists (Keil & DeLander, 1994). The 
above study clearly demonstrates that adenosine kinase plays a significant role in the 
regulation of opioid-stimulated antinociception. Another study demonstrated that both 
i.t. administered adenosine kinase inhibitors and nucleoside reuptake inhibitors greatly 
enhanced the effects of spinally administered morphine, resulting in over 80% 
reversal of allodynia compared with only 15% reversal without them, in a rat model of 
neuropathic pain (Lavand'homme et al, 1999).
All of the in vivo observations described to date clearly lead towards the suggestion of 
a mechanism in the CNS where opioids induce the release of adenosine, which in turn 
activates adenosine receptors in order to produce antinociception. This hypothesis is 
based on indirect evidence but a number of biochemical studies have been undertaken 
to demonstrate directly opioid-stimulated adenosine release in the CNS. These are 
discussed in the forthcoming section (1.4.2).
1.4.2. Opioid-induced adenosine release in the CNS
1.4.2.1. Biochemical evidence
The first in vitro study demonstrating that opioids directly enhanced purine release in 
the CNS was reported by Fredholm and Vemet (1978). Morphine was shown to 
increase depolarisation-induced release from rat cortical slices preloaded with [^ H]
labelled adenine (Fredholm et al, 1978). The same effect of morphine was observed 
in cerebral slices of mice (Stone, 1981). I.v. morphine was also shown to enhance 
purine release from rat cerebral cortex in vivo (Phillis et a l, 1980b). As these studies 
were unable to distinguish which purine(s) were released (e.g adenosine, adenine, 
adenine nucleotides, cAMP, inosine, hypoxanthine), further studies were carried out 
to demonstrate that endogenous adenosine itself was released by morphine 
stimulation. Sweeney et a l  (1987a) first demonstrated that morphine released 
adenosine from rat dorsal spinal cord synaptosomes. The same group showed that 
inhibition of ecto-5’-nucleotidases (enzymes that degrade nucleotides) had a minimal 
effect on morphine-induced accumulation of adenosine in the medium, indicating that 
endogenous adenosine itself and not a nucleotide, subsequently degraded to 
adenosine, was being released. The possibility that ATP might have been released in 
response to morphine administration on spinal cord synaptosomes was also dismissed 
as the firely luciferin luciferase assay did not detect any ATP release after morphine 
stimulation (Sweeney et al, 1989). The direct release of endogenous adenosine per se 
by morphine stimulation is in contrast with the source of adenosine released by 
noradrenaline and 5HT stimulation. Noradrenaline and 5HT stimulation are thought to 
release nucleotides, possibly cAMP, which are subsequently degraded to adenosine by 
ecto-5’-nucleotidases (Sweeney et al, 1987a; Sweeney et al, 1987b). The same group 
showed in vivo release of endogenous adenosine in response to morphine introduced 
in the superfusion medium of the rat spinal cord. Finally, i.c.v. morphine was reported 
to cause the release of adenosine from spinal cord via a mechanism that will be 
described in section 1.4.2.4.
In the large majority of the studies mentioned above, naloxone or naltrexone were 
shown to block the release of adenosine or purines caused by morphine stimulation, 
indicating that the effect of morphine in this case is opioid receptor-dependent 
(Fredholm et al, 1978; Phillis et al, 1980b; Stone, 1981; Sweeney et al, 1987a). This 
effect was demonstrated to be Ca"^ dependent as well (Sweeney et al, 1987b). In 
addition, morphine-evoked release of adenosine and Ca^ influx was shown to be 
sensitive to pertussis toxin in vitro and in vivo, suggesting that opioid-induced 
stimulation of Ca"*^  entry and adenosine release, is Gi or Go protein-mediated 
(Sawynok e^u/., 1990).
Another second messenger mechanism by which morphine could induce endogenous 
adenosine release was suggested by Nicholson et al (1991), who demonstrated that 
forskolin and phosphodiesterase inhibitors inhibited morphine-induced adenosine 
release by increasing the cAMP levels in spinal cord synaptosomes. That clearly 
suggests that morphine could induce adenosine release by inhibiting adenylate cyclase 
(via Gi or Go proteins) and thus decreasing intracellular cAMP levels. K*^  was also 
shown to evoke release of endogenous adenosine in rat dorsal spinal cord 
synaptosomes, which was reduced in the absence of Ca"^ in the medium (Sweeney et 
al, 1987a). The release of adenosine in the presence of both morphine and was 
demonstrated to be less than additive, suggesting either that both morphine and 
released adenosine from the same pool, or that morphine inhibits K'^-evoked release of 
adenosine (Sweeney et al, 1987b).
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As (I, Ô and k  opioid receptor agonists were all shown to induce antinociception and 
to interact with adenosine receptor agonists (DeLander et a l, 1994), there was a need 
to examine the opioid receptor subtype involved in opioid-stimulated adenosine 
release. That was carried out by Cahill et al (1995), who demonstrated that low 
concentrations (nM) of morphine, as well as the selective p opioid receptor agonists 
DAMGO and PL017, induced the release of adenosine from dorsal rat spinal cord 
synaptosomes. In contrast, the 5 opioid agonists DPDPE and deltorphin and the k  
opioid agonist U50488H could only induce the release of adenosine at pM 
concentrations, confirming a p opioid receptor effect. That study also showed that the 
release of adenosine by both p and ô opioid agonists was Ca^ dependent whereas the 
release by k  opioid agonists was not, indicating a common mechanism for adenosine 
release stimulated by only p and 8  selective agonists. The relative potency of opioid 
receptor-selective agonists to induce adenosine release in the partially depolarised 
synaptosomes at nM concentrations was DAMGO=PL017>morphine»DPDPE, 
deltorphin, U50488H. It has also been demonstrated that i.t. caffeine dose- 
dependently attenuated DAMGO, morphine and PL017 but not DPDPE, deltorphin 
and U50488H-mediated antinociception (Cahill et a l, 1995). All those observations 
clearly indicate that activation of the p receptor subtype is responsible for the opioid- 
induced release of adenosine from the spinal cord and that such release contributes to 
spinal antinociception induced by p receptor agonists.
In another study, the same group went on to investigate whether there was a possible 
association between the p opioid and the 8  opioid receptor subtypes in stimulating 
adenosine release. 8  opioid receptor agonists produced a synergistic effect with p
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opioid agonists to release adenosine from dorsal rat spinal cord synaptosomes (Cahill 
et al, 1996). Subnanomolar (10’^ ®, 10'^^M) concentrations of the p opioid receptor 
agonists morphine, DAMGO and [N-MePhe^ D-Pro'^Jmorphiceptin, which had no 
effect alone on enhancing adenosine release, induced considerable adenosine release 
from rat dorsal spinal cord synaptosomes when co-administered with Ô selective 
agonists DPDPE and [D-Ala ,^Cys"^]deltorphin, at doses which did not exhibit intrinsic 
adenosine release when added alone. Although it is not clear how the synergistic 
mechanism might take place, it is thought that receptor-receptor allosteric interactions 
at the cell surface level or second messenger interactions might be involved (Solomon 
& Gebhart, 1994; Cahill et al, 1996). That is supported by the fact that both p and 5 
receptors have been identified on presynaptic afferent nerve terminals in the dorsal 
horn of the spinal cord (Fields et al, 1980; Besse et al, 1991). Moreover, a p-ô 
receptor interaction has been broadly suggested in the literature (Qui et a l, 1990; 
Rossi et al, 1997; Gomes et al, 2000; Martin & Prather, 2001).
1.4.2.2. The role o f adenosine transporters in opioid-mediated adenosine release
From the evidence provided above, it is clear that morphine releases adenosine from 
spinal cord in a dose-dependent, opioid receptor-mediated and Ca'^-dependent 
manner. Yet there has been no evidence for vesicular storage or release of adenosine. 
There is, however, evidence for the presence of facilitated-diffusion nucleoside 
transporters in cells through which adenosine could be released or taken up 
(Wohlhueter & Plagemann, 1982). Two distinct forms of facilitated-diffusion
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nucleoside transporters exist and are classified on the basis of their sensitivity to 
inhibition by NBTI. These have been designated NBTI-sensitive and NBTI- 
insensitive transporters (Griffith & Jarvis, 1996). There is clear evidence that the 
NBTI-insensitive transporters have a lower affinity for nucleosides (including 
adenosine) than the NBTI-sensitive carrier. Apart fi-om [^HjNBTI, [^H]dipyridamole, 
an inhibitor of facilitated-diffusion nucleoside transporters, has been used to label 
NBTI-sensitive transporters firom brain and spinal cord tissues. Although 
[^H]dipyridamole was shown to label NBTI-insensitive carriers as well as NBTI- 
sensitive transporters, there is no conclusive evidence that it could be used as a probe 
of the NBTI-insensitive transporter (Griffith et al, 1996).
Sweeney et al (1993) investigated the potential role of NBTI- and dipyridamole- 
sensitive carriers on the release of endogenous adenosine firom rat spinal cord 
synaptosomes. The adenosine concentration, which was added in a rat spinal cord 
synaptosome preparation, was shown to decrease with time. Dipyridamole enhanced 
the recovery of exogenously added adenosine in a concentration-dependent manner, 
while NBTI neither inhibited the uptake of exogenous adenosine nor enhanced the 
basal adenosine accumulation. This observation clearly indicates that dipyridamole- 
sensitive carriers are responsible for adenosine uptake in rat spinal cord. Both 
dipyridamole and NBTI markedly attenuated the release of adenosine by both and 
morphine in the above model, suggesting an important role of NBTI- and 
dipyridamole-sensitive nucleoside transporters in morphine-stimulated endogenous 
adenosine efflux from neurons in rat spinal cord (Sweeney et a l, 1993).
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The importance of dipyridamole-sensitive transporters in mediating morphine- 
stimulated adenosine release from spinal cord was further elucidated by a recent study 
which investigated morphine-induced spinal release of adenosine in rats that had 
dorsal lumbar spinal nerves ligated in a model of neuropathic pain (Sandner-Kiesling 
et al, 2001). Moiphine was shown to release significantly less adenosine from dorsal 
lumbar spinal cord synaptosomes from neuropathic rats compared to normal animals. 
This reduced release was increased to normal values by dipyridamole, indicating a 
possible dipyridamole-sensitive disruption in the opioid-adenosine link in neuropathic 
pain (Sandner-Kiesling et al, 2001).
Most of the studies investigating the biochemical mechanism of opioid-stimulated 
adenosine release have been carried out in the spinal cord. However, one recent study 
investigated the effect of short-term administration of selective p, 5  and k  opioid 
receptor agonists on adenosine concentration in the striatum of rats (Halimi et a l, 
2000). The results showed that p or 5 but not k  opioid receptor agonists increased 
adenosine concentration in rat striata by decreasing adenosine uptake via the bi­
directional nucleoside transport system. The exact mechanism of this effect remains to 
be elucidated.
1.4.2.3 Neuronal origin o f adenosine released by morphine stimulation
The evidence suggesting morphine-induced release of endogenous adenosine from 
facilitated diffusional nucleoside transporters has been discussed above. The source of
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the adenosine released in response to morphine stimulation was investigated 
(Sawynok & Sweeney, 1989a; Sawynok et al, 1989b). Selective neurotoxins were 
used to determine the neuronal origin of the adenosine released by morphine 
stimulation. Specifically, i.t. pre-treatment with 5,7-di-hydroxy-tryptamine (DHT) and 
6 -hydroxydopamine, used to destroy serotonergic and noradrenergic nerve terminals 
respectively, did not alter the release of adenosine induced by morphine in the spinal 
cord. This suggested that adenosine released by morphine stimulation does not 
originate from noradrenaline or 5HT terminals (Sweeney et a l, 1989). However, pre­
treatment with i.t. capsaicin, a neurotoxin which produces degeneration of the spinal 
terminals of small diameter primary afferent nerves, was shown to reduce the release 
of adenosine evoked by spinal morphine stimulation, in vitro and in vivo. In addition, 
it was demonstrated that morphine stimulated the release of adenosine in dorsal but 
not ventral rat spinal cord synaptosomes (Sweeney et al, 1989). These data 
collectively suggest that endogenous adenosine released by morphine originates from 
capsaicin-sensitive small diameter primary afferent nerve terminals in the dorsal horn 
of the spinal cord.
This suggestion is further supported by anatomical studies using 
immunohistochemical and autoradiographic techniques. Very high levels of adenosine 
deaminase, adenosine and NBTI-sensitive adenosine transporters, as well as opioid 
receptors, have been observed on capsaicin-sensitive primary afferent neuronal 
terminals in the dorsal horns of the spinal cord. In contrast, low levels have been 
observed in the ventral horns of the spinal cord (Gamse et al, 1979; Nagy et al, 
1980; Geiger & Nagy, 1985; Nagy et al, 1985b; Braas et al, 1986). The possibility of
morphine-induced adenosine release from dorsal root ganglion cells has been 
suggested, as adenosine deaminase activity has been observed there (Nagy & 
Daddona, 1985a) and analogues of adenosine have been shown to inhibit Ca"^ 
dependent currents in dorsal root ganglion cells in culture (Dolphin et a l, 1986; 
MacDonald et a l, 1986).
I.4.2.4. Mechanisms o f opioid-adenosine interaction in the CNS
The mechanism implicated in adenosine- and opioid- mediated antinociception, as 
well as the evidence indicating adenosine release by opioids as an important 
mechanism mediating antinociception have been discussed (sections 1.2, 1.3, 1.4). By 
taking those into consideration, a possible mechanism for morphine-stimulated 
adenosine-mediated antinociception in the dorsal horns of the spinal cord has been 
proposed by Sawynok et a l (1989a) (see Figure 1.2). It was proposed that morphine 
activates opioid receptors located on small-diameter primary afferent nerve terminals, 
causing a Ca"^-dependent release of endogenous adenosine via facilitated diffusional 
nucleoside transporters. The extraneuronal adenosine, in turn, activates the 
postsynaptic Ai adenosine receptors, which are located on intrinsic neurons in the 
dorsal horns of the spinal cord, in particular in the substantia gelatinosa. Although 
Sawynok et a l (1989a) implicated the involvement of spinal A2A receptors in the 
mechanism of morphine-stimulated adenosine release-mediated antinociception, 
caution has to be exercised as to whether these receptors are actually present
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Figure 1.2. Possible mechanisms of morphine in the dorsal horn of the spinal cord 
(modified from Sawynok et a/., 1989a). a) Morphine activates opioid receptors on 
small diameter primary afferent terminals to inhibit substance P release or induce the 
release of adenosine, which in turn activates adenosine receptors and inhibits the 
transmission of nociceptive information, b) Adenosine inhibits Ca"^ currents in dorsal 
root ganglion cells and possibly neurotransmitter release from the nerve terminals of 
these cells. A\ adenosine receptors have been implicated in this action. The identity of 
the primary afferent neurotransmitter affected by adenosine has not yet been 
established, although neuropeptides and excitatory amino acids (EAA) are possible 
candidates.
in the spinal cord. The actions occurring downstream to adenosine binding on Ai 
adenosine receptors are likely to cause the inhibition of postsynaptic actions of 
substance P and excitatory amino acids, thus leading to inhibition of pain transmission 
(Figure 1.2a), Moreover, it is well accepted that morphine could cause antinociception 
by acting on opioid receptors located on small diameter primary afferent terminals, by 
inhibiting substance P release from those terminals (Jessell & Iversen, 1977; Yaksh & 
Noueihed, 1985), which is an action not performed by adenosine (Vasko & Ono,
1990) (Figure 1.2a). As a conclusion, it was proposed that the release of adenosine 
and the inhibition of substance P release by morphine may represent parallel actions 
of opioids, which are significant in the production of spinal antinociception (Sawynok 
eM/., 1989a).
Another mechanism describing morphine-stimulated adenosine release mediated- 
antinociception was proposed to take place in the dorsal root ganglion cells (Figure. 
1.2b). That was based on the observation that Ca"^-dependent currents in those cells 
were inhibited by activation of Ai adenosine receptors (Dolphin et a l, 1986). 
Sawynok et al (1989a) proposed a mechanism by which adenosine, released by 
morphine stimulation of dorsal root ganglion cell terminals, acts on Ai adenosine 
receptors located on dorsal root ganglion cell terminals. This would result in 
inhibition of Ca"  ^ currents and possibly in inhibition of neurotransmitter release, 
probably excitatory amino acids and/or neuropeptides from the nerve terminals and 
thus in inhibition of pain transmission (Figure. 1.2b).
As mentioned in section 1.4.1 . 1  of the Introduction, i.t. theophylline was shown to 
inhibit antinociception produced by i.c.v. morphine in mice (DeLander et al., 1992). 
Sweeney et al. (1991) also demonstrated that an increase of adenosine release from 
spinal cords of rats after i.c.v. morphine administration, suggesting that a supraspinal 
action of morphine could mediate the release of adenosine from the spinal cord. 
Release of adenosine and cAMP was reduced after i.t. pre-treatment with DHT, 
suggesting that descending serotonergic neurons were involved in adenosine release. 
I.t. perfusion with a non-selective 5HT receptor antagonist, methysergide, eliminated 
the release of adenosine and cAMP. This indicated that release of 5HT from spinal 
terminals and the subsequent activation of 5HT receptors were requirements for 
adenosine and cAMP release (Sweeney et al, 1991). This adenosine is believed to 
originate primarily from a released nucleotide (possibly cAMP) rather from 
endogenous adenosine efflux (Sweeney et al, 1988). Although morphine, acting 
supraspinally, was suggested to release adenosine from descending noradrenergic 
neurons in spinal cord (Sweeney et al, 1988), later in vivo evidence suggested that 
noradrenergic mechanisms did not appear to be involved in the release of purines 
from the spinal cord subsequent to i.c.v. morphine administration. Neither depletion 
of spinal noradrenaline nor blockade of spinal noradrenergic receptors had an effect 
on adenosine release (Sweeney et al, 1991). However, a synergism between 
adenosine and noradrenaline was proposed (Sweeney et a l, 1991). A diagram 
illustrating the proposed mechanism of the action of morphine in the brain is provided 
in Figure 1.3. While the mechanism for spinal adenosine release in response to 
supraspinal and spinal stimulation of opioid receptors has been proposed, the 
mechanism for opioid-induced release of adenosine from the brain requires further 
investigation.
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Figure 1.3. Possible mechanism of supraspinal action of morphine
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Figure 1.3. Possible mechanism for supraspinal action of morphine. Morphine acts 
postsynaptically on opioid receptors located on cell bodies of descending serotonergic 
neurons in the brain. Supraspinal activation of those receptors causes the stimulation 
of those serotonergic neurons, which subsequently release 5HT from their terminals, 
which are located in the dorsal horn of the spinal cord. 5HT then stimulates 5HT 
receptors located on small diameter primary afferent terminals which causes the 
release of a nucleotide, possibly cAMP, which in its turn is degraded extracellularly to 
AMP by phosphodiesterase (PDE) and adenosine (ado) by 5’ectonucleotidase (5- 
NTE). Adenosine then, binds and activates postsynaptic adenosine receptors resulting 
in inhibition of neuronal transmission of that nerve and hence antinociception.
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1.4.3. Opioid-adenosine interactions in opioid tolerance, dependence and 
withdrawal
1.4.3.1. Opioid tolerance, dependence and withdrawal: definitions and mechanisms
In addition to its involvement in the expression of opioid antinociception, a role for 
adenosine has been suggested in the development of opioid tolerance, dependence and 
withdrawal. Opioid dependence is a chronically recurring and relapsing illness 
consisting of uncontrolled and compulsive drug use and syndromes of drug tolerance 
and withdrawal. Opioid tolerance is characterized by shortened duration and 
decreased intensity of the euphoric, analgesic, and sedative effects of opioids. 
Physiological dependence is often associated with tolerance and is defined as a state 
in which continued presence of the drug is required for normal function. A withdrawal 
syndrome occurs when opioids are abruptly discontinued or after opioid antagonists 
are administered during chronic opioid use. Symptoms occur within hours of opioid 
discontinuation in man and include intense physical disturbances of anxiety, 
insomnia, tremors, restlessness, irritability, sweating, rhinorrhea, bone and muscle 
pain, intestinal spasms, diarrhoea, increasing heart rate and blood pressure (Jaffe,
1991).
Several mechanisms attempting to explain opioid tolerance and addiction in the CNS 
have been described. At the molecular level, chronic opioid treatment was shown to 
result in a compensatory upregulation of adenylate cyclase and cAMP-dependent
protein kinase A signalling pathways in several brain regions (Terwilliger et a/., 1991; 
Nestler & Aghajanian, 1997; Nestler, 2001). This effect was demonstrated to produce 
tolerance by opposing opioid-induced inhibition of adenylate cyclase. Removal of 
opioids resulted in the unopposed action of upregulated adenylate cyclase and protein 
kinase A, and this is thought to represent a molecular mechanism of opioid 
withdrawal. cAMP was shown to affect morphine tolerance and dependence. The 
repeated administration of cAMP was demonstrated to increase the rate of 
development of tolerance to morphine-antinociception and to enhance the precipitated 
withdrawal jumping response caused by naloxone in morphine-dependent mice (Ho et 
al, 1972). Many studies suggested functional uncoupling between opioid receptors 
and the G, protein, through which opioid agonists act to produce many of their effects, 
as well as downregulation of high affinity p opioid receptor binding sites, as possible 
molecular mechanisms of opioid tolerance (Puttfarcken et al., 1988; Werling et al, 
1989). However, recent studies contradict the above mechanisms, suggesting that the 
failure of morphine-activated receptors to uncouple from G protein and to endocytose 
is critical for the high level of physiological tolerance induced by morphine (Whister 
et al, 1999). Moreover, a wide range of studies failed to identify any changes in p 
receptor density in brain regions of morphine-withdrawn or dependent animals (Way, 
1979; Robson et a l, 1983; De Vries et al, 1993; Polastron et al, 1994; Reddy et al, 
1994; Buzas et al, 1996; Tao et al, 2000). In addition, tolerance in the whole animal 
is undoubtedly mediated by multicellular networks. For instance, increased neuronal 
firing rates have been shown to take place in the locus ceruleus of morphine- 
dependent animals compared to naïve animals (Nestler et al, 1999; Nestler, 2001).
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1.4.3.2, in vivo studies
As the acute effects of morphine were suggested to be mediated at least in part by the 
release of endogenous adenosine, it was expected that changes in the adenosine 
system could also be observed following chronic morphine treatment leading to 
morphine tolerance, dependence, and withdrawal. The first indication for such an 
interaction taking place was observed by Collier et al (1974), who demonstrated that 
administration of a methylxanthine followed by a small dose of naloxone, in opioid- 
naive rats, induced a state of behavioural excitation closely resembling the 
characteristics of the withdrawal syndrome precipitated by naloxone in morphine- 
dependent rats. This was thus called the quasi-morphine withdrawal (or abstinence) 
syndrome (Collier et al, 1974; Francis et al, 1975). As in morphine withdrawal, the 
effects of this syndrome were shown to be enhanced by treatment with naloxone and 
reversed by administration of heroin (Collier et a l, 1974). Since then, many studies 
have examined the effects of adenosine agonist and antagonist treatment on the 
expression of opioid withdrawal signs with mixed and contradictory results. The Ai 
receptor agonist R-PIA and the non-selective agonist NEC A blocked withdrawal 
diarrhoea, paw shakes, teeth chattering, body shakes and jumps in opioid-dependent 
rats, while the A2A selective agonist CV1808 blocked only withdrawal diarrhoea and 
teeth chattering (Dionyssopoulos et al, 1992). Those results were suggested to be due 
to non-specific motor depressant effects of the adenosine receptor agonists rather than 
due to inhibition of withdrawal behaviours. Similar results that could be explained by 
motor effects were also reported by Germany and co-workers (1990). Another study 
showed that the adenosine agonists CADO and CHA inhibited naloxone-precipitated
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withdrawal jumping, diarrhoea and weight loss in morphine-dependent mice, even 
when used at a non-sedative dose (Tucker et a l, 1984). In contrast, the adenosine 
receptor agonist R-PIA enhanced at low doses the development of naloxone- 
precipitated withdrawal in opioid-dependent mice (Ahlijanian et al, 1985). This 
discrepancy has now been clarified by recent studies which all agree that adenosine 
receptor agonists attenuate and adenosine receptor antagonists exacerbate opioid 
withdrawal signs in mice and in rats (Kaplan & Sears, 1996; Salem & Hope, 1997; 
Zarrindast et a l, 1999). The Ai agonist R-PIA reduced wet dog shakes and 
withdrawal diarrhoea and the A2A selective agonist CGS21680 significantly inhibited 
teeth chattering and forepaw treadings in morphine-dependent mice. The Ai 
antagonist DPCPX significantly increased weight loss and the A2 antagonist DMPX 
enhanced wet dog shakes and withdrawal diarrhoea in morphine-dependent mice 
(Kaplan et al, 1996). Similar results were obtained in rats (Salem et al, 1997) and in 
mice (Zarrindast et al, 1999). These observations, therefore, indicate that adenosine 
may be directly involved in the expression of opioid withdrawal behaviour. Indeed, an 
increase in the adenosine metabolites hypoxanthine and inosine was shovm using 
microdialysis in the nucleus accumbens of morphine-dependent rats following 
naloxone-treatment (Salem & Hope, 1999). Cross-withdrawal syndromes were also 
revealed when naloxone was administered to rats chronically treated with adenosine 
agonists NEC A and CPA and when the adenosine receptor antagonists DMPX and 
DPCPX were given to chronic morphine pre-treated rats, again illustrating the close 
links between the adenosine and the opioid systems (Coupar & Tran, 2001).
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In addition to in vivo studies, in vitro studies have been carried out, investigating the 
effects of adenosine Ai and A2 receptor agonists and antagonists on acute opioid 
withdrawal induced by morphine. The Ai receptor agonist CPA was shown to reduce, 
whereas the A2A receptor agonist CGS21680 was shown to enhance naloxone- 
precipitated withdrawal contraction in the guinea-pig isolated ileum. The non- 
selective adenosine receptor antagonist 8 -PT was shown to increase, whereas the A2 A 
receptor antagonist DMPX was shown to reduce this naloxone-precipitated 
withdrawal phenomenon (Capasso, 2000).
For opioid tolerance, there are several studies suggesting an adenosine involvement. 
However, these studies have yielded contradictory findings. For instance, Contreras et 
aL, (1990) showed that the adenosine agonist CADO blocked the development of 
tolerance to opioid antinociception and that this effect was reversed by caffeine. 
However, other Ai adenosine agonists, R-PIA and S-PIA, did not alter the 
development of opioid tolerance. Similarly, Germany et al. (1990) showed that only 
CHA but not R-PIA, S-PIA, CPA and CADO blocked the development of tolerance to 
opioid antinociception. In contrast, Ahlijanian and Takemori (1985) showed that the 
adenosine Ai agonist R-PIA enhanced the development of tolerance to the 
antinociceptive effects of opioids after chronic opioid treatment, while caffeine 
blocked this effect.
Another study giving further evidence for adenosine receptor involvement in 
morphine tolerance, dependence and/or reward, showed that the adenosine receptor 
antagonists, theophylline and DMPX, reduced the number of self-administered
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morphine infusions compared to the saline-treated rats, while the A2A receptor agonist 
CGS21680 increased morphine self-administration in the same model. In contrast, the 
Ai agonist CHA and the adenosine receptor antagonist 8 -PT had no effect on 
morphine self-administration (Sahraei et al, 1999). These data clearly suggest the 
involvement of the A2A, hut not the Ai, adenosine receptor subtype in the expression 
of morphine self-administration and/or reward mechanisms.
Most of the studies mentioned above involved experiments on morphine tolerance, 
dependence, withdrawal and self-administration in the CNS. Opioid tolerance and 
withdrawal experiments have been described in the periphery as well. Aley and 
Levine (1997) demonstrated that repeated intradermal injections of DAMGO in the rat 
hind paw produced cross-tolerance to the antinociceptive effect of CPA, and that 
repeated intradermal injections of CPA produced cross-tolerance to the 
antinociceptive effect of DAMGO. Moreover, the opioid antagonist naloxone was 
shown to elicit a cross-withdrawal hyperalgesia response in CPA-tolerant paws, and 
the Ai adenosine antagonist PACPX induced cross-withdrawal hyperalgesia response 
in DAMGO tolerant paws (Aley et a l, 1997). The demonstration of the bi-directional 
cross-tolerance and cross-withdrawal responses clearly suggests that both p-opioid 
and Ai adenosine receptors share a common second messenger pathway in the 
induction of tolerance and dependence. Moreover, the same group demonstrated that 
cross-tolerance and cross-withdrawal occurred between p, Ai and ai agonists in the 
rat hindpaw (Aley et al, 1997). From this, it was suggested that p opioid, ai 
adrenergic and Ai adenosine receptors might be linked in the periphery, either via 
second messenger systems or physically in the membrane.
1.4.3.3. Binding studies
From the behavioural studies described above, it is clear that an adenosine component 
is involved in the development of opioid tolerance and dependence. The molecular 
mechanism of this involvement is not clear, however, binding studies revealed 
interesting alterations in adenosine receptor expression in animals chronically treated 
with morphine. As in behavioural studies, binding studies yielded mixed results 
depending on the species, route of chronic morphine administration (systemic, i.t. or 
i.c.v.) and tissue regions analysed.
Tao and Liu (1992) demonstrated changes in A% adenosine receptors in rats treated 
chronically with i.p. morphine. They showed a significant decrease in [^H]CHA 
binding in the spinal cord but not in the cerebral cortex of chronically morphine- 
treated rats, with no significant change in the values. Another study by De Montis 
et al (1992) found no change in Ai binding in the striatum of morphine-dependent 
rats. In contrast, others have shown increased levels of cortical adenosine Ai agonist 
binding in morphine-dependent mice (Ahlijanian & Takemori, 1986; Kaplan et al, 
1994).
The experiments described above were carried out in mice and rats that were made 
morphine-dependent by systemic administration of morphine. However, Tao et al
(1996), using chronically-administred morphine in rats by multiple i.t. injections, 
observed no downregulation of spinal adenosine Ai receptors. In addition, it was
46
demonstrated that chronic i.c.v. administration of morphine downregulated spinal 
adenosine Ai receptors in rats, with no change in affinity (Tao et al., 1995), which is 
in full agreement with the systemic chronic morphine administration study (Tao et al.,
1992), One possible explanation for the above finding is that spinal and supraspinally 
administered morphine, release adenosine by different mechanisms. For spinal effects, 
activation of opioid receptors causing Ca^ entry has been proposed, and for 
supraspinal effects, activation of descending antinociceptive pathways leading to 
spinal release of adenosine has been suggested (Tao et al, 1996).
For A2 A receptors, Kaplan et al (1994) demonstrated that there was no change in A2 A 
receptor binding in the striatum of morphine-dependent mice. In contrast, De Montis 
et al (1992) observed a significant decrease in adenosine A2 receptor function and 
binding with no apparent change in affinity in morphine-dependent rats. These 
discrepancies could be due to species differences and/or due to the different 
radioactive ligands used for the two studies ([^H]GGS21680 and [^H]CGS21268 
respectively).
Apart from adenosine receptors, alterations in binding were demonstrated to occur in 
NBTI-sensitive nucleoside transporters in morphine-tolerant mice. Kaplan et al
(1997) showed an increase of [^HJNBTI binding in the striatum and hypothalamus, 
whereas no change was observed in the cortex, hippocampus, brain stem and 
cerebellum of morphine-tolerant mice. No significant change in Kj-values for 
[^H]NBTI binding were observed. This finding suggests an involvement of NBTI- 
sensitive nucleoside transporters in the development of morphine tolerance.
47
Finally, one study has demonstrated changes in adenosine receptor number and/or 
affinity in morphine-dependent rats in an indirect way. White et al (1995) showed 
that hypotensive responses to CHA were reduced in morphine-dependent intact rats, 
while in pithed rat preparations, the hypotensive actions of CHA were increased with 
morphine-dependence. Moreover, it was found that in both intact and pithed rat 
preparations, CGS21680 was more potent in morphine-dependent animals (White et 
al, 1995). These results suggested that adenosine Ai receptors might be 
downregulated and adenosine A2 receptors upregulated following morphine 
dependence (White et a l, 1995). However, changes in second messenger molecules 
could also be involved. The studies discussed in this section are summarised in Table
1.3.
The mechanism by which the changes in adenosine receptor number take place in 
morphine dependence and how these changes could affect morphine dependence is 
not clear. However, most studies suggest an increase of endogenous adenosine as a 
primary regulator. For instance, Tao and Liu (1992) speculated that chronic morphine 
treatment could cause a frequent release of adenosine from the spinal cord. That 
would downregulate Ai adenosine receptors and thus increase morphine tolerance. 
Others, however, supported the suggestion that enhanced adenosine Ai receptor 
number and function in some brain regions would provide a homeostatic mechanism 
in which endogenous adenosine could modulate morphine withdrawal, much like the 
effect of exogenous adenosine agonist treatment (Kaplan et al, 1994). Finally, 
increase of A\ receptors in mouse brains has been suggested to be partly the cause of 
the inhibition of dopaminergic transmission and function in mesolimbic and striatal 
pathways which is evident in morphine-withdrawn animals
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(Kaplan et al, 1997). Whatever the mechanism of changes in adenosine receptors and 
NBTI-sensitive nucleoside transporters, it is clear that the manipulation of the opioid 
system with chronic morphine administration can cause changes in the adenosine 
system.
1.5 Gene knockout technology
Until very recently, the issue of the contribution of each receptor type to their function 
was only addressed by pharmacological approaches because agonists and antagonists 
were the only available tools. However, it was sometimes difficult to interpret data 
due to the poor knowledge of selectivity of ligands in vivo as well as their distinct 
metabolic or pharmacokinetic properties. Although binding affinities and selectivities 
of compounds can be determined accurately in vitro using brain tissue homogenates 
(Corbett et al, 1993), one can never exclude the possibility that ligands which are 
thought to be highly selective to a receptor type in vitro, cross interact with another 
receptor type m vivo. As a result, the exact contribution of each receptor in mediating 
biological actions of a drug remained to be clarified by other approaches.
Manipulation of genes in the mouse genome to produce transgenic or gene-targeted 
animals represents a powerful new experimental tool with which one can study the 
functional importance of a particular gene product in complex physiological systems. 
Gene targeting techniques allow the introduction of a “loss of function” mutation into 
the germ line of fertile animals by homologous recombination. Such a mutation can 
represent, for example, disruption of a gene encoding for a particular receptor type. 
The mice produced by this method (knockout animals) can then be studied for any
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deficit in spontaneous and drug-treated behaviour. The great strength of this 
technology is that it can eliminate any specificity/selectivity problems of ligands 
present in other studies as the knockout mouse will have 1 0 0  % selectivity as far as 
the removal of the protein encoded for the gene that has been knocked out is 
concerned. Mice that lack a certain type of receptor have proven extremely useful to 
determine the molecular mode of action of certain drugs and represent invaluable 
tools in drug discovery programmes for the development of novel therapeutic drugs.
The methodology to produce targeted gene disruption in cells that subsequently 
contribute to the germ line was developed in the mid to late 1980s. Figure 1.4 shows a 
schematic diagram detailing the technique of homologous recombination, using the 
generation of receptor knockout animals as a specific example. Although gene 
knockout technology has been a great breakthrough in pharmacology, one has to be 
aware of its limitations and its problems. Firstly, a critical issue in designing and 
interpreting studies using knockout mice relates to the influence of genetic 
background and the choice of proper control strains. It is known that gene mutations 
can exhibit different phenotypes on different genetic backgrounds. Thus, only if the 
same background is used across experiments can it be concluded that differences in 
phenotype are due to the specific genetic alteration rather than differences caused by 
the random assortment of alleles at other loci, some of which may be nothing to do 
with the phenotype being examined (Faraci & Sigmund, 1999). In generating gene 
targeted knockout mice, the most common approach is to use embryonic stem cells 
for gene targeting and then to inject these genetically altered stem cells into 
blastocysts from another mouse strain (Figure 1.4). Germ line transmission of the 
altered genome by breeding, results in animals of a mixture of two different strains at
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Figure 1.4. Schematic diagram showing the generation of receptor knockout 
mice by homologous recombination
Genomic mouse library 
screened with mouse cDNA 
probe
Receptor-coding genomic 
fragment obtained and 
cloned into vector
Neomycin resistant cassette inserted, 
vector linearised and introduced to 
cells by electroporation
Neomycin resistant clones identified 
by Southern blot analysis
Positive clones micro­
injected into blastocysts
Normal Genotype
Pregnancy allowed to 
develop to term
Wild- Chimeric Offspring
\  X '  \
+ /-  + /-  
FI Generation
F2 Generation 4-/4- 4-/- - / -
Figure 1.4. Generation of mice with targeted mutation of genes encoding receptor 
proteins. A genomic fragment encoding a receptor protein obtained from genomic 
DNA libraries is cloned into a vector and a neomycin resistant cassette is inserted into 
the gene at specific restriction sites. Upon linearisation the vector is introduced into 
mouse embryonic stem cells by electroporation. Neomycin resistant clones are 
screened by Southern blot analysis. One of the positive clones is microinjected into 
blastocysts, giving rise to chimeric offsprings. The chimeras are bred with wild type 
mice to produce an FI generation consisting of wild type and heterozygous animals 
which possess one normal allele of the targeted gene and one containing the mutation. 
Mating of heterozygous animals produces an F2 generation of wild type (+/+), 
heterozygous (+/-) and homozygous (-/-) mice in the expected Mendelian frequency.
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the FI generation.
Moreover, another potential limitation of the knockout technology exists in that 
compensation may occur in the animal either during development or later, in response 
to deletion of the targeted gene. For example, another “redundant” gene product may 
replace the function of the gene that was disrupted. As a result, deletion of one gene 
product may not result in any detectable change in phenotype, which is the case in 
many knockout mice produced.
1.6. The aims of this thesis
1) To investigate by quantitative autoradiography if in the absence of the p 
opioid receptor or pre-proenkephalin there were any changes in the binding 
and/or distribution of adenosine A\ and A2A receptors, as well as of NBTI- 
sensitive adenosine transporters in the CNS.
2) To investigate by quantitative autoradiography if there were any changes in 
adenosine A% and A2A receptor binding and/or distribution in the brains of 
chronic naltrexone-treated mice.
3) To examine, by quantitative autoradiography, if there were any changes in p, 
5, K and ORLl opioid receptor binding and/or distribution in brains and spinal 
cords of A2A adenosine receptor knockout mice. To investigate further by p, ô 
and K receptor-mediated antinociception in A2A receptor knockout mice, the 
involvement of A2A adenosine receptors in modulating opioid effects.
4) To evaluate the role of A2A receptors in the expression of morphine 
withdrawal with the use of A2A receptor knockout mice. To further investigate
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by p opioid receptor binding and p opioid receptor-stimulated guanylyl 5’-[y- 
[^^S]thio]-triphosphate ([^^H]GTPyS) autoradiography, if the opioid system is 
altered in the absence of the A2 A receptor gene under conditions of morphine 
withdrawal. Moreover, to investigate by quantitative autoradiography if the 
expression of D2 dopamine receptors is altered in the absence of the A2A 
receptor gene under conditions of morphine withdrawal.
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CHAPTER 2
Quantitative autoradiography of adenosine 
receptors and NBTI-sensitive adenosine 
transporters in brains and spinal cords of p 
opioid receptor and enkephalin knockout mice
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2.1 INTRODUCTION
Enkephalins (endogenous opioids derived from the precursor pre-pro enkephalin 
protein) and p opioid receptors are abundant in the central nervous system and play a 
major neuromodulatory role in the control of nociceptive stimuli and several other 
behavioural responses (Diaz & Asai, 1990; Dickenson, 1991; Olsson et a l, 1994; 
Mansour et al, 1995). To further elucidate the physiological and behavioural roles of 
enkephalins and p opioid receptors, mice with a targeted disruption of the pre­
proenkephalin gene {Penk2) and mice with a targeted disruption of the p opioid 
receptor gene (MOR) have been generated (Konig et al, 1996; Matthes et al, 1996).
The generation of mice deficient in the p opioid receptor gene has been reported by 
several groups (Matthes et al, 1996; Sora et al, 1997b; Tian et a l, 1997; Loh et al, 
1998; Schuller e? al, 1999). The studies carried out in this thesis employed the p 
knockout animals generated by Brigitte Kieffer’s group in Strasbourg (Matthes et al, 
1996). No gross neuroanatomical or developmental defects and no indication of 
lethality from the gene deletion were reported in these animals, and they develop 
normally (Kieffer, 1999; Kitchen, 1999). However, some noticeable behavioural 
changes have been observed in p receptor knockout mice. Decreased horizontal 
locomotor activity was reported for those mutant animals which suggests that a basal 
p opioid receptor mediated tone regulates locomotion (Kieffer, 1999). Although the 
first p receptor knockout animals showed no differences in pain sensitivity in the tail- 
flick and hot-plate thermal tests (Matthes et a/., 1996), recent studies showed 
hyperalgesia in thermal tests and hypoalgesia in visceral (acetic acid writhing) and 
inflammatory tests but no alteration in paw pressure tests (Matthes et al, 1996; Fuchs
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et al, 1999; Sora et a l, 1999; Qiu et al, 2000). Moreover, enhanced haematopoiesis 
and reduced sexual function were observed in males (Kieffer, 1999). More 
importantly p receptor knockout mice were shown to exhibit complete loss of 
analgesic (supraspinal and spinal), dependence, withdrawal, respiratory depression 
and immunosuppression responses to morphine (Matthes et al, 1996; Sora gf al, 
1997b; Gaveriaux-Ruff et al, 1998; Loh et al, 1998; Matthes et a l, 1998; Schuller et 
al, 1999) demonstrating that p receptors represent the primary target for the 
expression of morphine responses. Although Ô receptor-mediated antinociception 
studies in p receptor deficient mice revealed conflicting results (Sora et a l, 1997a; 
Loh et al, 1998; Matthes et al, 1998), a discrete downregulation of ô receptors was 
observed in specific brain regions which have a high level of p receptor expression 
(Kitchen et al, 1997), which supports the existence of interactions between p and Ô 
receptors.
Proenkephalin, as mentioned in chapter 1 (section 1.3) is a precursor protein which 
yields small peptides after protein cleavage by enzymes. The amino acid sequence and 
the structural arrangement of proenkephalin is shown in Figure 2.1. High levels of 
proenkephalin mRNA and enkephalin peptides were found in the striatum (Hughes et 
al, 1975; Hughes et al, 1977; Zamir et al, 1985). The enkephalins are established 
neurotransmitters in the CNS and the neurones containing the endogenous opioid 
peptide are present in the regions that are involved in nociceptive responses, such as 
the thalamus, periaqueductal grey, limbic system and in the spinal cord (see 
Przewlocki & Przewloska, 2001). The products of proenkephalin bind to the 6 -opioid 
receptor with great affinity where they are thought to mediate their biological effects.
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Figure 2.1. Amino acid sequence of the proenkephalin products and structural 
arrangement of pre-proenkephalin (PENK)
Endogenous opioid peptide amino acid sequence 
PENK
[Met] enkephalin: 
[Leu] enkephalin:
[Met] enkephalin Arg^-Phe :^
[Met] enkephalin Arg^-Gly^-Leu^:
T yr-Gly-Gly-Phe-Met 
T yr-Gly-Gly-Phe-Leu 
T yr-Gly-Gly-Phe-Met-Arg-Phe 
T yr-Gly-Gly-Phe-Met-Arg-Gly-Leu
Schematic representation of structural arrangement of the opioid precursor pre­
proenkephalin
I
Signal Peptide
Legend:
COOH
Methionine enkephalin 
Leucine enkephalin
The amino acid sequences of the four peptides show a great deal of similarity in the 
residues. The structural arrangement was adapted from Noda et al. (1982) showing 
the peptides that result from the pre-proenkephalin.
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In addition the distribution of the enkephalins in various brain regions corresponds to 
many of the regions rich in 6 -opioid receptors (Kong et al, 1993).
The generation of mice deficient in the pre-pro enkephalin gene has been reported by 
two groups (Konig et a l, 1996; King et al, 1998). The studies carried out in this 
thesis employed the enkephalin knockout animals generated by Andreas Zimmer’s 
group (Konig et al, 1996). These animals are healthy, fertile and have no gross 
abnormalities (Konig et al, 1996). However, some behavioural abnormalities were 
observed in the enkephalin knockout animals. Comparable to the p knockout mice, 
enkephalin knockout mice showed a decrease in locomotor activity and supraspinal 
pain threshold following thermal stimulation (in response to hot plate but not tail flick 
test) (Konig et a l, 1996), suggesting a tonic involvement of these two components of 
the opioid system in modulating locomotion and pain. Moreover, enkephalin 
knockout mice were reported to be more anxious and males displayed increased 
offensive aggressiveness (Konig et al, 1996). Surprisingly though, no alteration in 
swim-stress-induced analgesia was observed in mutant mice, indicating that 
enkephalins may not be important opioid components of stress-induced analgesia 
(Konig et al, 1996). Furthermore, a specific upregulation of p and 6  opioid receptor 
binding was observed in enkephalin-rich areas of enkephalin knockout mice brains 
(Brady et al, 1999). The large upregulation of opioid receptors in limbic areas is 
consistent with the increased emotional and aggressive behaviours observed in the 
enkephalin knockout mice. Finally, it has been reported that the mutant mice did not 
display tolerance to morphine, suggesting that the enkephalin system is a requirement 
for pathways that mediate p receptor tolerance (King et a l , 1998).
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As reported in chapter 1, there is a large body of evidence indicating that both acute 
and chronic effects of opioids are mediated by adenosine (Sawynok, 1998). 
Antinociception induced by i.t or i.c.v administration of morphine was shown to be 
inhibited by i.t administration of theophylline in the tail flick assay in mice (DeLander 
& Wahl, 1988; DeLander et al., 1992). Morphine was shown to release adenosine 
from in vitro spinal cord preparations (Sweeney er a/., 1987; Sweeney et al, 1989). 
This release occurs from primary afferent nerve terminals in the dorsal horn of the 
spinal cord (Sweeney et a l, 1989) via NBTI-sensitive adenosine transporters 
(Sweeney et a l, 1993). Further, supraspinally administered morphine enhances purine 
release in the cortex in vivo and in vitro (Fredholm & Vemet, 1978; Phillis et al, 
1980; Stone, 1981) and i.c.v administered morphine has also been shown to release 
adenosine and cAMP from the spinal cord via a serotonergic mechanism (Sweeney et 
al, 1991). The above studies not only suggest a local opioid-adenosine interaction at 
the level of the spinal cord and brain, but also give evidence for spinal interactions 
with supraspinal opioid-stimulated descending antinociceptive pathways.
In addition to its involvement in the expression of opioid mediated antinociception 
(Sawynok et al, 1989; Keil & DeLander, 1994; Keil & Delander, 1995; Sawynok, 
1998; Lavand'homme & Eisenach, 1999), a role for adenosine in the development of 
opioid tolerance, dependence and withdrawal has also been suggested. While recent 
studies tend to agree that adenosine receptor agonists attenuate and antagonists 
exacerbate opioid withdrawal signs in the CNS of mice and rats (Kaplan & Sears, 
1996; Salem & Hope, 1997; Zarrindast et al, 1999), studies suggesting an adenosine 
involvement in opioid tolerance have yielded contradictory findings (Ahlijanian & 
Takemori, 1985; Contreras, 1990; Germany et al, 1990). However, cross-tolerance
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and cross-dependence between p-opioid, Ai adenosine and aj adrenergic 
antinociception in the periphery has been shown, suggesting a physical receptor 
interaction in the membrane or an interaction at the level of second messengers (Aley 
& Levine, 1997).
Some studies have demonstrated that interactions between chronically administered 
opioids and adenosine analogues reflect changes in central adenosine receptor and 
transporter expression. Chronic exposure to morphine has been demonstrated to 
upregulate Ai receptors in cortex (Kaplan et al, 1994) and brain homogenates 
(Ahlijanian & Takemori, 1986) and NBTI-sensitive adenosine transporter binding 
sites in the striatum and hypothalamus of mice (Kaplan & Leite-Morris, 1997). 
Moreover, this treatment was shown to downregulate adenosine A2 A receptors in 
striatum (De Montis, 1992) and Ai receptors in the spinal cord of rats (Tao & Liu, 
1992; Tao et al, 1995). In contrast, other groups have shown no change in A; and A2A 
receptor numbers in cortex and striatum of chronic morphine-treated rats and mice 
respectively (Tao gr al, 1992; Kaplan et al, 1994).
As there is a large body of evidence demonstrating that manipulation of the opioid 
system by morphine treatment leads to changes in the adenosine system, it was 
hypothesized that deletion of the genes encoding for p opioid receptors or pre­
proenkephalin would lead to alterations in adenosine receptor expression. 
Accordingly, quantitative autoradiography was used to examine if there are any 
changes in the binding and/or distribution of k \  or A2 A receptors as well as NBTI- 
sensitive adenosine transporters in the brains and spinal cords of heterozygous and
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homozygous p opioid receptor knockout mice compared to wild type and 
homozygous enkephalin knockout mice compared to wild type.
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2.2 MATERIALS AND METHODS
2.2.1 Generation of mice deficient in the p opioid receptor gene and mice 
deficient in the pre-proenkephalin gene
The mice deficient in the p opioid receptor gene used in this study were generated by 
Brigitte Kieffer’s group in Strasbourg, France. A murine 6  opioid receptor cDNA 
probe was used to screen a mouse genomic DNA library derived from the 129/Sv 
strain. The genomic fragment obtained encoded exons two and three of a p opioid 
receptor. A 6 . 8  kb Sol/Spel fragment was excised and subcloned into the vector 
pBlueScript (Stratagene). The p opioid receptor gene was inactivated by insertion of a 
neomycin-resistant (neo) cassette in part of exon 2 (Figure 2.2a). Thus, the coding 
sequence was disrupted at the level of the second intracellular loop. The targeting 
vector was linearised and transfected into 129/Sv embryonic stem cells by 
electroporation. Neomycin resistant clones were screened by Southern blot analysis 
using 5’, 3’ and neo probes. One of the clones was microinjected into preimplantation 
blastocysts (C57BL/6 strain) giving rise to chimeric offsprings. Chimeric mice were 
genotyped by Southern blot analysis of tail DNA to determine germline transmission 
of the mutation. The chimeras were bred with wild type C57BL/6 mice to produce an 
FI generation consisting of wild type and heterozygous animals. Mating of 
heterozygous littermates produced an F2 generation of wild type, heterozygous and 
homozygous mice. Wild type, heterozygous and homozygous p opioid receptor 
knockout mice generated as described above were shipped over from France to the 
University of Surrey and were left to acclimitise for at least one week before being 
used for experimental purposes.
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Mice deficient in the pre-pro enkephalin gene used in this study were generated by 
Andreas Zimmer’s group in the University of Bonn (Germany). The wild type 
enkephalin locus consists of three exons (Ei, E2 , E3) with exon 3 containing all 
enkephalin-coding sequences (Figure 2.2b). The pre-pro enkephalin gene was 
inactivated by replacing the 5’ part of exon 3 with a neomycin-resistant {neo) cassette 
(Figure 2.2b). Chimeric mice were generated by morula aggregation or blastocyst 
injection with two targeted embryonic stem (ES) cell lines one of which transmitted 
the mutant allele. This ES cell clone had an unexpected partial duplication of exon 3 
sequences (Figure 2.2b). Chimeric animals were backcrossed with wild type CDl 
mice to produce an FI generation consisting of wild type and heterozygous animals. 
Mating of heterozygous littermates produced an F2 generation of wild type, 
heterozygous and homozygous mice with the expected Mendelian frequency.
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Figure. 2.2. Knockout strategy for the disruption of the p- opioid receptor and proenkephalin genes 
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Figure 2.2. Disruption of the (a) p receptor genes and (b) pre-proenkephalin genes. 
Restriction maps are shown for the wild type genome (top), targeting vector (centre) 
and targeted genome (bottom).
neo\ neomycin resistant cassette. Ei, E] and E3 represent exons one, two and three of 
the p opioid receptor gene or pre-pro enkephalin gene.
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2.2.2 Tissue preparation and spinal cord removal
26-27 week old male and female wild type (+/+), heterozygous (+/-) and homozygous 
(-/-) p knockout mice as well as male wild type (+/+) and homozygous (-/-) 
enkephalin knockout mice were killed by decapitation and intact brains and spinal 
cords were removed. The tissues were rapidly frozen in isopentane at -20°C and 
stored at -80°C for up to one month before sectioning. The above procedure was 
carried out for the p knockout mice brains and spinal cords at the University of 
Surrey, whereas for the enkephalin knockout mice brains it was carried out in 
Germany (Bonn). The brains were couriered in dry ice to England and were stored at - 
80°C upon arrival.
Immediately following decapitation, the spinal column of the mouse was carefully cut 
out of its body and placed in an ice cold Petri dish. The intact spinal column was then 
cut into three identifiable parts (cervical, thoracic and sacrolumbar regions). Each of 
these sections was inserted in a rubber plastic tube (5 mm diameter, 35 mm length) 
which was connected at the other end to a 1 0  ml syringe containing ice-cold saline 
buffer (0.9% w/v NaCl, pH 7.4). The spinal column was tightly held in the rubber 
tube. The spinal cord regions were then ejected with hydraulic pressure from the 
syringe into a ice cold Petri dish. Each of the spinal cord regions obtained were 
rapidly frozen in isopentane at -20°C and stored as described above.
2.2.3 Tissue sectioning
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2.2.3.1. Sectioning o f brains
Whole frozen brains, from either +/+, +/- and -/- p knockout mice or +/+ and -/- 
enkephalin knockout mice were placed on a mounting stage with the use of a plastic 
embedding medium (O.C.T compound, BDH Chemicals, Poole, U.K). Tissue 
sectioning was carried out at -21°C using a cryostat (Zeiss Microm 505 E).
20 pm frozen coronal sections were cut with a 300 pm interval starting from the 
olfactory bulbs and going through to the hindbrain. The sections were thaw-mounted 
onto precleaned and gelatin subbed ice-cold microscope slides. Adjacent sections 
were cut for the determination of total and non-specific binding of each ligand. Extra 
sections were also taken for early developments and scrapes (see sections 2 .2 .5.3, 
2.2.6) at the level of the caudate. Finally, the sections were dried using anhydrous 
calcium sulphate (Drierite-BDH Chemicals, Poole, U.K) at 4°C for 2 hours, to prevent 
the formation of crystals, before storage at -20°C for one week.
2.2.3.2. Sectioning o f spinal cord
The frozen cervical, thoracic and sacrolumbar regions of the spinal cord of +/+, +/- 
and -/- p knockout mice were embedded in mounting solution (O.C.T., BDH, 
Chemicals, Poole, U.K) and mounted on a mounting stage prior to sectioning. The 
sectioning of the embedded tissue was carried out at -21°C in a cryostat (Zeiss 
Microm 505 E). 20 pm thick coronal sections were cut rostro-caudally at 300 pm 
intervals throughout the spinal cord regions. Adjacent sections were cut for 
determination of total and non-specific binding of each ligand as previously described
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for brain tissue. Separate slides were prepared for early developments and scrapes (see 
sections 2.2.5.3, 2.2.6) with sections collected throughout the length of the cord 
regions. Finally, the sections were dried using anhydrous calcium sulphate (Drierite- 
BDH Chemicals, Poole, U.K) at 4°C for 2 hours, to prevent the formation of ice 
crystals, before storage at -20°C for one week.
2.2.4 Cleaning and subbing of microscope slides
Slides were soaked overnight in a hot detergent (Decon) and water solution. All slides 
were then rinsed in hot running water for 15 min followed by cold distilled water for a 
further 15 minutes. The slides were then left to soak in a solution of 10% HCl/90% 
ethanol (96%) for 20 minutes before they were rinsed again in distilled water for 15 
minutes. Slides were then soaked in a 1% gelatin/ chrome-alum solution for 2 minutes 
and were then left to dry before use.
2.2.5. Radioligand Binding
2.2,5.1 Adenosine receptor and NBTI-sensitive adenosine transporter binding
[^ H] l,3-dipropyl-8-cyclopentylxanthine- ([^HJDPCPX), phenylethylamino-5’-N- 
[^H]2-[p-(2-carbonylethyl)phenylethylamino]-5’-N-ethylcarboxamidoadenosine- 
([^H]CGS21680) and [^H]nitrobenzylthioinosine- ([^HJNBTI) were used for binding 
of Al, A2a adenosine receptors and NBTI-sensitive adenosine transporters 
respectively.
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[^H]DPCPX was made up in incubation buffer of 170 mM Tris HCl (pH 7.4 at 25°C), 
2 U/ml adenosine deaminase type VIII (Sigma-Aldrich, Dorset, U.K), at 3 nM for 
determination of total and non-specific binding. The above concentration represents 
three times Kd as previously determined in our laboratory (Peachey et a l, 1999). N-6 - 
cyclopentyl adenosine (CPA) was added in the incubation buffer containing 
[^HJDPCPX at a concentration of 1 pM for determination of non-specific binding.
For [^HJDPCPX binding, all slides were placed in binding trays and 1ml of either total 
or non-specific binding solution was pipetted on the sections (1 ml per slide). 
Incubation was carried out at room temperature for 120 minutes (Peachey et al,
1999). Following the incubation period all slides were washed 3 times for 5 minutes 
with ice-cold rinse buffer (170 mM Tris-HCl, pH 7.4 at 0°C) followed by one 5- 
minute rinse in ice-cold reverse osmosis water.
[^H]CGS21680 was made up in incubation buffer containing 170 mM Tris-HCl, 10 
nM MgCl] (BDH, Chernicals, Poole) and 2 U/ml adenosine deaminase, type VIII 
(Sigma-Aldrich, Dorset, U.K) (pH 7.4 at 25°C), for determination of total and non­
specific binding. The concentration chosen was 5-10 nM approximating three to four 
times the Kd as previously described in the literature (Johansson & Fredholm, 1995). 
In addition, solutions for non-specific binding contained NECA at a concentration of 
20 pM.
The slides used for [^H]CGS21680 binding were pre-incubated for 30 minutes in 170 
mM Tris-HCl plus 1 mM ethylenediaminetetraacetic acid (EDTA) and 2 U/ml 
adenosine deaminase type VIII (Sigma-Aldrich, Dorset, U.K), pH 7.4 at 25°C, to
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remove endogenous adenosine. The slides were subsequently placed in binding trays 
and solutions for the determination of total and non-specific binding were applied ( 1  
ml per slide). Incubation was carried out at room temperature for 120 minutes as 
previously described (Peachey et al, 1999). Following the incubation period, all 
slides were washed 3 times for 5 minutes with ice-cold rinse buffer (170 mM Tris- 
HCl, pH 7.4 at 0°C) followed by three rapid washes in ice-cold reverse osmosis water.
[^HJNBTI was made up in incubation buffer of 50 mM Tris-HCl (pH 7.4 at 25°C) at 
4.5 nM concentration for determination of total and non-specific binding. The 
concentration chosen was approximately three times the Kd as determined in pilot 
experiments (data not shown). In addition, solutions for non-specific binding 
contained 10 pM unlabelled NBTI.
Slides used for [^HJNBTI binding were pre-incubated for 30 minutes in 50 mM Tris- 
HCl (pH 7.4 at 25°C) and 2 U/ml adenosine deaminase type VIII (Sigma-Aldrich, 
Dorset, U.K). The slides were then placed in binding trays and 1 ml of either total or 
non-specific solutions were pipetted on the sections (1 ml per slide). Incubation was 
carried out at room temperature for 30 minutes as cited in literature (Ekonomou et al,
2000). Following the incubation period all the slides were washed three times for 5 
minutes in ice-cold rinse buffer (50 mM Tris-HCl, pH 7.4 at 0°C) and twice in ice 
cold reverse osmosis water.
All slides from [^H]DPCPX, [^H]CGS21680 and [^H]NBTI binding studies were then 
rapidly dried for two hours in a cold air stream. Dehydration was continued at room
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temperature for a further seven days in airtight boxes containing anhydrous calcium 
sulphate (Drierite, BDH Chemicals, Poole, U.K.).
2.2.5.2 p  opioid receptor binding
[^ H] D-Ala^-MePhe"^-Gly-ol  ^enkephalin (DAMGO) was used for binding of p opioid 
receptors in brains of wild type (+/+), heterozygous (+/-) and homozygous (-/-) p 
opioid receptor knockout mice in order to confirm their genotype. [^H]DAMGO was 
made up in incubation buffer of 50 mM Tris-HCl, pH 7.4 at 25°C (Sigma-Aldrich, 
Dorset, U.K), at 4 nM concentration for determination of total and non-specific 
binding. The concentrations chosen was approximately three times the Kd for the 
ligand (Kitchen et al, 1997). Naloxone was added to the incubation buffer containing 
the radioligands for determination of non-specific binding at 1 pM.
Slides used for [^H]DAMGO binding were pre-incubated for 30 minutes in 50 mM 
Tris-HCl (Sigma-Aldrich, Dorset, U.K), 0.9% NaCl (Fisher Scientific, Loughborough, 
U.K.), pH7.4 at 25°C, buffer to remove endogenous opioids. All slides were then 
placed in binding trays and 1 ml of either total or non-specific binding (NSB) 
solutions was pipetted onto the sections (1 ml per slide). Incubation was carried out at 
room temperature for 60 minutes (Kitchen et al, 1997). Following the incubation 
period, slides were washed three times for 5 minutes in ice-cold rinse buffer (50 mM 
Tris-HCl, pH 7.4 at 0°C). Slides were then dried for two hours in a cold air stream. 
Drying was continued for a further 7 days using anhydrous calcium sulphate (Drierite- 
BDH Chemicals, Poole, U.K.).
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2.2.5.3. Determination o f scrape binding
Sections from the level of the caudate were cut and mounted on slides (one for total 
and one for non-specific binding per radioligand per brain or spinal cord) for scrape 
binding to confirm the binding of the ligands before the slides were laid on films. 
Those sections were treated identically to the other slides as far as radioligand binding 
is concerned. However, after the rinsing step, the sections from each scrape slide were 
wiped off with a piece of filter paper (Whatmann, GF/B filter) and placed into a 
scintillation vial. 0.5 ml of tissue solubiliser (NCS-II, Amersham International Pic, 
Buckinghamshire, U.K) was added. Vials were left overnight before the addition of 4 
ml Unisolve E scintillation fluid. Scintillation counting was carried out 24 hours later 
using a Wallac (1410 model) liquid scintillation counter. Specific binding was 
determined by subtracting non-specific counts from total counts. Radioligand stocks 
were also counted to check their concentrations.
2.2.6. Autoradiographic film preparation
[^Hjmicroscales (Amersham International Pic, Buckinghamshire, U.K) in the range of 
0.07-33.4 nCi/mg, which served as tritium standards were apposed to the same [^H]- 
sensitive Hyperfilm (Amersham International Pic, Buckinghamshire, U.K) together 
with the sections from +/+, +/- and -/- p knockout or with those from +/+ and -/- 
enkephalin knockout brains or spinal cords. The Hyperfilm was laid, emulsion side 
down, directly onto the tissue sections which were securely placed inside the 
hypercassettes. The hypercassettes were sealed with opaque tape, to prevent light
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exposure, and were stored flat until development. The above procedure was carried 
out in a dark room under safe light conditions (red filter).
The exposure times varied according to the ligand and the type of tissue (brain or 
spinal cord) used. All of those times were determined by the use of early 
developments in this laboratory. The exposure times used for each radioligand bound 
tissue can be found in Table 2.1.
One slide with three sections was collected for early development during wild type 
brain and spinal cord sectioning for [^HJNBTI binding and during wild type spinal 
cord sectioning for [^HjDPCPX and [^H]CGS21680. Early developments were 
processed for total radioligand binding as normal and were apposed to individual 
pieces of Hyperfilm. These were stored in a light resistant box until development. The 
small pieces were developed before the whole film to ensure that the images were at a 
suitable intensity for analysis.
Table 2.1. Exposure times of radioligand bound brain and spinal cord sections to 
a [^H]-sensitive hyperfilm
Exposure times (weeks)
Ligand Brain Spinal cord
[■‘H]DAMGO 3 weeks (Kitchen et al, 1997)
fH]DPCPX 3 weeks (Slowe, 1999) 5 weeks (determined by pilot 
studies)
[•’H]CGS-21680 3 weeks (Slowe, 1999) 2 0  weeks (determined by 
pilot studies)
[■‘H]NBTI 4 weeks (determined by pilot 
studies)
5 weeks (determined by pilot 
studies)
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2.2.7. Film development
Films were developed using an aqueous solution of 50% v/v Kodak D19 developer 
(Sigma-Aldrich, Dorset, U.K) for three minutes. The reaction was stopped by placing 
films in a solution of distilled water and glacial acetic acid for 30 seconds. Fixation of 
images was carried out in Kodak rapid fix solution for 2 minutes. The above 
procedure was carried out under safe light condition (red filter) in a dark room. Films 
were then rinsed in fresh distilled running water for 2 0  minutes and dried overnight in 
a fume cupboard.
2.2.8 Image analysis
Quantitative analysis of receptor binding autoradiography was carried out by video- 
based computerised densitometry using an MCED image analyser (Imaging research, 
Canada). Specific receptor binding was determined by subtraction of non-specific 
binding from total binding images. Specific binding was expressed in frnol/mg tissue 
equivalents as determined by reference to [^H]microscale calibrations laid down with 
the film.
2.2.8.I. Image analysis o f brain autoradiography films
Measurements were taken from the right and left hemispheres for each region and 
therefore represented a duplicate determination for each region. For central structures 
such as thalamus, hypothalamus, lateral septum, ventral limb of diagonal band, 
periaqueductal grey and interpeduncular nucleus, one measure was taken.
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Computerised tools were used to take measures from each region. The following 
structures were analysed by sampling 5-14 times with a box tool (box size in 
parentheses): cortex (8 x8 mm), olfactory tubercle (6 x6 mm), olfactory bulbs (5x5mm), 
zona incerta (6 x6 mm), hippocampus stratum oriens (3x3mm) and hippocampus 
stratum radiatum (3x3mm). The mean of the samples for each region was calculated. 
All other regions were analysed by freehand drawing of anatomical areas. Structures 
were identified by reference to the mouse atlas of Franklin and Paxinos (1997). For 
Bregma co-ordinates see Tables in the Result section.
2.2.8.2. Image analysis o f spinal cord autoradiography films
Measurements were taken from both right and left side for each region of the spinal 
cord, therefore representing a duplicate determination for each region. The only 
structures measured on their own, were lamina X and white matter of the spinal cord. 
All anatomical areas of the spinal cord such as superficial layers (laminae I and II), 
laminae III-VI, laminae VII-IX, laminae VIII-IX lamina X, dorsal horn, ventral horn 
and white matter were analysed by freehand drawing. Structures were analysed by 
reference to the rat atlas of Paxinos and Watson (1986). The actual segments of spinal 
cord analysed were: Cl and C6  for cervical, T3 and T6  for thoracic and S4 for sacral 
spinal cord (see rat atlas of Paxinos and Watson).
2.2:9. Data analysis
The mean and standard error of the mean of each ligand binding (fmol of radioligand 
bound/mg of tissue) was calculated in each region for each genotype. The percentage
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changes in binding levels from wild type to heterozygous or homozygous brains and 
spinal cords of p receptor knockout mice, and the percentage changes in binding 
levels from wild type to homozygous brains of enkephalin knockout mice were 
determined. Comparison of quantitative measures of autoradiographic binding for 
each ligand in brains and spinal cords from +/+, +/- and -/- animals was carried out 
using two-way ANOVA (for factors region of brain or laminae of spinal cord and 
genotype).
Regression analysis was also carried out to determine whether a correlation existed 
between the levels of p receptor expression in regions of wild type brains and changes 
in Ai, A2 A receptor and NBTI-sensitive adenosine transporters in regions of 
heterozygous and homozygous p receptor knockout mice or homozygous enkephalin 
knockout mice. Another regression analysis was carried out to determine whether a 
correlation existed between the levels of p or 5 receptor expression in regions of wild 
type brains and changes in Ai, A2 A receptor and NBTI-sensitive adenosine 
transporters in homozygous enkephalin knockout mice brains. Finally, regression 
analysis was carried out to determine whether a correlation existed between the 
changes in Ai receptor and NBTI-sensitive adenosine transporter expression in 
regions of enkephalin knockout mice brains compared to wild type and changes in p 
and 5 receptor expression in regions of enkephalin knockout mice brains compared to 
wild type which was described by Brady et al (1999).
2.2.10. Ligands
2.2.10.1. [^H]-Iabelled ligands
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[^ H] DAMGO- Specific activity 56.0 Ci/mmol (2.07 TBq/mmol). It was purchased 
from Amersham International Pic (Buckinghamshire, U.K.). The concentration of the 
stock used was 17.9 pM. The purity of the ligand is >99% as determined by HPLC.
[^ H] DPCPX- Specific activity 111.6 Ci/mmol (4.13 TBq/mmol). It was purchased 
from NBN life Science Products, Inc. The concentration of the stock used was 9.0 
pM. The purity of the ligand is >97% as determined by HPLC.
[^H]CGS21680- Specific activity 42.5 Ci/mmol (1.57 TBq/mmol). It was purchased 
from NEN life Science Products, Inc. The concentration of the stock used was 23.5 
pM. The purity of the ligand is >97% as determined by HPLC.
[^HjNBTI-Specific activity 30 Ci/mmol (1.1 TBq/mmol). It was purchased from 
NEN life Science Products, Inc. The concentration of the stock used was 33.3 pM. 
The purity of the ligand is >97% as determined by HPLC.
2.2.10.2. Unlabelled ligands
Naloxone hydrochloride was purchased from Sigma-Aldrich, Dorset, U.K.
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2.3 RESULTS
2.3.1 p opioid receptor knockout mice
2.3.1.1 Confirmation o f genotype
Binding of p opioid receptors with [^HJDAMGO showed a complete loss of p-sites in 
homozygous mice brain, and a lower number of p binding sites in heterozygous mice 
brains compared to wild type (Figure 2.3) which is consistent with the findings of 
Kitchen et al. (1997). These findings confirmed the genotype of the p opioid receptor 
knockout mice used in this study.
Figure 2.3. The distribution of p opioid receptors in wild type (+/+), heterozygous 
(+/-) and homozygous (-/-) p opioid receptor knockout mice
RD + /+  +/-
Computer enhanced autoradiograms o f coronal brain sections from wild type (+/+), 
heterozygous (+/-) and homozygous (-/-) p-opioid receptor knockout mice. The 
sections shown are from the level o f the hippocampus (Bregma -1 .70mm). p  receptors 
were labelled with [^HJDAMGO (4 nM). The colour bar shows pseudo-colour 
interpretation o f relative density o f black and white film image. Sections from +/+, 
+/- and -/- brains were processed in parallel. R.D: relative optical density
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2.3.1.2 Al adenosine receptor autoradiography
Quantitative autoradiography of Ai receptors from coronal sections of fore, mid and 
hind brain wild type mice showed a very widespread distribution (Figure 2.4). High 
levels of [^H]DPCPX binding (200-300 finol/mg of tissue) were detected in the 
thalamus, the lateroposterior thalamic nucleus, the stratum radiatum of the 
hippocampus, the dentate gyrus, the subiculum, the presubiculum and in all the 
cortical regions quantified apart from the motor and cingulate cortex (Table 2.2). 
Exceptionally high levels of [^H]DPCPX binding (> 300 finol/mg tissue) were 
detected in the stratum oriens and moleculare of the hippocampus. Moderate levels of 
binding (1 0 0 - 2 0 0  frnol/mg tissue) were observed in the nucleus accumbens, the 
caudate putamen, the lateral dorsal and lateral intermediate septum, the corpus 
callosum, the ventral pallidum, the globus pallidus, the basolateral amygdala, the 
medial mamillary nucleus, the substantia nigra, the periaqueductal grey, the 
superficial grey layer of the superior colliculus and in the motor and cingulate cortex. 
Lower levels of binding (<100 frnol/ mg of tissue) were detected in the olfactory 
bulbs, the medial septum, the vertical limb of the diagonal band, the amygdala, the 
hypothalamus and the interpeduncular nucleus.
The pattern of distribution of Ai receptors in heterozygous (+/-) and homozygous (-/-) 
p opioid receptor knockout mice brains was identical to wild type (+/+) (Figure 2.4). 
There were, however, some small quantitative differences in specific binding in the 
mutant mice compared to wild type. Two-way ANOVA demonstrated a significant 
quantitative difference (P<0.01) in the levels of [^HjDPCPX binding between
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genotypes in the brain (Table 2.2). Although the median change for all regions was 
only 4-5%, 73% of the regions analysed in heterozygous and homozygous knockout 
mice showed a downregulation in Ai expression. The greatest loss of A; sites (16- 
2 0 %) in homozygous brains was found in areas of high p-opioid receptor expression 
(nucleus accumbens shell, basolateral amygdala). Regression analysis was carried out 
to determine if there was a relationship between the levels of expression of p- 
receptors in regions of wild type brains and the % change in Ai receptors in regions of 
mutant brains compared to wild type, and revealed a significant correlation for the -/- 
homozygous group (r=0.45, n=19, P<0.05) (Figure 2.5).
The interanimal variation, as reflected in standard error of the mean (S.E.M) values, 
for each individual region of each genotype was for the majority of the regions less 
than 10% of the mean specific binding values for each region of each genotype (n=5) 
(Table 2.2).
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Figure 2.4. The distribution of Aj adenosine receptors in wild type (+/+), heterozygous
(+/-) and homozygous (-/-) p opioid receptor knockout mice brains
+/+ + /- ■/-
I
Computer enhanced autoradiograms of coronal brain sections from wild type (+/+), 
heterozygous (+/-) and homozygous (-/-) p opioid receptor knockout mice. The sections 
shown are from the level of the caudate (Bregma 1.10mm) and the hippocampus (Bregma 
-1.70mm). Ai receptors were labelled with [^H]DPCPX (3nM). The colour bar shows 
pseudo-colour interpretation of relative density of black and white film image calibrated 
in fmol/mg tissue. Sections from +!+, +/- and -/- brains were processed in parallel.
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Table.2.2.
Quantitative autoradiography of Aj receptors in the brains of wild type (+/+), heterozygous (+/-
and homozygous (-/-) p opioid receptor knockout mice
Region Bregma [ H]DPCPX Specific Binding % Change in
co-ordinates (fmol/mg) binding
Wild-type
(+/+)
Heterozygous Homozygous (+/-) (-/-)
Olfactory bulb 4.28mm
Ext. plexiform layer 47.1±3.6 49.64=4.2 50.84=4.8 5.3 7.9
Glomerular layer 48.14=2.9 45.14=4.2 49.04=5.5 -6 . 2 1.9
Granule layer 73.24=2.4 69.14=4.1 69.3±5.7 -5.6 -5.3
Anterior olfactory 3.20mm 83.04=4.1 75.34=5.8 74.74=7.1 -9.3 - 1 0 . 0
nucleus
Cortex
Motor 2.46mm
Superficial layers 1464=8.8 1424=16.2 1414:14.3 -2.7 -3.4
Deep layers 1634=8.9 1634=15.2 1634=11.4 0 . 0 0 . 0
Rostral somatosensory 1.10mm
Superficial layers 2234=9.7 2084=17.7 2124=14.2 -6.7 -4.9
Deep layers 1954=8.1 1924=13.5 186=bl3.3 -1.5 -4.6
Cingulate 1 .1 0 mm
Superficial layers 1664=8.1 1484=14.2 150=tl5.4 - 1 0 . 8 -9.6
Deep layers 1664=8.1 1664=15.4 1674=13.3 0 . 0 0 . 6
Caudal somatosensory -1.7mm
Superficial layers 223±19.0 2064=21.0 2144=17.1 -7.6 -4.0
Deep layers 2094=10.5 1954=18.6 2104=10.2 -6.7 0.5
Auditory -2.80mm
Superficial layers 1824=10.7 1804=20.3 1714=10.4 - 1 . 1 -6 . 0
Deep layers 2164=8.7 2084=26.0 2144=14.8 -3.7 -0.9
Visual -2.80mm
Superficial layers 2034=11.6 1704=20.5 1754=14.9 -16.3 -13.8
Deep layers 2184=11.2 2074=22.6 2164=10.2 -5.0 -0.9
Reterosplenial -2.80mm
Superficial layers 2044=7.1 1824=18.9 1894=6.8 - 1 0 . 8 -7.3
Deep layers 2314=8.0 1934=19.7 2054=9.2 -16.5 -11.3
Nucleus accumbens 1.34mm
Shell 1484=16.1 1404=20.5 1194=9.6 -5.4 -19.6
Core 1444:12.4 1384=15.2 1324=10.3 -4.2 -8.3
Caudate-putamen 1 .1 0 mm 1784=8.6 1714=15.5 1754=12.3 -19 -1.7
Septum 0 .8 6 mm
Medial 81.84=3.9 80.54=7.8 76.34=4.6 - 1 . 6 -6.7
Lateral dorsal 1924=21.4 1944=17.1 2014=19.3 1 . 0 4.7
Lateral intermediate 1634=19.3 1704=23.6 1684=32.1 4.3 3.1
84
Table.2.2 (continued)
Region Bregma [^HJDPCPX Specific Binding % Change in
co-ordinates (fmol/mg) binding
Wild-type Heterozygous Homozygous (+/-) (-/-)
(+/+) (+/-) (-/-)
Vertical limb of 0 .8 6 mm 69.14=3.3 66.14=5.2 63.74=4.5 -4.3 -7.8
diagonal band
Corpus callosum 0 .8 6 mm 1034=7.1 1044=10.1 1104=5.9 1 . 0 6 . 8
Ventral pallidum 0.14mm 1414=8.8 1464=24.9 1284=12.1 3.6 -9.2
Globus pallidus -0 .1 0 mm 1294=7.2 144±14.4 1394=12.9 1 1 . 6 7.8
Thalamus -1.70mm 2394:6.3 2234=19.0 2194=11.1 -6.7 -8 A
Lateroposterior 2714=10.6 2654=18.4 2654=13.1 -2 . 2 -2 . 2
nucleus
Ventroposterior 1694=11.3 1674=18.7 1394=10.2 -1 . 2 -17.8
nucleus
Amygdala -1.70mm 82.84=8.7 84.24=10.1 81.44=5.2 1.7 -1.7
Basolateral 1694=17.8 1514=20.3 1414=16.5 -10.7 -16.6
Hypothalamus -1.70mm 76.84=7.9 75.64=10.5 69.44=5.6 - 1 . 6 -9.6
Hippocampus -2.46mm
Stratum oriens 3154=15.1 3074=11.5 3244=13.5 -2.5 2.9
Stratum radiatum 2164=7.3 1864:19.3 1994=11.8 -13.9 -7.9
Stratum moleculare 3144=10.9 2984=20.2 2904=19.2 -5.1 -7.6
Dentate gyrus -2.46mm 1994=21.6 2004=20.5 2084=20.2 0.5 4.5
Medial mammillary -2.80mm 1294=8.5 1124=14.8 1104:15.4 -13.2 -14.7
nucleus
Periaqueductal grey -3.40mm 1114=2.7 1034=14.9 1024=8.5 -7.2 -8 . 1
Substantia nigra -3.40mm 95.24=4.7 98.14=2.8 954=4.7 3.0 -0 . 2
Subiculum -3.40mm 2444=9.6 2064=21.4 2294=9.3 -15.6 -6 . 1
Superficial grey layer -3.40mm 1624=8.1 156=bl4.6 1434=12.7 -3.7 -11.7
of superior colliculus
Presubiculum -4.04mm 1964=10.2 1964=16.7 1984=8.2 0 . 0 1 . 0
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Table 2.2. The mean specific binding (n=5) of [^HJDPCPX (fmol/mg) ± S.E.M. in 
brain regions of wild type (+/+), heterozygous (+/-) and homozygous (-/-) p opioid 
receptor knockout mice. Measures in the regions were carried out at the Bregma co­
ordinates taken from the mouse atlas of Franklin and Paxinos (1997). Regional 
determinates were made from both left and right sides of the sections, which were cut 
300 pm apart. The labelling was carried out on sections from +/+, +/- and -/- mice in a 
completely paired protocol. Specific binding was >80% in all regions. Comparison of 
genotypes was statistically significant (P<0.01, ANOVA). The percentage (%) change 
in binding represents the change in binding levels in +/- or -/- brains compared to +/+. 
A minus sign indicates a percentage decrease in binding levels. The overall mean and 
median percent changes across regions was -4.1% (+/-), -4.7% (-/-) and -3.8% (+/-), 
-5.1% (-/-) respectively.
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Figure 2.5. Regression analysis of percentage changes in [^HJDPCPX binding in 
brain regions of heterozygous (+/-) or homozygous (-/-) p opioid receptor knockout 
mice versus p opioid receptor expression in brain regions of wild type animals
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Figure 2.5. Graph showing regression analysis of [^HJDAMGO binding to p opioid 
receptors (ffnol/mg tissue) in regions of wild type mice brain versus a) percentage 
change (%) in [^H]DPCPX binding to adenosine Ai receptors in regions of 
heterozygous (+/-) p opioid receptor knockout mice brains and b) percentage change 
(%) in [^HJDPCPX binding to adenosine Ai receptors in regions of homozygous (-/-) 
p opioid receptor knockout mice brains. Correlation coefficients, r, and number of 
regions are shown for each comparison. There was a significant correlation (P<0.05) 
between levels of p opioid receptor binding and % change in [^H]DPCPX binding in 
homozygous (-/-) p opioid receptor knockout mice, p opioid receptor binding data in 
wild type animals were taken from Kitchen et al. (1997).
2.3.1.3. A2a adenosine receptor autoradiography
As opposed to [^HJDPCPX binding, quantitative autoradiography of A2A receptors 
from coronal sections of fore, mid and hindbrain of wild type mice showed a very 
restricted localisation (Figure 2.6). More specifically, [^H]CGS21680 binding was 
restricted to the nucleus accumbens, the caudate putamen, the olfactory tubercle, 
where a high level of binding was detected (200-300 frnol/mg tissue) and to the 
globus pallidus which had a lower level of A2A binding (Figure 2.6, Table 2.3). 
Binding was low to undetectable in all other regions and was therefore not quantified.
The pattern of distribution of A2A receptors in heterozygous (+/-) and homozygous (-/- 
) p opioid receptor knockout mice brains was identical to wild type (+/+) (Figure 2.6). 
Two-way ANOVA demonstrated that there were no significant differences in the 
levels of A2A receptor expression between genotypes (P>0.05). Regression analysis to 
determine if there was a relationship between levels of expression of p receptors in 
regions of wild type brains and the percent change in A2A receptors in mutant brains 
compared to wild type showed no significant correlation (P<0.05) (r=0.53, P=0.8 for 
+/- and r=0.4, P=0.9 for -/- change).
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Figure 2.6. The distribution of Aja adenosine receptors in wild type (+/+), heterozygous
(+/-) and homozygous (-/-) p opioid receptor knockout mice brains
+/+ + /- - / -
‘2 A
fmol/mg
Computer enhanced autoradiograms of coronal brain sections from wild type (+/+), 
heterozygous (+/-) and homozygous (-/-) p-opioid receptor knockout mice. The sections 
shown are from the level of the caudate (Bregma 1.10mm) and the globus pallidus 
(Bregma -0.22mm). A2A receptors were labelled with [^H]CGS21680 (10nM). The 
colour bar shows pseudo-colour interpretation of relative density of black and white film 
image calibrated in fmol/mg tissue. Sections from +/+, +!- and -/- brains were processed 
in parallel.
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Table.2.3.
Quantitative autoradiography of A2A receptors in the brains of wild type (+/+),
heterozygous (+/-) and homozygous (-/-) p opioid receptor knock out mice
Region Bregma [^H]CGS-21680 Specific Binding % Change in
co-ordinates (fmol/mg) binding
Wild-type Heterozygous Homozygous (+/-) (-/-)
(+/+) (+/-) (-/-)
Nucleus accumbens 1.34mm
Shell 2094=15.0 1914=17.2 1824=18.9 -8 . 6 -12.9
Core 1824=8.1 1754=15.6 1714=15.2 -3.8 -6 . 0
Caudate-putamen 1 .1 0 mm 2964=18.5 300±19.5 2944=10.2 1.4 -0.7
Olfactory tubercle 1 .1 0 mm 2744=16.2 2664=21.4 2524=17.1 -2.9 -8 . 0
Globus pallidus -0 .1 0 mm 87.74=8.1 93.54=3.9 98.04=5.7 6 . 6 11.7
The mean specific binding (n=5) of [^H]CGS21680 (fmol/mg) ± S.E.M. in brain 
regions of wild type (+/+), heterozygous (+/-) and homozygous (-/-) p opioid receptor 
knockout mice. Measures in the regions were carried out at the Bregma co-ordinates 
taken from the atlas of Franklin and Paxinos (1997). Regional determinates were 
made from both left and right sides of the sections, which were cut 300 pm apart. The 
labelling was carried out on sections from +/+, +/- and -/- mice in a completely paired 
protocol. Specific binding was >95% in all regions. Comparison of genotypes was not 
statistically significant (P>0.05,ANOVA). The percentage (%) change in binding 
represents the change in binding levels in +/- or -/- brains compared to +/+. A minus 
sign indicates a percentage decrease in binding levels. The overall mean and median 
percentage changes across regions was -1.5 % (+/-), -3.2 % (-/-) and -2.9 %( +/-), -  
6 . 0  % (-/-) respectively.
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2.3.L4. NBTI-sensitive adenosine transporter autoradiography
Quantitative autoradiography of NBTI-sensitive adenosine transporters from coronal 
sections of fore, mid and hindbrain of wild type mice showed a very widespread 
distribution (Figure 2.7). High levels of [^H]NBTI binding (200-300 frnol/mg tissue) 
were detected in the vertical limb of the diagonal band, the central lateral and central 
medial thalamic nuclei, the hypothalamus, the dorsomedial and ventromedial 
hypothalamic nuclei, the medial mamillary nucleus, the periaqueductal grey and the 
superficial grey layer of superior colliculus. Exceptionally high levels of [^H]NBTI 
binding (> 300finol/mg tissue) were found in the reuniens, the habenula and the 
substantia nigra (Table 2.4). Moderate levels of binding (100-200 frnol/mg tissue) 
were detected in the nucleus accumbens, the caudate putamen the medial septum, the 
globus pallidus, the thalamus, the laterodorsal, ventrolateral and ventromedial 
thalamic nuclei. Lower levels of [^HJNBTI binding (< 100 finol/mg tissue) were 
observed in all the cortical regions, the lateral septum, the ventral posterolateral and 
posteromedial thalamic nuclei, the reticular thalamic nucleus, the amygdala, the 
hippocampus and the dentate gyrus (Table 2.4).
The pattern of distribution of NBTI-sensitive adenosine transporters in heterozygous 
and homozygous p opioid receptor knockout mice brains was identical to wild type 
(Figure 2.7). Two-way ANOVA demonstrated a significant quantitative difference 
(P<0.001) in the levels of [^HJNBTLbinding between genotypes in the brain. 36 brain 
regions out of 46 analysed in heterozygous brains showed a downregulation compared 
to wild type. There was an overall decrease in NBTI-sensitive adenosine transporters 
binding in the heterozygous brains with a median change of 11%. No significant
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correlation (P>0.05) was found between levels of expression of p receptors in regions 
of wild type brains and the % change in the NBTI-sensitiye adenosine transporter 
binding in regions of mutant mice compared to wild type (r=0.18, n=26 for +/-; 
r=0.16, n=26 for -/- brains).
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Figure 2.7. The distribution of NBTI-sensitive adenosine transporters in wild type (+/+),
heterozygous (+/-) and homozygous (-/-) p opioid receptor knockout mice brains
+/+ + /-
NBTI
mol/mg
Computer enhanced autoradiograms of coronal brain sections from wild type (+/+), 
heterozygous (4-/-) and homozygous (-/-) p-opioid receptor knockout mice. The sections 
shown are from the level of the caudate (Bregma 1.10mm) and the hippocampus 
(Bregma -1.70 mm). NBTI-sensitive adenosine transporters were labelled with [^H]NBTI 
(4.5 nM). The colour bar shows pseudo-colour interpretation of relative density of black 
and white film image calibrated in fmol/mg tissue. Sections from +/+, 4-/- and -/- brains 
were processed in parallel.
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Table.2.4.
Quantitative autoradiography of the NBTI sensitive adenosine transporters in the brains of wild
type (+/+), heterozygous (+/-) and homozygous (-/-) p opioid receptor knock out mice
Region Bregma [ HJNBTI Specific Binding 
co-ordinates (fmol/mg)
% Change in 
binding
Wild-type Heterozygous Homozygous (+/-) (-/-)
(+/+) (+/-) (-/-)
Olfactory bulb
Anterior olfactory 3.20mm 1164=8.9 1164=15.3 93.84:8.2 0 -19.1
nucleus
Cortex
Motor 2.46mm
Superficial layers 49.14=5.0 51.14=8.0 48.14=3.2 4.1 -2
Deep layers 58.74:6.7 53.84=8.2 58.94:7.3 -8.3 0.3
Pre-limbic 2.46mm 94.74=8.3 80.94=4.7 84.84=8.5 -14.6 -10.5
Rostral somatosensory 1.10mm
Superficial layers 36.64=5.1 40.84=7.3 41.14=2.5 11.5 12.3
Deep layers 66.34=4.0 57.94=8.8 65.04=7.1 -12.7 -2
Cingulate 1.10mm
Superficial layers 64.44=9.5 54.54=9.4 49.14=4.2 -15.4 -23.8
Deep layers 65.24=7.2 54.04=7.5 46.64=2.9 -17.2 -28.5
Caudal somatosensory -1.7mm
Superficial layers 36.84=4.4 38.14=11.3 58.94=9.7 3.5 60
Deep layers 62.34=3.8 57.24=9.5 73.04=6.0 -8.2 17.2
Auditory -2.80mm
Superficial layers 87.54=10 69.24=5.9 90.04=8.8 -20.9 2.9
Deep layers 85.84=9.6 84.64:9.0 98.14=9.6 -1.4 14.3
Visual -2.80mm
Superficial layers 54.54=12.7 44.34=8.3 41.7 -18.7 -23.5
Deep layers 66.74=8.7 54.84=8.9 66.94=12.3 -17.8 0.3
Retrosplenial -2.80mm
Superficial layers 48.24=7.7 36.94=3.4 55.74=4.1 -23.4 15.6
Deep layers 55.04=14.5 31.64:8.9 47.34=8.4 -42.5 -14.0
Nucleus accumbens 1.34mm 1474:12.6 1314=6.7 1304=3.9 -10.9 -11.6
Caudate-putamen 1.10mm 1424=9.2 1314=10.7 1304:4.9 -7.7 -8.5
Septum 0.86mm
Medial 1914:17.8 1754=19.0 1734=18.8 -8.4 -9.4
Lateral 88.04=7.4 85.44=16.3 80.04=8.1 -3.0 -9.1'
Vertical limb of 0.86mm 2454=7.9 2274=32.7 1984=11.8 -7.3 -19.2
diagonal band
Globus pallidus -0.10mm 1464=4.7 1404=6.6 1484=6.1 -4.1 1.4
Thalamus -1.70mm 1794=7.9 1564=5.9 1764=13.7 -12.8 -1.7
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Table.2.4 (continued) 
Region Bregma [ HJNBTI Specific Binding 
co-ordinates (fmol/mg)
% Change in 
binding
Wild-type
(+/+)
Heterozygous Homozygous 
(+/-) (-/-)
(+/-) (-/-)
Thalamic nuclei -1.70mm
Laterodorsal 1444=7.8 1484=12.3 1744=21.0 2.8 20.8
(dorsomedial)
Laterodorsal 1304=11.0 1234=4.3 1674=22 -5.4 28.5
(ventrolateral)
Central lateral 2124=10.5 1774=15.6 165±9.3 -16.5 -22.2
Central medial 2394=17.8 2424=24.7 1924=9.9 1.3 -19.7
Ventrolateral 1304=9.0 96.74=7.0 1394=19.3 -25.6 6.9
Ventromedial 1354=4.4 1114=10.4 1514=18.0 -17.8 11.9
Ventral posterolateral 73.74=8.3 90.44=16.0 1034=16.4 22.7 39.8
Ventral posteromedial 97.74=4.9 87.74=6.1 1154=20.7 -10.2 17.7
Reuniens 4084=37.6 3434=38.5 3364:26.2 -15.9 -17.6
Reticular 90.74=8.9 70.64=3.0 95.64=14.6 -22.2 5.4
Amygdala -1.70mm 93.74=6.4 94.74=14.5 1174=13.6 1.1 24.9
Hypothalamus -1.70mm 2214=18.8 1874=19.7 2164=21.1 -15.4 -2.3
Hypothalamic nuclei -1.70mm
Dorsomedial 2634:23.7 1934=26.3 2364=12.9 -26.6 -10.3
Ventromedial 2234=29.8 1784=32.1 2184=21.1 -20.2 -2.2
Hybenula -1.70mm 3824=15.2 293±21.8 354±44.4 -23.3 -7.3
Hippocampus -2.46mm
Stratum oriens 30.54=2.5 32.54=3.2 30.44=5.4 6.6 -0.3
Stratum radiatum 23.14=4.1 28.24=7.7 30.74=4.1 22.1 32.9
Stratum molecular 82.04=3.7 72.64=11.6 88.34:4.3 -11.5 7.7
Dentate gyrus -2.46mm 92.04=3.1 78.54=12.5 86.64=8.8 -14.7 -5.9
Medial mammillary -2.80mm 2484=6.1 2404=23.3 2404=4.0 -3.2 -3.2
nucleus
Periaqueductal grey -3.40mm 2834=11.3 2544=39.7 2904=0.9 -10.2 2.5
Substantia nigra -3.40mm 3124=36.4 2774=31.5 2964=23.0 -11.2 -5.1
Superficial grey layer -3.40mm 2344=25.3 156=t9.9 2464=14.7 -33.3 5
of superior colliculus
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Table 2.4. The mean specific binding (n=3) of [^HJNBTI (frnol/mg) ± S.E.M. in brain 
regions of wild type (+/+), heterozygous (+/-) and homozygous (-/-) p opioid receptor 
knockout mice. Measures in the regions were carried out at the Bregma co-ordinates 
taken from the atlas of Franklin and Paxinos (1997). Regional determinates were 
made from both left and right sides of the sections, which were cut 300 pm apart. The 
labelling was carried out on sections firom +/+, +/- and -/- mice in a completely paired 
protocol. Specific binding was >70 % in regions of high binding. Comparison of 
genotypes was statistically significant (P<0.001, ANOVA). The percentage (%) 
change in binding represents the change in binding levels in +/- or -/- brains compared 
to +/+. A minus sign indicates a percentage decrease in binding levels. The overall 
mean and median percentage changes across regions was -10.1% (+/-), 1.1% (-/-) and 
-11.1 % (+/-), -1.9% (-/-) respectively.
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2.3.2. p opioid receptor knockout mice spinal cords
2.3.2.1. A] adenosine receptor autoradiography
Similar to the brain, quantitative autoradiography of A; receptors from cervical, 
thoracic and sacral regions of the spinal cord of wild type mice showed a widespread 
distribution (Figure 2.8). The levels of [^H]DPCPX specific binding of the regions of 
cervical spinal cord analysed were very similar to those of the respective regions of 
thoracic and sacral spinal cord analysed (Table 2.5) suggesting that the pattern of 
distribution of Ai receptors in the spinal cord is homogeneous along it. The highest 
levels of [^H]DPCPX binding (> 100 fmol/mg tissue) were detected in the superficial 
layers of the spinal cord. Slightly lower levels of binding (> 75 ffnol/mg) were 
detected in laminae III-IV , lamina X and in the ventral horns of the spinal cord. The 
lowest levels of binding (< 30 ffnol/mg tissue) were detected in the white matter of 
the spinal cord.
The pattern of distribution of Ai receptors in heterozygous (+/-) and homozygous (-/-) 
p opioid receptor knockout mice spinal cords was identical to wild type (+/+) (Figure 
2.8). Two-way ANOVA demonstrated that there were no significant differences in the 
levels of Ai receptor expression between genotypes (P>0.05).
98
Figure 2.8. The distribution of A, adenosine receptors in wild type (+/+), heterozygous
(+/-) and homozygous (-/-) p opioid receptor knockout mice spinal cords
+/+ + /-
fmol/mg
A,
Computer enhanced autoradiograms of coronal cervical (row a), thoracic (row b) and 
sacral (row c) spinal cord sections from wild type (+/+), heterozygous (+/-) and 
homozygous (-/-) p knockout mice. The sections taken were C6 segment for cervical, T3 
for thoracic and S4 for sacral spinal cord according to the rat atlas of Paxinos and Watson 
(1986). A, receptors were labelled with [^H]DPCPX (3n M). The colour bar shows 
pseudo-colour interpretation of relative density of black and white film image calibrated 
in fmol/mg tissue. Sections from +/+, +/- and -/- spinal cords were processed in parallel
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Table.2.5.Quantitative autoradiography of Aj adenosine receptors in the spinal cords of wild
type (+/+), heterozygous (+/-) and homozygous (-/-) p opioid receptor knock out mice
Region Segments [^H]DPCPX Specific Binding % Change in
from rat atlas (fmol/mg) binding
Wild-type Heterozygous Homozygous (+/-) (-/-)
(+/+) (+/-) (-/-)
Cervical C1&C6
Superficial layers 1094:9.7 1074=14.4 1054=10.4 -1.8 -3.7
(laminae I&II)
Laminae IE-VI 94.84=7.9 92.04=12.7 107.04=11.5 -3.0 12.9
Lamina X 89.04=11.7 77.64=7.6 91.84=14.1 -12.8 3.1
Ventral horn 84.84=6.4 80.74=10.5 91.64=8.1 -4.8 8.0
(laminae VII-IX)
Dorsal horn 99.84=8.5 99.94=14.5 1064=10.4 0.1 6.2
(laminae I-VI)
White matter 22.34=1.64 23.84=4.8 22.84=4.1 6.7 2.2
Thoracic T3&T6
Superficial layers 1164=10.7 1084=12.1 1174=13.4 -6.9 0.9
(laminae I&II)
Laminae III-VI 99.94=9.7 98.14=9.3 1114=13.2 -1.8 11.1
Lamina X 91.54=9.6 83.14=8.9 90.54=13.8 -9.2 -1.1
Ventral horn 78.24=7.1 76.04:6.8 87.64=10.0 -2.8 12.0
(laminae VII-IX)
Dorsal horn 1084=10.3 1014=9.7 1124=12.4 -6.5 3.7
(laminae I-VI)
White matter 20.04=2.3 19.64=3.3 21.34=2.0 -2.0 6.5
Lumbar-sacral S4
Superficial layers 1104=11.6 1014=26.4 1024=13.9 -8.2 -7.3
(laminae I&II)
Laminae III-VI 95.34=7.0 96.94=20.4 98.04=11.9 1.7 2.8
Lamina X 86.34:8.2 85.34=28.4 85.34:11.8 -1.2 -1.2
Ventral horn 76.5=45.6 80.24=14.7 84.84=10.4 4.8 10.8
(laminae VII-IX)
Dorsal horn 1044=9.5 1014=28.4 1014=13.6 -2.9 -2.9
(laminae I-VI)
White matter 26.84:2.3 24.14=2.3 26.94=3.7 -10.1 0.4
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Table 2.5. The mean specific binding (n=4) of [^HJDPCPX (ffnol/mg) ± S.E.M. in 
spinal cord regions of wild type (+/+), heterozygous (+/-) and homozygous (-/-) p 
opioid receptor knockout mice. Measures in the regions were carried out at the 
Bregma co-ordinates taken ffom the rat atlas of Paxinos and Watson (1986). Regional 
determinates were made ffom both left and right sides of the sections, which were cut 
300 pm apart. The labelling was carried out on sections ffom +/4-, +!- and -/- mice in a 
completely paired protocol. Specific binding was >80 % in all regions. Comparison of 
genotypes was not statistically significant (P>0.05, ANOVA). The percentage (%) 
change in binding represents the change in binding levels in +/- or -/- spinal cords 
compared to +/+. A minus sign indicates a percentage decrease in binding levels.
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2.3.2.2. Â 2A adenosine receptor autoradiography
No [^H]CGS21680 binding was observed in either wild type, heterozygous or 
homozygous knockout mice even after 20 weeks film exposure (results not shown).
2.3.2.3. NBT-sensitive adenosine transporter autoradiography
Quantitative autoradiography of NBTI-sensitive adenosine transporters ffom coronal 
sections of the cervical, thoracic and sacral regions of the spinal cords of wild type 
mice, showed a widespread distribution (Figure 2.9). The levels of [^HJNBTI specific 
binding of the regions of cervical spinal cord analysed were very similar to those of 
the respective regions of thoracic and sacral spinal cord analysed (Table 2.6) 
suggesting that the pattern of distribution of NBTI-sensitive adenosine transporters in 
the spinal cord is homogeneous along it. The highest level of [^HJNBTI binding (>150 
ffnol/mg) was detected in the superficial layers and in lamina X of the spinal cord. 
Lower levels of binding (< 100 finol/mg tissue) were observed in laminae III-VI and 
with still lower binding in the ventral horns of the spinal cord. No quantifiable 
[^HJNBTI binding was detected in the white matter of the spinal cord (Table 2.6).
The pattern of distribution of NBTI-sensitive adenosine transport receptors in 
heterozygous (+/-) and homozygous (-/-) p opioid receptor knockout mice spinal 
cords was identical to wild type (+/+). In contrast with the brain, there was no 
significant difference in the levels of NBTI-sensitive adenosine transporter expression 
in the spinal cords between genotypes (P>0.05).
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Figure 2.9. The distribution of NBTI-sensitive adenosine transporters in wild type (+/+),
heterozygous (+/-) and homozygous (-/-) p, opioid receptor knockout spinal cords
+/+ + /-
NBTI
fmol/mg
m
Computer enhanced autoradiograms of coronal cervical (row a), thoracic (row b) and 
sacral (row c) spinal cord sections from wild type (+/+), heterozygous (+/-) and 
homozygous (-/-) p, knockout mice. The sections taken were C6 segment for cervical, T3 
for thoracic and S4 for sacral spinal cord according to the rat atlas of Paxinos and Watson 
(1986). NBTI-sensitive adenosine transporters were labelled with pH]NBTI (4.5 nM). 
The colour bar shows pseudo-colour interpretation of relative density of black and white 
film image calibrated in fmol/mg tissue. Sections from 4-/4-, +/- and -/- spinal cords were 
processed in parallel
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TabIe.2.6.Quantitative autoradiography of the NBTI sensitive adenosine transporters in the spinal
cords of wild type (+/+), heterozygous (+/-) and homozygous (-/-) p opioid receptor
knock out mice
Region Segments [^H]NBTI Specific Binding % Change in
from rat atlas (fmol/mg) binding
Wild-type Heterozygous Homozygous 
(+/+) (+/-) (-/-)
(+/-) (-/-)
Cervical
Superficial layers
C1&C6
1714=10.5 1934=16.0 1894=9.9 1Z9 10.5
(laminae I&II) 
Laminae XU-VI 80.5±4.8 85.44=10.9 83.54=4.2 6.1 3.7
Lamina X 1664=4.4 1704=16.4 1684=14.5 2.4 1.2
Ventral horn 72.14=4.6 73.74=8.0 63.54=2.0 22 -11.9
(laminae VII-IX) 
Dorsal horn 1054=7.1 1234=8.0 1254=6.8 17.1 19.0
(laminae I-VI) 
Thoracic
Superficial layers
T3&T6
2024=14.0 1824=14.4 1844=16.6 -9.9 -8.9
(laminae I&II) 
Laminae III-VI 90.04=5.0 88.34=3.3 86.14=7.1 -1.9 -43
Lamina X 1714=12.2 156±8.9 1644=11.8 -8.8 -4.1
Ventral horn 76.24=5.9 84.04=5.4 77.74=4.9 10.2 2.0
(laminae VII-IX) 
Dorsal horn 1294=9.4 1224=7.5 1204=10.3 -5.4 -7.0
(laminae I-VI) 
Sacral
Superficial layers
S4
1624=8.7 1894=10.8 1824=18.2 16.7 12.3
(laminae I&II) 
Laminae III-VI 1004=6.8 97.74=4.5 92.54=7.4 -2.3 -7.5
Lamina X 1674=10.3 1764=16.8 1894=10.6 5.4 13.1
Ventral horn 86.34=7.7 86.14=6.0 73.04=3.6 -0.2 -15.4
(laminae VII-IX) 
Dorsal horn 1224=2.7 1344=4.5 1274=8.4 9.8 4.1
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Table 2.6. The mean specific binding (n=3) of [^H]NBTI (fmol/mg) ± S.E.M, in 
spinal cord regions of wild type (+/+), heterozygous (+/-) and homozygous (-/-) p 
opioid receptor knockout mice. Measures in the regions were carried out at the 
Bregma co-ordinates taken from the atlas of Paxinos and Watson (1986). Regional 
determinates were made from both left and right sides of the sections, which were cut 
300 pm apart. The labelling was carried out on sections than +/+, +/- and -/- mice in a 
completely paired protocol. Specific binding was >80 %. Comparison of genotypes 
was not statistically significant (P>0.05, ANOVA). The percentage (%) change in 
binding represents the change in binding levels in -/- or +/- spinal cords compared to 
+/+. A minus sign indicates a percentage decrease in binding levels
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2.3.3. Enkephalin knockout mice brains
2.3.3.1 Aj adenosine receptor autoradiography
The qualitative and quantitative distribution of Ai adenosine receptors labelled with 
[^HJDPCPX (3 nM) in coronal sections of brains of the species of wild type mice used 
in this study was similar to the one used in the previous study (section 2.3.1.2). The 
pattern of distribution of Ai receptors was identical between wild type and 
homozygous enkephalin knockout mice (Figure 2.10). However, small quantitative 
changes in [^H]DPGPX binding were detected in brain regions of enkephalin 
knockout mice compared to wild type. Two-way ANOVA demonstrated a significant 
quantitative difference (P<0.001) in the levels of [^H]DPCPX binding between 
genotypes (Table 2.7). Although the median change was only 4 %, specific regions 
showed marked upregulation in enkephalin knockout mice brains. The hippocampus, 
thalamus, thalamic nuclei, basolateral amygdala and hypothalamus were regions 
where a big upregulation of Ai adenosine receptors (10-30 %) was observed in 
homozygous mice brains. In contrast, in cortical regions no great changes in Ai 
adenosine receptor binding were observed (Table 2.7).
Regression analysis carried out to determine if there was a relationship between the 
levels of expression of p or 5 receptors in regions of wild type brains and the 
percentage (%) change in Ai receptors in regions of mutant brains compared to wild 
type, revealed no significant correlation (P>0.05) (r=0.25, n=17 for p vs % Ai, 
r=0.09, n=17 for ô vs % Ai). Regression analysis carried out to determine if there was 
a relationship between changes in Ai receptor binding in regions of enkephalin
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knockout mice with changes in p or Ô receptor binding observed in regions of the 
same animals by Brady et al (1999) revealed a significant correlation only between 
change in Ai vs changes in p binding (r=0.55, n=15) (Figure 2.11). Thus, the greatest 
increase of Ai sites in enkephalin knockout mice was found in areas where the highest 
increase of p binding was observed in the same animals.
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Figure 2.10. Computer enhanced autoradiograms of coronal brain sections from wild 
type (+/+) and homozygous (-/-) enkephalin knockout mice. The sections shown are 
from the level of the caudate (Bregma 1.10 mm), the hippocampus (Bregma -1.70 
mm) and the periaqueductal grey (Bregma -3.40 mm). Ai receptors were labelled 
with [^HJDPCPX (3 nM). The far right panel shows the non specific binding images 
(NSB). The colour bar shows pseudo-colour interpretation of relative density of black 
and white film image calibrated in fhiol/mg tissue. Sections from +/+ and -/- brains 
were processed in parallel.
109
Table.2.7. Quantitative autoradiography of adenosine receptors
in the brains of wild type (+/+)and homozygous (-/-) enkephalin
knockout mice
Region Bregma [ H]DPCPX 
co-ordinates
Specific Binding % Change in 
binding
Wild-type Homozygous
(+/+) (-/-) (-/-)
Olfactory bulb 4.28mm
Ext. plexiform layer 53.74=2.9 52.64=3.0 -2.1
Glomerular layer 46.64=3.1 46.24=1.6 -0.9
Granule layer 55.54=2.8 53.14=2.5 -4.3
Anterior olfactory 3.20mm 1454=4.8 1324=4.4 -9.0
nucleus
Cortex
Motor 2.46mm
Superficial layers 1604=7.5 1514=9.4
Deep layers 1734=7.5 165±6.7 -4.6
Primary somatosensory 1.10mm
Superficial layers 2044=9.5 200=411.9 -2.0
Deep layers 1904=5.0 2054=12.5 7.9
Cingulate 1.10mm
Superficial layers 1484=4.6 1494=11.0 0.7
Deep layers 1634=4.0 1644=8.5 0.6
Caudal somatosensory -1.7mm
Superficial layers 1904=6.2 1914=5.5 0.5
Deep layers 1944=3.8 2144=5.3 103
Auditory -2.80mm
Superficial layers 1954=11.3 1844=13.8 -5.6
Deep layers 2314=12.1 2194=15.4 -53
Visual -2.80mm
Superficial layers 1744=11.0 174±83 0.0
Deep layers 2084=11.2 2074=9.0 0.0
Reterosplenial -2.80mm
Superficial layers 2024=17.5 215=49.1 6.4
Deep layers 2034=21.7 214=47.3 5.4
Nucleus accumbens
Shell 1314=9.6 107=45.7 -183
Core 1284=11.1 121=410.3 -5.5
Caudate-putamen 1.10mm 1634=5.9 1664=7.5 1.8
Septum 0.86mm
Medial 1034=11.6 1074=15.1 3.9
Lateral dorsal 2114=8.2 2224=10.5 5.2
Lateral intermediate 1584=8.7 1674=10.7 5.7
Vertical limb of 0.86mm 77.64=13.2 8334423 7.4
diagonal band
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Table.2.7. Continued
Region Bregma [ HjDPCPX Specific Binding % Change in 
co-ordinates binding
Wild-type Homozygous
(+/+) (-/-) (-/-)
Corpus callosum 0.86mm 10146.5 10742.6 5.9
Ventral pallidum 0.14mm 12144.7 13044.4 7.4
Globus pallidus -0.10mm 11442.7 12444.3 8.8
Thalamus -1.70mm 18044.3 20346.9 12.8
Lateroposterior 23248.9 25846.2 11.2
nucleus
Ventroposterior 14548.2 17945.7 233
nucleus
Amygdala -1.70mm
Basolateral 19547.5 22043.0 128
Hypothalamus -1.70mm 66.742.7 79.243.1 18.7
Hippocampus -2.46mm
Stratum oriens 282411.8 31545.7 11.7
Stratum radiatum 195411.8 22046.6 128
Stratum moleculare 217413.3 28744.1 323
Dentate gyrus -2.46mm 191413.4 20149.5 5.2
Medial mammillary -2.80mm 137413.6 12949.5 -5.8
nucleus
Periaqueductal grey -3.40mm 96.842.4 10145.4 4.3
Substantia nigra -3.40mm 17044.5 15947.1 -6.5
Subiculum -3.40mm 248410.3 256413.7 3.2
Interpednuclear -3.40mm 10746.4 115411.0 7.5
nucleus
Superficial grey layer -3.40mm 181411.8 17446.1 -3.9
of superior colliculus
Presubiculum -4.04mm 20249.6 20248.7 0.0
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Table 2.7. The mean specific binding (n=5) of [^HjDPCPX (fmol/mg) ± S.E.M. in 
brain regions of wild type (+/+) and homozygous (-/-) enkephalin knockout mice. 
Measures in the regions were carried out at the Bregma co-ordinates taken from the 
mouse atlas of Franklin and Paxinos (1997). Regional determinates were made from 
both left and right sides of the sections, which were cut 300 pm apart. The labelling 
was carried out on sections from +/+ and -/- mice in a completely paired protocol. 
Specific binding was >80 % in all regions. Comparison of genotypes was statistically 
significant (P<0.001, ANOVA). The percentage (%) change in binding represents the 
change in binding levels in -/- brains compared to +/+. A minus sign indicates a 
percentage decrease in binding levels. The overall mean and median percentage 
changes across regions was 3.5 % and 3.6% respectively.
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Figure 2.11. Regression analysis of percentage changes in [^H]DPCPX binding in 
regions of the brains of homozygous (-/-) enkephalin knockout mice versus 
percentage changes in p and ô opioid receptor expression in regions of the same
animals
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Figure 2.11. Graph showing regression analysis of percentage change (%) in 
[^HJDPCPX binding to adenosine Ai receptors in regions of enkephalin knockout 
mice brains versus a) percentage change (%) in p receptor binding in regions of 
enkephalin knockout mice brains and b) percentage change (%) in 8 receptor binding 
in regions of enkephalin knockout mice brains. Correlation coefficients, r, and number 
of regions are shown for each comparison. There was a significant correlation 
between changes in p opioid receptor binding and % change in [^HJDPCPX binding 
in homozygous (-/-) enkephalin knockout mice. The data for % change in p and 8 
binding in enkephalin knockout mice compared to wild type were taken from Brady et 
g/. (1996).
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2.3.3.2. Â2A adenosine receptor autoradiography
The qualitative distribution of A2A adenosine receptors labelled with [^H]CGS21680 
in coronal sections of brains of the species of wild type mice used in this study 
(Figure 2.12) was similar to the one used in the previous one (Figure 2.6) (section 
2.3.1.3). The qualitative distribution of A%A receptors in mutant mice was identical to 
the one observed in wild type animals (Table 2.8). Two-way ANOVA demonstrated 
that there was no significant difference in the levels of A%A adenosine receptor 
expression between genotypes (P>0.05). The interanimal variation, as reflected in 
standard error of the mean (S.E.M) values, for each individual region of each 
genotype was for the majority of the regions less than 10 % of the mean specific 
binding values for each region of each genotype (n=5).
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Figure 2.12. Computer enhanced autoradiograms of coronal brain sections from wild 
type (+/+) and homozygous (-/-) enkephalin knockout mice. The sections shown are 
from the level of the caudate (Bregma 1.10 mm) and the globus pallidus (Bregma -  
0.22 mm). A2A receptors were labelled with [^H]CGS21680. The far right panel shows 
the non-specific binding images (NSB). The colour bar shows pseudo-colour 
interpretation of relative density of black and white film image calibrated in finol/mg 
tissue. Sections from +/+ and -/- brains were processed in parallel.
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Table.2.8. Quantitative autoradiography of adenosine receptors
in the brains of wild type (+/+)and homozygous (-/-)
enkephalin knockout mice
Region Bregma [^H]CGS-21680 % Change in
co-ordina Specific Binding binding
Wild-type Homozygous
(+/+) (-/-) (-/-)
Nucleus accumbens 1.34mm
Shell 63.9±8.7 70.7±7.3 10.9
Core 70.5±9.3 63.9±5.0 -9.4
Olfactory tubercule 138±12.2 140±12.2 1.5
Caudate-putamen 1.10mm 148±19.6 159±14.7 7.4
Globus pallidus -0.10mm 41.5±8.3 47.1±8.9 13.5
The mean specific binding (n=5) of [^H]CGS21680 (fmol/mg) ± S.E.M. in brain 
regions of wild type (+/+) and homozygous (-/-) enkephalin knockout mice. Measures 
in the regions were carried out at the Bregma co-ordinates taken from the mouse atlas 
of Franklin and Paxinos (1997). Regional determinates were made from both left and 
right sides of the sections, which were cut 300 pm apart. The labelling was carried out 
on sections from +/+ and -/- mice in a completely paired protocol. Specific binding 
was >80 % in all regions. Comparison of genotypes was not statistically significant 
(P>0.05, ANOVA). The percentage (%) change in binding represents the change in 
binding levels in -/- brains compared to +/+. A minus sign indicates a percentage 
decrease in binding levels. The overall mean and median percent changes across 
regions was 4.8 % and 7.4 % respectively.
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2.3.3.3. NBTI-sensitive adenosine transporter autoradiography
The qualitative and quantitative distribution of NBTI-sensitive adenosine transporters 
labelled with [^HJNBTI (4.5 nM) in coronal sections of brains of the species of wild 
type mice used in this study (Figure 2.13), was similar to the one used in the previous 
one (section 2.3.1.4). The qualitative distribution of NBTI-sensitive adenosine 
transporters in mutant mice was identical to the one observed in wild type animals 
(Table 2.9). Two-way ANOVA demonstrated a significant quantitative difference 
(P<0.01) in the levels of [^HJNBTI binding between genotypes (Table.2.9). In the 
homozygous brain there was an upregulation of the NBTI-sensitive adenosine 
transporter sites in 38 out of the 47 regions analysed. A large increase (15-40 %) was 
observed especially in the thalamus, thalamic nuclei, medial septum, vertical limb of 
diagonal band, habenula, hippocampus and in some cortical regions. Regression 
analysis carried out to determine if there was a relationship between the levels of 
expression of p receptors or 6 receptors in regions of wild type brains and the 
percentage (%) change in NBTI-sensitive adenosine transporters in regions of mutant 
brains compared to wild type, revealed no significant correlation (r=0.3, n=15, P>0.05 
for p vs % NBTI-sensitive adenosine transporters, r=0.04, n=15, P>0.05 for ô vs % 
NBTI-sensitive adenosine transporters). Regression analysis carried out to determine 
if there was a relationship between the change in NBTI-sensitive adenosine 
transporter binding in regions of enkephalin knockout mice with the changes in p or 5 
receptor binding observed in regions of the same animals by Brady et al. (1999) 
revealed no significant correlation (r=0.13, n=15, P>0.05 for % p vs % NBTI- 
sensitive adenosine transporters; r=0.08, n=15, P>0.05 for % ô vs % NBTI-sensitive
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adenosine transporters).
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Figure 2.13. Computer enhanced autoradiograms of coronal brain sections from wild 
type (+/+) and homozygous (-/-) enkephalin knockout mice. The sections shown are 
from the level of the caudate (Bregma 1.10 mm), the hippocampus (Bregma -1.70 
mm) and the periaqueductal grey (Bregma -3.40 mm). NBTI-sensitive adenosine 
transporters were labelled with [^HJNBTI (4.5 nM). The far right panel shows the 
non-specific binding images (NSB). The colour bar shows pseudo-colour 
interpretation of relative density of black and white film image calibrated in frnol/mg 
tissue. Sections from +/+ and -/- brains were processed in parallel.
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Table.2.9. Quantitative autoradiography of NBTI sensitive adenosine transporters
in the brains of wild type (+/+)and homozygous (-/-)
enkephalin knockout mice
Region Bregma [^HjNBTI Specific Binding % Change
co-ordinates binding
Wild-type Homozygous
(+/+) (-/-) (-/-)
Olfactory bulb 4.28mm
Ext. plexiform layer 42.8±5.1 52.4±9.1 22.4
Glomerular layer 123±9.0 125±15.6 1.6
Granule layer 49±5.0 52±6.8 6.6
Anterior olfactory 3.20mm 78.6±4.4 76.4±8.9 -2.8
nucleus
Cortex
Motor 2.46mm
Superficial layers 45.5±2.5 45.1±4.7 -0.9
Deep layers 55.7±3.5 62.1±4.5 11.5
Pre-limbic 2.46mm 137±16.0 128±8.9 -6.6
Rostral somatosensory 1.10mm
Superficial layers 40.7±4.4 46.1±5.4 13.3
Deep layers 60.4±4.2 67.9±6.1 12.4
Cingulate 1.10mm
Superficial layers 50.1±3.4 58.3±8.6 16.4
Deep layers 51.0±4.1 59.5±16.5 16.7
Auditory -2.80mm
Superficial layers 69.2±5.1 72.6±8.3 4.9
Deep layers 83.5±3.7 89.6±4.9 7.3
Visual -2.80mm
Superficial layers 43.6±5.4 46.7±5.2 7.1
Deep layers 59.8±3.3 62.0±4.4 3.7
Retrosplenial -2.80mm
Superficial layers 44.6±2.9 55.5±5.9 24.4
Deep layers 48.3±3.0 53.0d=3.8 9.7
Nucleus accumbens 1.34mm 133±5.1 142±7.4 6.8
Caudate-putamen 1.10mm 133±5.8 1333=7.0 0
Septum 0.86mm
Medial 208±10.4 250±24.4 20.2
Lateral - 97.8±9.8 1013=8.9 3.5
Vertical limb of 0.86mm 225±5.1 2663:11.1 18.2
diagonal band
Globus pallidus -0.10mm 144±6.8 1493=6.1 2.8
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Region Bregma rHJNBTI 
co-ordinates
Specific Binding % Change ii
binding
Wild-type
(+/+)
Homozygous
(-/-) (-/-)
Thalamus -1.70mm 1593=11.3 1893=8.9 18.9
Thalamic nuclei -1.70mm
Central lateral 2163=11.5 2513=8.9 16.2
Central medial 2993:21.1 3383=12.8 13
Ventral posterolateral 1003=11.9 1033=8.2 3
Ventral posteromedial 98.73=6.4 1123=6.3 13.5
Reuniens 3123=24.2 3753=34.1 20.2
Reticular 1033=17.2 1203=14.7 16.5
Amygdala -1.70mm 83.93=5.1 85.23=4.5 1.6
Hypothalamus -1.70mm 2233=12.8 23 83=16.0 6.7
Hypothalamic nuclei -1.70mm
Dorsomedial 2513=20.1 2703=18.4 7.6
Ventromedial 2673=24.0 2453=32.8 -8.2
Habenula -1.70mm 3843=18.9 4553=14.9 18.5
Caudal somatosensory -1.7mm
Superficial layers 44.73=2.4 51.03=3.9 14.1
Deep layers 65.23=3.7 68.13=4.1 4.5
Hippocampus -2.46mm
Stratum oriens 32.23=4.7 32.13=4.3 -0.3
Stratum radiatum 20.03=4.0 32.73=4.6 63.5
Stratum molecular 61.03=3.2 71.73=2.8 17.5
Dentate gyrus -2.46mm 73.93=5.5 77.23=10.1 4.5
Medial mammillary -2.80mm 2513=24.2 2893=20.2 15.1
nucleus
Periaqueductal grey -3.40mm 2833=11.3 2653=9.1 6.4
Substantia nigra -3.40mm 3253=12.4 2993=20.2 -8
Superficial grey layer -3.40mm 2193=14.0 2043=18.8 -6.9
of superior colliculus
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Table 2.9. The mean specific binding (n=5) of [^HJNBTI (fmol/mg) ± S.E.M. in brain 
regions of wild type (+/+) and homozygous (-/-) enkephalin knockout mice. Measures 
in the regions were carried out at the bregma co-ordinates taken from the mouse atlas 
of Franklin and Paxinos (1997). Regional determinates were made from both left and 
right sides of the sections, which were cut 300 pm apart. The labelling was carried out 
on sections from +/+ and -/- mice in a completely paired protocol. Specific binding 
was >80% in all regions. Comparison of genotypes was statistically significant 
(P<0.001, ANOVA). The percentage (%) change in binding represents the change in 
binding levels in -/- brains compared to +/+. A minus sign indicates a percentage 
decrease in binding levels. The overall mean and median percentage changes across 
regions was 9.7 % and 7.3 % respectively.
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2.4 Discussion
[^HJDPCPX, [^H]CGS21680 and [^HJNBTI were chosen to label selectively A] 
receptors, A2 A receptors and NBTI-sensitive adenosine transporters not only because 
of their receptor or transporter specificity (140-150,000 fold), (Verma & Marangos, 
1985; Lohse et al, 1987; Jarvis et al, 1989) but also because all three ligands have 
extremely low non-specific binding. In wild type mice the qualitative pattern of Ai, 
A2A receptors and NBTI-sensitive transporters was similar to the studies that have 
been reported by other groups in rat or mouse brain and spinal cord (Lewis et al, 
1981; Geiger et al, 1984a; Geiger & Nagy, 1984b; Geiger & Nagy, 1985; Lee & 
Reddington, 1986; Fastbom et al, 1987; Weber et al, 1988; Jarvis et al, 1989; 
Johansson et al, 1993; Ekonomou et al, 2000; Snell et al, 2000).
The significant decrease and increase in [^HjDPCPX in p knockout and enkephalin 
knockout mice brains respectively, clearly suggests an interaction between opioid and 
adenosine systems which is in agreement with a large body of evidence indicating the 
involvement of adenosine in a number of functional opioid effects including 
antinociception and the expression of tolerance and dependence. In p opioid receptor 
knockout mice, the nucleus accumbens shell and the basolateral amygdala, which 
have high levels of p receptor expression in wild type animals, were the regions 
which showed the greatest downregulation of Ai binding (16-20%). These decreases 
in binding correlated significantly with the levels of p receptor expression in wild 
type animals suggesting that where p receptors were in abundance there were 
decrements in Ai receptor binding following the loss of these p receptors, implying 
the existence of a p-Ai receptor functional interaction in the brain. This supports the
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assertion that has been made by Aley and Levine (1997) that there is a p, 
tt2 , Ai physical receptor complex mediating antinociception in the periphery. 
Furthermore, it has been suggested that p-Ai interactions could take place at the level 
of the second messenger (G, or Go proteins) as both receptors share a common second 
messenger pathway in the induction of tolerance and withdrawal (Aley et al, 1997; 
Schlicker & Gothert, 1998). It is also worthy of note that 6-opioid receptors are down- 
regulated in p-knockout mice, especially in regions where p receptors are normally 
highly expressed (Kitchen et al, 1997) and 6 receptors have also been implicated in 
regulation of adenosine release (Cahill et al, 1996).
A reduction of adenosine release which might result from the lack of p opioid 
receptor stimulation in -/- mice brains seems unlikely to be the mechanism by which 
A] receptor number is decreased in -/- brains. A reduction in adenosine release would 
most probably lead to an upregulation of Ai receptors, as opposed to the observed 
downregulation. In support of this, it has been shown that adenosine Ai receptors were 
downregulated following prolonged incubation of adipocytes with an Ai receptor 
agonist R-PIA, whereas an upregulation of brain Ai receptors was observed in 
chronically caffeine-treated animals (Fredholm, 1982; Boulenger et al, 1983; Wu & 
Coffin, 1984; Green, 1987). It is more likely that the lack of stimulation of p opioid 
receptors in the knockout mice is the direct cause of the changes in Ai receptors, and 
this is supported by the opposite upregulation in Ai receptors which has been reported 
to occur after chronic morphine treatment (Ahlijanian et al, 1986; Kaplan et al, 
1994).
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As far as the results from the enkephalin knockout mice are concerned, the thalamus 
and hypothalamus, which are areas of high density of enkephalin positive nerve 
terminals (Khachaturian et al, 1985; McLean et al, 1985; Fallon & Leslie, 1986), 
were the regions which showed the greatest upregulation of Ai binding (10-20%) in 
enkephalin knockout mice. These increases in binding correlated significantly with 
the increases in p receptor binding observed in enkephalin knockout mice by Brady et 
al (1999), suggesting that where there were increments of p binding there were 
increments in Ai receptors as well. That implies the existence of a p-Ai receptor 
functional interaction in the brain and supports the data obtained from the p opioid 
receptor knockout mice.
As far as changes in A2A receptor numbers in p opioid receptor and enkephalin 
knockout mice brains are concerned, no significant overall changes were observed 
which also accords with a study that failed to find changes in A2 A receptor binding in 
brains of chronically morphine-treated mice (Kaplan et al, 1994). Although one study 
has suggested an upregulation of A2A receptors in chronically morphine-treated rats 
(White et al, 1995), the current study suggests that A2A-P receptor interactions are not 
relevant in the mouse. Moreover, it would be worthwhile mentioning that no binding 
of A2A receptors was observed in the spinal cord of wild type or knockout mice. This 
is in agreement with a study that showed no significant expression of the A2A receptor 
gene in the rat spinal cord (Kaelin-Lang et al, 1999).
The overall significant downregulation of NBTI-sensitive adenosine transporters in 
brains of p knockout mice is consistent with the study by Kaplan and Leite-Morris 
(1997) that showed upregulation of NBTI-sensitive adenosine transporter binding
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sites in the striatum and hypothalamus of opioid tolerant mice. The decrease in NBTI 
binding could be due to the reduction of p receptors (Gj, Go coupled) in mutant brains 
which would lead to an increased activation of adenylate cyclase (and an expected 
increase of cAMP) and an increased activation of protein kinase A pathway. 
Activation of the cAMP pathway was demonstrated to result in a significant reduction 
of NBTI-sensitive adenosine transporter in Neuro-2A neuroblastoma and chromaffin 
cells (Sen et al, 1998; Sen et al, 1999). However, the lack of significant correlation 
between levels of expression of p receptors in regions of +/+ brains and % change of 
NBTI-sensitive transporters in regions of knockout brains implies that their 
interaction is more complex and that other factors linked to p opioid receptor function 
could be involved in the regulation of NBTI-sensitive adenosine transporters.
In contrast with p knockout brains, an overall significant upregulation of NBTI- 
sensitive adenosine transporters was observed in enkephalin knockout mice which is 
consistent with the study by Kaplan and Leite Morris (1997) in morphine tolerant 
mice. The increase in NBTI binding could be due to the upregulation of p and 5 
opioid (Brady et al, 1999) and Ai adenosine receptors (all G\, Go coupled) observed 
in mutant brains. That would lead to a decreased activation of adenylate cyclase (and 
expected decrease of cAMP) and decreased activation of the protein kinase A 
pathway. That would eventually lead, as discussed above, to an attenuated reduction 
of NBTI sensitive adenosine transporters (as activation of adenylate cyclase decreases 
NBTI-sensitive adenosine transporter numbers), thus [^HJNBTI upregulation. The 
lack of significant correlation between % change in p and 6 binding in enkephalin 
knockout mice as observed by Brady et al (1999) and % change in Ai binding 
implies again that their interaction is more complex.
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The changes observed in both Ai receptor and NBTI-sensitive adenosine transporter 
binding observed in both p receptor and enkephalin knockout mice are more likely to 
be due to changes in receptor or transporter number than to changes in affinity. 
Although the use of a single concentration of radioligand does not allow 
discrimination between a change in receptor number or a change in receptor affinity, 
homogenate binding carried out by several groups in chronically morphine-treated 
mice and rats did not find any change in affinity for either A\ receptors or NBTI- 
sensitive adenosine transporters whilst the Bmax had changed significantly (Tao et al, 
1992; Tao et al, 1995; Kaplan et al, 1997). In addition, homogenate binding carried 
out in 6 knockout mice (Filliol et al, 2000) found no change in affinity for either p 
and K receptor ligands. The same was true for p and k  knockouts (Matthes et al, 
1996; Simonin et al, 1998). As a result, it is most likely that the changes observed in 
binding at a single ligand concentration reflect changes in receptor density rather than 
receptor affinity. Whether the small changes in receptor and transporter expression 
translate to biologically relevant effects remains to be determined, but it should be 
noted that in heterozygous p knockout mice the 50% loss of receptors correlates with 
a 6-fold loss of antinociception (Sora et al, 1999) and significant changes in opioid 
antinociception in A2A knockout mice were shown to correlate with changes of 
receptor expression which are less than 20% (See Chapter 4). It is also worth noting 
that the effects on the Ai receptor and NBTI-sensitive adenosine transporter are not 
related to gene dosage and in several structures the changes are as marked in 
heterozygous as well as homozygous mice. The lack of gene dosage on compensatory 
changes in receptors has been seen in ORLl knockout mice (Clarke et al, 2001) and
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it is thus evident that loss of 50% of receptors can be as disruptive to the animal as 
complete deletion of the gene.
In contrast with the brain, no significant changes in Ai receptor and NBTI-sensitive 
adenosine transporter numbers were observed in the spinal cord of p opioid receptor 
knockout mice, suggesting a lack of interaction at the spinal level. This is unexpected 
considering the large body of evidence suggesting an interaction between opioids and 
adenosine in the spinal cord (see General Introduction). However, Tao et al. (1992; 
1995; 1996) showed that chronic systemic or intracerebroventricular morphine 
administration decreased spinal A% receptors whereas chronic intrathecal morphine 
administration did not. This was suggested to be due to the fact that spinal and 
supraspinal morphine, releases adenosine by different mechanisms, such as activation 
of opioid receptors causing Ca'^ ’*' entry, or as the result of spinal release of 5HT 
respectively.
In conclusion, deletion of the p opioid receptor or the pre-proenkephalin gene causes 
small decreases or increases in A\ receptors and NBTI-sensitive adenosine 
transporters respectively in the mouse brain. The biggest changes in Ai receptors in p 
knockout mice are observed in areas of high p expression in the brain, whereas in 
enkephalin knockout mice they are observed in areas where large increases in p 
receptors were found in these animals. The above results are supportive of an 
interaction between p and Ai receptors and therefore between opioid and adenosine 
systems which may be of functional importance.
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CHAPTER 3
Quantitative autoradiography of adenosine 
receptors in brains of chronic naltrexone-
treated mice
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3.1 INTRODUCTION
In addition to chronic morphine treatment and to deleting the genes for opioid 
receptors and ligands, another way of manipulating the opioid system is by chronic 
treatment with an opioid receptor antagonist such as naltrexone. Although naltrexone 
(Figure 3.1) is seen as a universal antagonist at opioid receptors, it has greater affinity 
for p than for ô receptors (Corbett et al, 1993) or greater antagonist “potency” at 
blocking agonist activity at p compared to Ô receptors (Takemori & Portoghese, 
19&0 .
Figure 3.1 Chemical structure of naltrexone.
HO
HO
Naltrexone is used clinically for the treatment of alcohol dependence (Volpicelli et 
al, 1992). It has been found to decrease the mean number of drinking days per week, 
the frequency of relapse and the desire to drink in alcohol-dependent patients 
(O'Malley et al, 1992; Volpicelli et al, 1992). Moreover it has been widely reported 
that naltrexone decreases alcohol drinking or alcohol self-administration in rodents 
and monkeys (Altshuler et al, 1980; Myers et al, 1986; Volpicelli et al, 1986;
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Stromberg et al, 1998; Holter & Spanagel, 1999) probably by blocking the activation 
of the opioid system which is thought to be important for the maintenance of alcohol- 
drinking behaviour. Apart from alcoholism, naltrexone has been suggested as a 
potential candidate for the treatment of opioid and cocaine addiction since it has been 
shown to decrease self-administration of opioids and cocaine in rats (Van Ree, 1996).
Many studies have demonstrated that treatment with chronic opioid antagonist (e.g 
naltrexone) produces an increase in the density of opioid receptors, particularly of the 
p but also of the ô-subtype in the brain (Tempel et al, 1985; Yobum et al, 1986; 
Yobum et al, 1988; Yobum et al, 1989; Cote et al, 1993; Unterwald et al, 1995; 
Yobum et al, 1995; Castelli et al, 1997; Duttaroy et al, 1999). Parallel in vivo and in 
vitro comparisons have revealed that the increase in receptors is closely correlated 
with increases in potency of various opioid agonists. Moreover, the coupling of these 
up-regulated receptors to G-proteins may be altered as evidenced by an increased 
sensitivity of agonist binding to inhibition by guanyl nucleotides (Zukin et al, 1982; 
Tempel et al, 1985). Moreover, chronic naltrexone administration was shown to 
produce an increase in Met-enkephalin content in the striatum and nucleus accumbens 
(Tempel et al, 1984) and an increase in the levels of proenkephalin mRNA in the 
striatum, hippocampus and hypothalamus (Tempel et al, 1990). Decreases in p- 
endorphin immunoreactivity in the hypothalamus, thalamus and amygdala have been 
found following chronic opioid receptor antagonist administration (Ragavan et al, 
1983). Finally, in contradiction with the upregulation of p. opioid receptors, the p 
opioid receptor mRNA levels did not change following chronic naltrexone 
administration (Unterwald et al, 1995; Castelli et al, 1997).
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As it has been demonstrated that manipulation of the opioid system either by chronic 
morphine treatment (section 1.4.3.3) or by deletion of the genes encoding for opioid 
receptors or pre-proenkephalin (see Chapter 2) leads to changes in the adenosine 
system, it was hypothesized that chronic blockade of opioid receptors with an opioid 
antagonist would lead to alterations in adenosine receptor expression. Accordingly, 
quantitative autoradiography was carried out to examine if there were changes in p, 
Ai and A2A receptors in the brains of chronic naltrexone-treated mice.
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3.2 MATERIALS AND METHODS
3.2.1 Animals
Adult male mice (25-30 gr) of the strain C57BL/6 were used for this study. They were 
purchased from Charles River (Margate, UK) and housed in groups in a temperature- 
controlled room with a 12h light/dark schedule. Food and water were available ad 
libitum.
3.2.2 Minipump implantation and preparation
After an adjustment period in the University of Surrey animal unit, osmotic 
minipumps (Alzet, model 1007D, Charles River Margate, UK) were implanted 
subcutaneously in the dorsal mid-line position under ether (Merck eurolab, Briare Le 
Canal, France) anaesthesia. Prior to surgical implantation, the minipumps were filled 
either with sterile 0.9% saline (Phoenix Pharma Ltd, Gloucester, UK) or with 
approximately 20 mg/ml naltrexone (Sigma-Aldrich, Dorset, U.K) dissolved in sterile 
0.9% saline. Their contents were delivered at a constant rate of 0.5 pl/h resulting in a 
dose of naltrexone of 8 mg/kg/day.
Mice were anaesthetised by placing them in a chamber containing ether for 5 min. A 
10 mm incision was made along the dorsal midline and a subcutaneous pocket was 
formed with surgical scissors. The minipumps were implanted in such a way that the 
drug ejection point was always pointing towards the direction of the tail. Michelle 
clips were used to suture the opening and the mice were immediately placed into new
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cages to acclimatise as before. Seven days after the pumps were implanted, mice were 
killed by decapitation and the intact brains were removed immediately and rapidly 
frozen in isopentane at -20°C. Brains were stored at -80°C for a maximum period of 1 
month until sectioning.
3.2.3 Receptor autoradiography
Both chronic saline and naltrexone-treated brains were sectioned as described earlier 
(section 2.2.3). Binding of p opioid receptors with [^HJDAMGO, Ai adenosine 
receptors with [^HJDPCPX and A2A adenosine receptors with [^H]CGS21680 was 
carried out on the above brain sections. Receptor binding, autoradiographic film 
preparation, development and analysis were carried out as described in Chapter 2 
(sections 2.2.S-2.2.9). The mean and standard error of the mean for each ligand 
binding density (fmol of radioligand bound/mg of tissue) was calculated in each 
region for each treatment group. The percentage changes in binding levels from 
chronic saline-treated to chronic naltrexone-treated brains were determined. 
Comparison of quantitative measures of autoradiographic binding for each ligand in 
brains of chronic saline and naltrexone-treated animals was carried out using two-way 
ANOVA (for factors region and treatment).
Moreover, to determine if there was an association between regions where changes in 
Ai receptor binding in chronic naltrexone-treated mice were observed, and regions of 
high p-receptor expression in saline-treated animals, a correlation analysis was carried 
out for all regions where p receptors are co-expressed with A% receptors. Correlation 
analysis was also carried out between changes in A% receptor binding in regions of
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chronic naltrexone-treated mice and changes in p receptor binding in regions of the 
same animals. Finally, to determine if there was a correlation between regions where 
changes in Ai receptor binding in chronic naltrexone-treated mice brains were 
observed and regions where changes in A% receptor binding in homozygous p opioid 
receptor knockout mice brains were observed (see chapter 2, section 2.3.1.2), a 
regression analysis was carried out for all regions where Ai receptors are expressed.
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3.3 RESULTS
3.3.1 p opioid receptor autoradiography
p-opioid receptors labelled with [^HJDAMGO were widely expressed throughout the 
brains of saline-treated mice (Figure 3.2). The greatest level of p receptor binding 
throughout the brain (>200 finol/mg tissue) was observed in the medial habenula 
nucleus. High levels of [^HJDAMGO binding (100-200 finol/mg tissue) were detected 
in the nucleus accumbens, the basolateral amygdala and the superficial grey area of 
the superior colliculus. Other regions demonstrating moderate levels of [^HJDAMGO 
binding (50-100 finol/mg tissue) included the caudate-putamen, the endopiriform 
nucleus, the medial septum, the bed nucleus of stria terminalis, the preoptic area, the 
thalamus, the zona incerta, the medial amygdala, the hypothalamus, the 
periaqueductal grey, the substantia nigra and the intermediate grey layer of the 
superior colliculus. Lower levels of [^HJDAMGO labelling were detected in layers of 
the olfactory bulb, the lateral septum, the vertical limb of the diagonal band, the 
basomedial amygdala, the hippocampus and in all cortical regions including the 
superficial layers of the visual cortex which exhibited the lowest binding of all regions 
analysed (Table 3.1).
The pattern of distribution of p receptors was identical in chronic naltrexone-treated 
compared to chronic saline-treated mice brains. However, notable quantitative 
changes in specific binding were detected between treatment groups. All regions 
analysed showed an up-regulation in p receptor expression in naltrexone-treated mice 
(P<0.001, ANOVA) (Table 3.1). Increases in [^H]DAMGO binding ranged from 10%
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in the nucleus accumbens shell up to 129% in the preoptic area. Other regions of the 
naltrexone-treated brains that demonstrated a large increase in p receptor binding 
were the vertical limb of the diagonal band (125.7%) the basomedial amygdala 
(104.8%), the zona incerta (94%) and the hypothalamus (91.3%). The mean and 
median percentage increase in [^H]DAMGO binding was 49% and 37.3% respectively 
(Table 3.1).
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Figure 3.2. Computer enhanced autoradiograms of adjacent coronal brain sections 
showing p receptor binding in the brains of chronic saline- and naltrexone-treated 
mice, p opioid receptors were labelled with [^HjDAMGO (4nM) and non-specific 
binding images (NSB), shown in the far right column, were determined in the 
presence of unlabelled naloxone (IpM). The sections were taken from the level of the 
caudate (Bregma 1.10mm), the thalamus (Bregma -1.70mm) and the level of the 
periaqueductal grey (Bregma -2.80mm). The colour bar represents a pseudo-colour 
interpretation of relative black and white film images in finol/mg tissue equivalent. 
Sections cut from chronic saline- and naltrexone-treated brains were processed in 
parallel.
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Table. 3.1. Quantitative autoradiography of p-opioid receptors in the brains of
chronic saline and naltrexone treated mice
Region Bregma
co-ordinates
rH]DAMGO Specific 
Binding (fmol/mg)
% Change 
in binding
Saline Naltrexone
Olfactory bulb 4.28mm
Ext. plexiform layer 29.75=1.8 34.05=3.7 14.5
Granule layer 23.95=1.9 35.95=2.9 50.2
Cortex
Motor 2.46mm ’
Superficial layers 22.15=3.2 29.45=2.8 32
Deep layers 38.15=3.0 49.15=3.1 28.9
Orbital 2.46mm
Superficial layers 44.6=t5.7 63.75=4.3 428
Deep layers 41.8=t3.0 57.4=1=3.2 37.3
Rostral somatosensory 1.10mm
Superficial layers 19.45=3.7 26.0=t2.5 34
Deep layers 34.25=3.9 44.4±2.3 2&8
Cingulate 1.10mm
Superficial layers 29.85=4.1 32.25=4.3 8
Deep layers 40.35=5.6 51.55=4.7 27.8
Auditory -2.80mm
Superficial layers 24.55=3.2 32.55=4.6 32J
Deep layers 39.05=4.6 55.55=4.0 42.3
Visual -2.80mm
Superficial layers 17.65=3.9 22.55=2.1 27.8
Deep layers 25.2=t4.6 38.7±1.2 53.6
Retrosplenial -2.80mm
Superficial layers 22.55=2.9 34.15=2.0 51.6
Deep layers 26.35=1.4 37.U3.3 41.1
Nucleus accumbens 1.34mm
Shell 1115=5.7 1225=13.1 10
Core 1145=8.6 1505=13.4 31.6
Caudate-putamen 1.10mm 79.35=16.2 93.95=9.8 18.4
Endopiriform nucleus 1.10mm 81.65=6.2 1025=8.7 25
Septum 0.86mm
Medial 58.0=1=6.6 94.65=8.1 63.1
Lateral 43.15=6.9 54.55=7.0 26.5
Vertical limb of 0.86mm 44.35=7.3 1005=5.6 125.7
diagonal band
Bed nucleus of stria -0.22mm 84.95=4.7 1355=19.8 59
terminalis
Preoptic area -0.22mm 55.05=4.2 1265=15.3 129
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Table. 3.1. Continued
Region Bregma
co-ordinates
[^H)DAMGO Specific 
Binding (fmol/mg)
% Change 
in binding
Saline Naltrexone
Medial habenula nucleus -1.70mm 2035=43.8 265=t41.8 30.5
Thalamus -1.70mm 63.05=5.3 97.2=bl5.2 54.3
Zona incerta 
Amygdala
-1.70mm
-1.70mm
54.U10.7 1055=19.0 94
Basolateral 1095=7.7 1485=14.0 35^
Basomedial 49.85=3.9 1025=16.6 104.8
Medial 86.75=6.9 1485=21.9 70.7
Hypothalamus -1.70mm 59.65=4.9 1145=12.1 91.3
Hippocampus -2.46mm 20.85=2.0 28.55=3.5 37
Periaqueductal grey -3.40mm 72.55=7.2 1305=11.8 79J
Substantia nigra -3.40mm 63.55:11.9 1145=16.5 79.5
Superficial grey layer 
of superior colliculus
-3.40mm 1055=8.9 1445=9.6 37.1
Intermediate grey layer 
of superior colliculus
-3.40mm 91.65:8.3 1435=10.8 56.1
Table 3.1. The mean specific binding (n= 3-4) ± S.E.M of [ HJDAMGO (finol/mg) 
in brain regions of chronic saline and naltrexone-treated mice. Quantitative 
measurements were carried out in the regions of the brains at the Bregma co-ordinates 
taken from the mouse atlas of Franklin and Paxinos (1997). Regional determinations 
were made from both left and right sides of the sections that were 300 pm apart. The 
labelling was carried out on sections from saline and naltrexone-treated mice in a 
completely paired protocol. Specific binding was >95 % in regions of high binding. 
The percentage (%) change in binding represents the change in binding levels in the 
brains of chronic naltrexone-treated mice compared to those of saline-treated ones. 
There was a significant difference between treatment groups (P<0.001, ANOVA). 
The overall mean and median percentage changes across all regions were 49% and 
37.3% respectively.
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3.3.2 Al adenosine receptor autoradiography
The qualitative and quantitative distribution of Ai adenosine receptors labelled with 
[^HJDPCPX (3 nM) in coronal sections of brains of chronic saline-treated mice was 
similar to the previous study (sections 2.3.1.2 and 2.3.3.1). The pattern of distribution 
of Ai receptors was identical between chronic naltrexone- and saline-treated mice 
(Figure 3.3). However, small but significant quantitative changes in [^HJDPCPX 
binding were detected in brain regions of chronic naltrexone-treated mice compared to 
saline-treated animals.
Two-way ANOVA demonstrated a significant quantitative difference for the factor 
treatment (P<0.01) in the levels of [^HJDPCPX binding (Table 3.2). Although the 
median change for all regions was only 5.6 %, 75 % of the regions analysed in the 
naltrexone-treated mice showed an upregulation in A% expression. The greatest 
increase of A% sites (30-40 %) in chronic naltrexone-treated mice brains was found in 
areas of high p-opioid receptor expression (nucleus accumbens and superficial grey 
layer of superior colliculus) (Table 3.2). Regression analysis revealed a significant 
correlation (r=0.42, n=25, P<0.05) between increases in Ai receptor binding observed 
in regions of naltrexone-treated brains and regions of high p receptor expression in 
saline-treated brains (Figure 3.4a). This suggests that where p receptors were in 
abundance, there were increments in Ai receptor binding following chronic naltrexone 
treatment. As regions of big A% receptor decrease in homozygous (-/-) p opioid 
receptor knockout mice also correlated with regions of high p receptor expression in 
wild type animals (see chapter 2, section 2.3.1.2), it was investigated whether regions 
showing Ai receptor downregulation in homozygous (-/-) p opioid receptor knockout
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mice correlated with regions of upregulation of Ai receptors in chronic naltrexone- 
treated brains. The regression analysis revealed a significant correlation (r=0.43, 
n=25, P<0.05) (Figure. 3.4.b). Finally, regression analysis was carried out to 
determine if regions where increases in Ai receptor binding in chronic naltrexone- 
treated brains correlated with regions showing increases in p receptor binding in 
naltrexone-treated brains. The regression analysis didn’t reveal a significant 
correlation (r=0.05, n=25, P>0.05).
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Figure 3.3. Computer enhanced autoradiograms of adjacent coronal brain sections 
showing Ai receptor binding in the brains of chronic-saline and naltrexone-treated 
mice. Adenosine Ai receptors were labelled with [^HJDPCPX (3 nM) and non-specific 
binding images (NSB), shown in the far right colunrn, were determined in the 
presence of unlabelled CPA (1 pM). The sections were taken from the level of the 
caudate (Bregma 1.10 mm), the thalamus (Bregma -1.70 mm) and the level of the 
periaqueductal grey (Bregma -2.80 mm). The colour bar represents a pseudo-colour 
interpretation of relative black and white film images in finol/mg tissue equivalent. 
Sections cut from chronic saline- and naltrexone-treated brains were processed in 
parallel.
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Table. 3.2. Quantitative autoradiography of adenosine Aj receptors in the brains of
chronic saline and naltrexone treated mice
r3iRegion Bregma
co-ordinates
rHJDPCPX Specific
Binding (fmol/mg)
% Change 
in binding
Saline Naltrexone
Cortex
Motor 2.46mm
Superficial layers 1745=4.8 1675=7.1 -4.0
Deep layers 2025=8.3 1965=6.7 -3.0
Rostral somatosensory 1.10mm
Superficial layers 2715=24.3 2645=13.5 -2.6
Deep layers 2605=9.6 2635=11.4 1.1
Cingulate 1.10mm
Superficial layers 1625=7.3 1745=12.6 7.4
Deep layers 2055=6.4 2215=9.6 7.8
Caudal somatosensory -1.7mm
Superficial layers 2265=12.4 2375=12.2 4.9
Deep layers 2445=10.7 2615=13.6 7
Auditory -2.80mm
Superficial layers 2145=17.3 2245=15.8 4.7
Deep layers 2565=16.3 2575=14.8 0.4
Visual -2.80mm
Superficial layers 1955=7.9 2115=13.6 8.2
Deep layers 2335=13.1 2565=11.4 9.9
Reterosplenial -2.80mm
Superficial layers 1665=12.8 1805=15.2 8.5
Deep layers 2255=7.9 2395=9.2 6.2
Nucleus accumbens 1.34mm
Shell 1585=17.3 2265=23.0 43.0
Core 1765=5.5 2005=14.0 13.6
Caudate-putamen 1.10mm 2095=10.7 2105=13.4 0.5
Septum 0.86mm
Medial 88.35=3.1 116=tl7.4 31.3
Lateral dorsal 2065=10.7 2405=22.8 16.5
Lateral intermediate 1175=8.7 1505=14.8 28.2
Vertical limb of 0.86mm 71.95=5.8 96.85=13.9 34.6
diagonal band
Corpus callosum 0.86mm 1145=9.6 1285=14.4 12.3
Ventral pallidum 0.14mm 1725=6.3 1855=17.4 7.6
Globus pallidus -0.10mm 1795=10.3 1925=21.9 7.3
Thalamus -1.70mm 2685=12.7 2705=15.7 0.7
Lateroposterior nucleus 3045=10.9 3025=19.3 -0.7
Ventroposterior nucleus 2265=16.6 2135=15.1 -5.8
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Table. 3.2. Continued
Region Bregma
co-ordinates
[^HJDPCPX Specific 
Binding (fmol/mg)
% Change 
in binding
Saline Naltrexone
Amygdala -1.70mm
Basolateral 2195=8.7 2345=9.2 6.8
Hypothalamus -1.70mm 94.95=9.9 87.25=8.0 -8.1
Hippocampus -2.46mm
Stratum oriens 3915=17.7 4095=28.7 4.6
Stratum radiatum 4355=14.5 4725=30.0 8.5
Stratum moleculare 3085=8.7 3235=22.9 4.9
Dentate gyrus -2.46mm 2605=2.8 2645=11.0 1.5
Periaqueductal grey -3.40mm 1085=8.8 1115=0.5 2.8
Substantia nigra -3.40mm 1935=12.5 1785=14.3 -T8
Subiculum -3.40mm 2615=19.0 2625=5.4 0.4
Superficial grey layer -3.40mm 1385=18.5 1835=3.5 32.6
of superior colliculus
Presubiculum -4.04mm 2155=20.1 2255=12.6 4.7
Table 3.2. The mean specific binding (n= 3-4) ± S.E.M of [^HJDPCPX (fmol/mg) in 
brain regions of chronic saline and naltrexone-treated mice. Quantitative 
measurements were carried out in the regions of the brains at the Bregma co-ordinates 
taken from the mouse atlas of Franklin and Paxinos (1997). Regional determinations 
were made from both left and right sides of the sections which were cut 300 pm apart. 
The labelling was carried out on sections from saline- and naltrexone-treated mice in a 
completely paired protocol. Specific binding was >80 % in regions of high binding. 
The percentage (%) change in binding represents the change in binding levels in the 
brains of chronic naltrexone-treated mice compared to the brains of saline-treated 
animals. A minus sign indicates a percentage decrease in binding levels. There was a 
significant difference between treatment groups (P<0.01). The overall mean and 
median percentage changes across all regions were 7.8 % and 5.6 % respectively.
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Figure 3.4. Regression analysis of percentage changes in Ai binding in brain regions 
of naltrexone-treated mice versus p opioid receptor expression in brain regions of 
saline-treated animals and versus the percentage changes in Ai binding in regions of 
homozygous (-/-) p receptor knockout mice
r=0.42, n=25, P<0.0550n
25-
-25
0 25 50 75 100 125
p binding in regions of saline-treated 
mouse brain (fmol/mg)
5 0 i
r=0.43, n=25, P<0.05
T3
25-
V
-25
-30 -10-20 0 10
% Change Aj in regions of -/- p knockout 
mouse brain
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Figure 3.4. Graphs showing regression analysis of a) [^HJDAMGO binding to p 
opioid receptors (fmol/mg tissue) in regions of saline-treated mouse brain versus 
percentage change in [^H]DPCPX binding to Ai adenosine receptors in regions of 
chronic naltrexone-treated mice brains, b) percentage change in [^HJDPCPX binding 
to Ai adenosine receptors in regions of naltrexone-treated mice brains and percentage 
change in [^HJDPCPX binding in regions of homozygous (-/-) p opioid receptor 
knockout mice brains.
Correlation coefficients, r, and number of regions are shown for each comparison. 
There was a significant correlation between p opioid receptor expression in chronic 
saline-treated mice and % change in [^H]DPCPX binding in chronic naltrexone- 
treated mice (r=0.42, n=25, P<0.05). There was a significant correlation between % 
change in [^HJDPCPX binding in chronic naltrexone-treated mice and % change Ai 
adenosine receptor binding in homozygous (-/-) p opioid receptor knockout mice 
brains (r=43, n=25, P<0.05). Data for % change in regions of homozygous (-/-) p 
opioid receptor knockout mice brains were taken from chapter 2 (section 2.3.1.2).
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3.3.3 A2a adenosine receptor autoradiography
The qualitative and quantitative distribution of A2A adenosine receptors labelled with 
[^H]CGS21680 (10 nM) in coronal sections of brains of chronic saline-treated mice 
(Figure 3.5) was similar to the previous study (section 2.3.1.3). The qualitative 
distribution of A%A receptors in chronic naltrexone-treated mice was identical with 
that observed in chronic saline-treated animals (Table 3.3). Two-way ANOVA 
demonstrated that there were no significant differences in the levels of A2A receptor 
expression between treatment groups (P>0.05).
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Figure 3.5. Computer enhanced autoradiograms of adjacent coronal brain sections 
showing A2A receptor binding in the brains of chronic saline and naltrexone-treated 
mice. Adenosine A2A receptors were labelled with [^H]CGS21680 (10 nM) and non­
specific binding images (NSB), shown in the far right column, were determined in the 
presence of unlabelled NECA (20 pM). The sections were taken from the level of the 
caudate (Bregma 1.10 mm) and the level of the globus pallidus (Bregma -0.22 mm). 
The colour bar represents a pseudo-colour interpretation of relative black and white 
film images in frnol/mg tissue equivalent. Sections cut from chronic saline and 
naltrexone-treated brains were processed in parallel.
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Table. 3.3. Quantitative autoradiography of adenosine A2A receptors in the brains of
chronic saline and naltrexone treated mice
Region Bregma
co-ordinates
rH]CGS-21680 Specific 
Binding (fmol/mg)
% Change in 
binding
Saline Naltrexone
Nucleus accumbens 1.34mm
Shell 118±12.5 1345=13.1 13.6
Core 235±17.1 2185=14.8 -7.2
Caudate-putamen 1.10mm 3285=20.3 3195=19.8 -2.7
Olfactory tubercle 1.10mm 2435=23.9 2565=31.5 5.3
Globus pallidus -0.10mm 97.45=5.5 92.95=9.0 -4.6
Table 3.3. The mean specific binding (n= 3-4) ± S.E.M of [^H]CGS21680 (finol/mg) 
in brain regions of chronic saline and naltrexone-treated mice. Quantitative 
measurements were carried out in the regions of the brains at the Bregma co-ordinates 
taken from the mouse atlas of Franklin and Paxinos (1997). Regional determinations 
were made from both left and right sides of the sections, 300 pm apart. The labelling 
was carried out on sections from saline and naltrexone-treated mice in a completely 
paired protocol. Specific binding was >95 % in regions of high binding. The 
percentage (%) change in binding represents the change in binding levels in the brains 
of chronic naltrexone-treated mice compared to the brains of saline-treated mice. A 
minus sign indicates a percentage decrease in binding levels. There was no significant 
difference between treatment groups (P>0.05). The overall mean and median percent 
changes across all regions were 0.9 % and -2.7 % respectively.
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3.4 Discussion
[^H]DAMGO, [^H]DPCPX and [^H]CGS21680 were chosen to label selectively p, Ai 
and A2A receptors respectively not only because of their selectivity (Lohse et al, 
1987; Yeadon & Kitchen, 1988; Jarvis et al, 1989), but also because all three ligands 
have extremely low non-specific binding. They were also chosen for consistency with 
the other studies carried out in this thesis. In saline-treated mice the qualitative pattern 
of p. A] and A2A receptors was similar to the studies that have been reported by this 
and other groups in rat and mouse brains (Lewis et al, 1981; Lee & Reddington, 
1986; Fastbom et a l, 1987; Weber et a l, 1988; Jarvis et a l, 1989; Johansson et al, 
1993; Kitchen et al, 1997; Ekonomou et al, 2000; Snell et al, 2000). They were also 
similar to the studies described in chapter 2.
This is the first full quantitative mapping of p opioid receptor subtype in chronic 
naltrexone-treated mice. There is a clear upregulation of p opioid receptors in the 
brains of chronic naltrexone-treated mice in all regions analysed. This is in agreement 
with a large body of studies (mostly whole brain homogenates) which showed an 
increase in p receptor binding in mice and rats after chronic exposure to naltrexone 
(Zukin et a l, 1982; Tempel et al, 1984; Yobum et al, 1986; Danks et al, 1988; 
Yobum et al, 1988; Rothman et al, 1989; Yobum et a l, 1989; Cote et a l, 1993; 
Unterwald et al, 1995; Yobum et al, 1995; Castelli et al, 1997; Duttaroy et al, 
1999). The data suggest that chronic naltrexone exposure induces a general 
upregulation, although there were differences in the level of increase in p binding 
throughout regions. The preoptic area, the vertical limb of the diagonal band, the 
basolateral amygdala, the zona incerta, the hypothalamus, the periaqueductal grey and
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the substantia nigra showed a large increase (80-125 %) in p binding whereas the 
cingulate cortex, the nucleus accumbens and the caudate putamen showed relatively 
less upregulation (10-30 %). This is not in agreement with Diaz et al. who described 
large increases in [^HJDAMGO binding in the caudate putamen and the nucleus 
accumbens of rats (Diaz et al, 2002). There is indeed some disagreement in the 
literature about which areas are more sensitive than others to chronic naltrexone- 
induced p opioid receptor upregulation. Zukin et al. observed high increases in opioid 
receptors in the limbic system (Zukin et al, 1982) in contrast with other groups that 
found low increases in this precise area (Tempel et al, 1984; Morris et al, 1988). The 
reasons for these discrepancies could be differences in treatment protocol (pellets, 
minipump, injections, dose, exposure time) and differences in species. Indeed, a 
greater increase of p receptor density has been observed in animals which have been 
treated with a higher dose or longer exposure of opioid receptor antagonist suggesting 
that the upregulation is dependent on the proportion of occupancy of opioid receptors 
by the antagonist (Morris et al, 1988). Moreover, a great range of ligands, with 
different selectivity to opioid receptors, have been used in order to label the p 
receptors. The difference in selectivity of the ligands to the p receptors and the lack of 
good differentiation of some ligands between subtypes of opioid receptors could 
account for the discrepancies observed. In this study, however, [^HJDAMGO has been 
used to label p opioid receptors which is highly selective to p receptors and allows 
good differentiation from the other subtypes of opioid receptors.
The changes observed in p receptor binding in naltrexone-treated mice are most likely 
to represent changes in receptor number (Bmax) rather than changes in affinity (K d). 
Although, the use of a single concentration of radioligand does not allow
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discrimination between a change in receptor number or a change in affinity, 
homogenate binding carried out by several groups in chronic naltrexone-treated 
animals did not find any change in affinity for p opioid receptors whilst the Bmax had 
increased significantly (Yobum et al, 1989; Giordano et al, 1990; Cote et al, 1993; 
Unterwald et al, 1995; Yobum et al, 1995; Castelli et a l, 1997; Duttaroy et al, 
1999).
The mechanism of p opioid receptor upregulation induced by naltrexone has yet to be 
elucidated. Regulatory mechanisms other than control of transcription or mRNA 
stability are likely, since no change was observed in p opioid receptor mRNA levels 
following chronic naltrexone treatment (Unterwald et al, 1995; Castelli et a l, 1997; 
Duttaroy et al, 1999). Additionally, in cultures of mouse spinal cord ganglion 
explants, antagonist-induced opioid receptor up-regulation does not require the 
synthesis of new receptor molecules as cyclohexamide, a protein synthesis inhibitor, 
does not block receptor up-regulation (Tempel et al, 1985).
A possible mechanism by which naltrexone could produce p receptor upregulation is 
by inhibiting normal downregulation of p receptors, presumably by preventing the 
binding of endogenous opioids (Unterwald et al, 1995). Studies on opioid receptor 
trafficking have focused on opioid receptor down-regulation, endocytosis and 
sequestration induced by opioid receptor agonists. In neurons of the enteric nervous 
system and in cells transfected with the p opioid receptor, exposure to opioid receptor 
agonists produced rapid intemalisation of opioid receptors from cell surfaces to 
vesicle-like stmctures. The receptors were then redistributed throughout the 
cytoplasm and inside perinuclear vesicles (Keith et a l, 1996; Stemini et a l, 1996).
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These findings suggest that p opioid receptors are internalised by an endocytic 
pathway, which is similar to that of other G protein-coupled receptors (Stemini et al, 
1996). Blocking of this endogenous ligand-p opioid receptor interaction would thus 
block this intemalisation and recycling process.
Other mechanisms by which naltrexone could produce p receptor up-regulation have 
been suggested. As it has been shown that naltrexone decreases lysosomal enzyme 
activity in neuroblastoma hybrid cells (Belcheva et al, 1991), naltrexone induced up­
regulation might be due to a decrease in receptor degradation. Naltrexone may also 
enhance the coupling of p receptors to G proteins (Belcheva et al, 1991). Several 
lines of evidence support this mechanism. The sensitivity of opioid agonist binding to 
inhibition by guanyl nucleotides has been shown to be increased after naltrexone 
administration (Zukin et a l, 1982; Tempel et al, 1985). Moreover, Unterwald et al 
(1998) observed discrepancies between quantitative p opioid receptor 
immunoreactivity and quantitative p opioid receptor autoradiography in some regions; 
i.e. in some regions receptor binding was enhanced without change in 
immunoreactivity. This suggests an increase in the number of active receptors without 
a change in the total number of receptors. Whatever the underlying mechanism, the 
significant increase of p receptors in chronic naltrexone-treated mice brains found in 
this study clearly proves that the treatment was successful.
In addition to the upregulation of p receptor binding observed, quantitative 
autoradiography revealed a significant increase in A% receptor binding following 
chronic naltrexone treatment, where 75% of the brain regions analysed showed an 
upregulation. The observed change in Ai receptor binding is consistent with the large
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body of evidence indicating the involvement of adenosine in a number of functional 
opioid effects including antinociception and the expression of tolerance, dependence 
and withdeawal. Moreover, it is in agreement with studies that demonstrated changes 
in Ai receptor binding following the manipulation of the opioid system by chronic 
morphine treatment (Ahlijanian & Takemori, 1985), by removal of p opioid receptors 
or by removal of the pre-proenkephalin gene (Chapter 2).
The nucleus accumbens shell and the superficial grey layers of the superior colliculus, 
which have high levels of p receptor expression, showed the greatest upregulation of 
Ai binding (32-42 %). Overall the level of the regional increases in binding correlated 
significantly with the levels of high p receptor expression in saline-treated animals 
suggesting that where p receptors were in abundance, there were increments in Ai 
receptor binding following chronic naltrexone treatment. This is in accordance with 
the study described in chapter 2 (section 2.3.1.2) where the decreases in Ai binding in 
regions of p opioid receptor knockout mice brains correlated significantly with 
regions showing high p receptor expression in wild type animals (Figure 3.4.a). 
Indeed, areas showing increases in Ai binding in naltrexone-treated mice brains 
correlated significantly with the decreases in Ai binding in p receptor knockout mice 
brains (Figure 3.4.b). On the other hand, the regions where large increases in Ai 
binding were observed in chronic naltrexone-treated mice, did not correlate with the 
regions where large increases of p binding were observed. These data imply the 
existence of a p-Ai functional and/or structural interaction in the brain that is more 
prominent in areas where p receptors are normally highly expressed. However, this p- 
Ai interaction seems to be independent from the upregulation of p receptors in the 
brains of chronic-naltrexone treated mice.
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As with p opioid receptor upregulation induced by naltrexone, the mechanism 
involved in upregulation of Ai receptors following chronic naltrexone treatment can 
only be hypothesised. It is possible that naltrexone inhibits normal down-regulation of 
a p-Ai receptor complex by preventing the binding of endogenous opioids to p 
receptors. Another possibility is that the increase in Ai binding is the consequence of 
a naltrexone-induced decrease of lysosomal enzyme activity (Belcheva et al, 1991), 
which would decrease receptor degradation. However, this is unlikely because no 
change in A%A receptor binding occurred following chronic naltrexone treatment. 
Naltrexone may also enhance the coupling of Ai receptors or a p-Ai receptor complex 
to Gj/o proteins, thus increasing Ai binding. This is also unlikely, as the ligand used 
for labelling Ai receptors (DPCPX) was an antagonist which has been shown not to 
discriminate between coupled and uncoupled receptors.
Finally, a reduction of adenosine release which might result from the lack of or 
decrease in p and ô opioid receptor stimulation in chronic naltrexone-treated mice 
brains, might be the mechanism by which Ai receptor number is increased. A 
reduction in adenosine release would probably lead to an upregulation of Ai receptors 
as it has been shown that adenosine Ai receptors were downregulated following 
prolonged incubation of adipocytes with the Ai receptor agonist phenylisopropyl- 
adenosine (PIA) (Green, 1987). In addition, an upregulation of brain Ai receptors was 
observed in chronically caffeine-treated animals (Fredholm, 1982; Boulenger et al, 
1983; Wu & Coffin, 1984; Green, 1987). This is also consistent with the study 
described in chapter 2 where an upregulation of Ai receptors was observed in mice 
deficient in the pre-pro enkephalin gene.
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No significant overall changes were observed in A2A receptor numbers in chronic 
naltrexone-treated mice brains, which is in accordance with a study that failed to find 
changes in A2A receptor binding in brains of chronically morphine-treated mice 
(Kaplan et al, 1994). Moreover it is in agreement with the results fi*om chapter 2 
where no change in A2A receptor binding was observed in brains of mice deficient in 
the p opioid receptor gene and those deficient in the pre-proenkephalin gene (Chapter 
2, sections 2.3.1.3, 2.3.3.2). All these studies suggest that A2A-P receptor interactions 
are not relevant in the mouse brain.
In conclusion, chronic naltrexone treatment causes increases in p and A% receptor 
binding in the brains of mice. The largest increase in A% receptors is observed in areas 
of high p receptor expression, supporting an interaction between these two receptors 
and therefore between opioid and adenosine systems which may be of functional 
importance.
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CHAPTER 4
Changes in the opioid system in mice deficient 
in the A%A receptor gene
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4.1 INTRODUCTION
Two groups have reported the generation of A2 A adenosine receptor knockout mice of 
different strains (Ledent et al, 1997; Chen et al, 1999). The studies carried out in this 
thesis employed the A2A knockout animals generated by Catherine Ledenf s group in 
Brussels (Ledent et al, 1997). No gross anatomical deficits were evident in these 
animals and they bred normally. However, they had a bigger body weight than wild 
type (Ledent et al, 1997). A2 A knockout mice scored higher than wild type in anxiety 
tests and male mice carrying the knockout genotype were much more aggressive 
towards intruders. Blood pressure, heart rate and platelet aggregation were all 
increased in A2A receptor knockout mice, and the A2A receptor agonist CGS21880 lost 
all of its biological activity (Ledent et al, 1997). Furthermore, more recent studies 
showed a decrease in haloperidol (D2 dopamine receptor antagonist), SCH23390 (Di 
dopamine receptor antagonist) and pilocarpine (acetylcholine muscarinic receptor 
agonist) induced catalepsy in A2A receptor knockout mice compared to their wild type 
littermates, suggesting a role for A2A receptors in Di, D2 , and muscarinic receptor- 
mediated neurotransmission (El Yacoubi et al, 2001). Finally, an abolishment in the 
stimulatory effects of caffeine (El Yacoubi et al, 2000) and impairment in long-term 
potentiation in the nucleus accumbens (D'Alcantara et a l, 2001) was observed in the 
knockout mice.
There is evidence indicating that both acute and chronic effects of opioids are partly 
mediated by adenosine acting on A2A adenosine receptors in the CNS. Chronic 
exposure to morphine has been demonstrated to downregulate adenosine A2A 
receptors in the striatum of rats (De Montis, 1992). Moreover, more recent evidence
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suggests that A%A receptor selective agonists attenuate and antagonists exacerbate 
opioid withdrawal signs in the CNS of mice (Kaplan & Sears, 1996; Zarrindast et al,  
1999) and rats (Salem & Hope, 1997) suggesting a role of A2A receptors in the 
development of opioid withdrawal. A specific interaction has been suggested between 
A2A receptors and the ô opoid receptor subtype as DPDPE (a selective 6 receptor 
agonist) has been shown to inhibit the A2A receptor-mediated increase of DARPP-32 
(dopamine and cAMP regulated phosphoprotein) occurring in striatopallidal neurons 
(Lindskog et al,  1999). Moreover, nociceptin has been shown to block stress and to 
have anxiolytic like effects (Mogil et al,  1996; Jenck et al,  1997), whereas A2A 
receptor antagonists were shown to trigger anxiety like behaviour (Svenningsson et 
al,  1999). The involvement of the opioid-related peptide nociceptin in stress and 
anxiety behaviour combined with the modulatory role of A2A adenosine receptors in 
those behaviours have led to the suggestion of a possible interaction between ORLl 
and A2A receptors (Dassesse et al,  2000).
In addition to the brain, opioid-adenosine interactions have been reported in the spinal 
cord. Morphine was shown to enhance adenosine release from the spinal cord in vitro 
and in vivo (Sweeney et al,  1987; Sweeney et al,  1989; Cahill et al,  1995; Cahill et 
al,  1996). Although neither ô  or k  selective opioid receptor agonists seem to enhance 
adenosine release from spinal cord synaptosomes (Cahill et al,  1995), a synergistic 
interaction between p and ô  receptors in mediating adenosine release has been 
suggested (Cahill et al,  1996). Adenosine in turn activates Ai adenosine receptors in 
the spinal cord in order to suppress the transmission of nociceptive information 
(Sawynok et al,  1989). Apart from Ai receptors, A2A adenosine receptors have been 
suggested to be involved in the expression of opioid-mediated antinociception. An
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additive interaction between p-selective opioid receptor agonists and the A2A selective 
adenosine agonist, CGS21680 has been observed at the spinal level (DeLander & 
Keil, 1994). However, synergistic or multiplicative interactions have been observed 
between ô or k  selective opioid receptor agonists and CGS21680, suggesting a more 
complex functional interaction between those receptors (DeLander et a l, 1994).
The likelihood of the presence of opioid-A2A receptor interactions has been reinforced 
by the findings that mice deficient in the A2A receptor gene are hypoalgesic when 
tested in the hot plate and tail flick tests (Ledent et al, 1997). Moreover, in situ 
hybridisation experiments revealed a decrease of the opioid peptide precursor 
proenkephalin and of the substance P precursor protachykinin transcripts in the 
striatum of homozygous A2 A receptor knockout mice (Ledent et al, 1997). The results 
suggest the likelihood of alterations in pain processing in these mice and in the 
modulatory effects of the opioid systems.
To test the hypothesis that opioid systems are altered in the absence of the A2A 
receptor gene, quantitative autoradiography was carried out to examine if there are 
any changes in p, 5, k  and ORLl opioid receptors in brains and spinal cords of A2A 
adenosine receptor knockout mice. To investigate further the involvement of A2A 
adenosine receptors in modulating opioid effects, p, ô  and k  receptor-mediated 
antinociception was also investigated in these animals.
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4.2 MATERIALS AND METHODS
4.2.1 Generation of A z a  receptor knockout mice and experimental conditions
The mice deficient in the A2A receptor gene used in this study were generated by 
Catherine Ledent's group in Brussels (Belgium). The coding region of the mouse A2A 
receptor gene consists of two exons (Ei and E2) which are interrupted by a single 
intron at a position corresponding to the second intracellular loop of the receptor 
(Figure 4.1). The A2A receptor gene was inactivated in embryonic stem (ES) cells of 
129/Sv strain of mouse by replacement of part of exon 1 with a neomycin-resistant 
(neol) cassette (Figure 4.1). Neomycin resistant clones were screened by Southern blot 
analysis using A2A receptor and neo  ^gene fragments as probes. One of the clones was 
microinjected into pre-implantation blastocysts giving rise to chimeric offsprings. The 
chimeras were bred with wild type GDI mice to produce an FI generation consisting 
of wild type and heterozygous animals. The heterozygous mice were bred for four 
generations on a GDI background to produce wild type, heterozygous and 
homozygous A2A receptor knockout mice which were obtained with the expected 
Mendelian frequency. Wild type (+/+), heterozygous (+/-) and homozygous (-/-) A za 
receptor knockout mice were shipped over to the University of Surrey (U.K.) animal 
unit. Knockout and wild type mice from the same litters were bred from heterozygous 
mice and were genotyped by PGR at weaning.
Mice aged between 10-12 weeks were used in autoradiography and in vivo studies. 
Mice were housed in groups in a temperature-controlled room with a 12h light/dark 
schedule. Food and water were available ad libitum. For antinociception experiments
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animals were tested in the same building in which they were housed, between 2-5pm 
and were allowed to acclimatise to the testing room for at least 1 h before each 
experiment. All studies were carried out in accordance with protocols approved by the 
Home Office (Animal Act 1986) U.K.
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4.2.2 Opioid receptor autoradiography
4.2.2.1 Tissue preparation and sectioning
10-12 week old male wild type and A2A receptor knockout mice were killed by 
decapitation and intact brains and spinal cords were removed, frozen at -20°C and 
sectioned as described earlier (sections 2.2.2, 2.2.3),
4.2.2.2 Opioid receptor and A 2A receptor binding
Sections from brain or spinal cord of each wild type (+/+) and A2 A receptor knockout 
(-/-) mice were processed for binding using identical stock solutions. All slides were 
allowed to defrost for not less than 30 minutes prior to binding.
Binding of opioid receptors (p, 5, k  and ORLl) as well as binding of A2A adenosine 
receptors was carried out on brain and spinal cord sections taken from wild type and 
A2A receptor knockout mice. [^H] D-Ala^-MePhe'^-Gly-ol^ enkephalin (DAMGO), 
[^ H] D-Ala^deltorphin-I (deltorphin-I), [^ H] ((-)-A-Methyl-A-[7-( 1 -pyrrodinyl)-1 - 
oxospirol[4,5]dec-8-yl]-4-benzofliranacetamide (CI-977) and [^H] nociceptin were 
used for binding of p, 5, k  and ORLl opioid receptors respectively. The first three 
radioligands were made up in incubation buffer of 50 mM Tris-HCl, pH 7.4 at 25°C 
(Sigma-Aldrich, Dorset, U.K), at 4 nM, 7 nM and 2.5 nM concentrations respectively 
for determination of total and non-specific binding. The concentrations chosen were 
approximately three times the Kd for each ligand (Kitchen et al, 1997; Slowe et al, 
1999; Clarke et al, 2001). Naloxone was added to the incubation buffer containing
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the radioligands for determination of non-specific binding at 1 pM for [^HJDAMGO, 
[^H]CI-977 and 10 pM for [^H]deltorphin-I.
Tritiated and unlabelled nociceptin were made up in a methanol:HC1(50:50) solution 
diluted 1:64 in incubation buffer (50 mM Tris-HCl, 3mM MgClz, 0.2 mM EGTA, 
bacitracin and 0.1% BSA, pH 7.4 at 25°C). [^HJnociceptin was made up at a 
concentration of 0.4 nM (three times Kd as determined from Clarke et al, 2001) for 
the determination of total and non-specific binding. Cold nociceptin was added to the 
incubation buffer containing the radioligand at a concentration of 100 pM for the 
determination of non-specific binding.
Slides used for [^H]DAMGO, [^H]deltorphin-I, [^H]CI-977 and [^H]nociceptin 
binding were pre-incubated for 30 minutes in 50 mM Tris-HCl, 0.9% NaCl (Fisher 
Scientific, Loughborough, U.K.), pH 7.4 at 25°C, buffer to remove endogenous 
opioids. All slides were then placed in binding trays and 1 ml of either total or non­
specific binding (NSB) solutions was pipetted onto the sections (1ml per slide). 
Incubation was carried out at room temperature for 60 minutes for [^H]DAMGO, 
[^H]Deltorphin-I, [^H]CI-977 (Kitchen et a l, 1997; Slowe et al, 1999; Clarke et al, 
2001) and 180 minutes for [^HJnociceptin binding (Clarke et a l, 2001). Following the 
incubation period, slides used for [^HJDAMGO, [^H]Deltorphin-I and [^H]CI-977 
binding were washed three times for 5 minutes in ice-cold rinse buffer (50 mM Tris- 
HCl, pH 7.4 at 0°C). [^Hjnociceptin slides were washed three times for 5 minutes in 
ice cold rinse buffer containing 50 mM Tris-HCl, 3 mM MgCL (BDH Chemicals, 
Poole, UK) and 1% w/v bovine serum albumin, fraction V (Sigma-Aldrich, Dorset, 
U.K), pH 7.4 at 0°C. Slides were then dried for two hours in a cold air stream. Drying
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was continued for a further 7 days using anhydrous calcium sulphate (Drierite-BDH 
Chemicals, Poole, U.K.).
A2A receptor binding with [^H]CGS21680 (10 nM) to spinal cord and brain sections 
taken from the level of the striatum of each mouse was carried out as described earlier 
(section 2.2.5.1) in order to confirm the genotype.
4.2,23 Autoradiographic film preparation, development and analysis o f  images and 
data
The determination of scrape binding, the autoradiographic film preparation, 
development and analysis were carried out as described earlier (section 2.2.5.3-2.2.9). 
The exposure times of the sections to the film varied according to the ligand and the 
type of tissue (brain or spinal cord) used. Most of those times have been taken from 
literature but some others were determined by the use of early developments in this 
laboratory (section 2.2.6). The exposure times used for each radioligand bound tissue 
can be found in Table 4.1.
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Table 4.1. Exposure times of radioligand bound brain and spinal cord sections to 
a [^H]-sensitive Hyperfilm
Exposure times
Ligand Brain Spinal cord
[^H]DAMGO 3 weeks (Kitchen et al, 1997) 11 weeks (Rahman et al, 1998)
[^HJDeltorphinl 3 weeks (Kitchen et al, 1997) 14 weeks
[^H]Cl-977 6 weeks (Kitchen et al, 1997) 18 weeks
[^H]0RL1 3 weeks (Clarke et al, 2001) 8 weeks
[■*H]CGS21680 3 weeks (Slowe, 1999) 3 weeks
Image analysis of autoradiography films of brain and spinal cord sections labelled 
with radioligands was carried out as described earlier (section 2.2.8). The mean and 
standard error of the mean of each ligand binding (fmol of radioligand bound/mg of 
tissue) was calculated in each region for each genotype. The percentage changes in 
binding levels from wild type to homozygous brains and spinal cords of A2A receptor 
knockout mice were determined. Comparison of quantitative measures of 
autoradiographic binding for each ligand in brains and spinal cords from +/+ and -/- 
animals was carried out using two-way ANOVA (for factors region or laminae and 
genotype).
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3.2.2.4 Ligands
Labelled ligands
[ H]DAMGO Specific activity 56.0 Ci/mmol (2.07 TBq/mmol). It was purchased 
from Amersham International Pic (Buckinghamshire, U.K.). The concentration of the 
stock used was 17.9pM. The purity of the ligand is >99% as determined by HPLC.
[^H]deltorphin-I- Specific activity 50 Ci/mmol (1.85 TBq/mmol). It was purchased 
from Amersham International Pic (Buckinghamshire, U.K.). The concentration of the 
stock used was 20pM. The purity of the ligand is >97% as determined by HPLC.
[^H]CI977- Specific activity 41.0 Ci/mmol (1.52 TBq/mmol). It was purchased from 
Amersham International Pic (Buckinghamshire, U.K.). The concentration of the stock 
used was 24.3 pM. The purity of the ligand is >98% as determined by HPLC.
[^HjNociceptm- Specific activity 164 Ci/mmol (6.07 TBq/mmol). It was purchased 
from Amersham International Pic (Buckinghamshire, U.K.). The concentration of the 
stock used was 0.12pM. The purity of the ligand is >98% as determined by HPLC.
[^H]CGS21680- Specific activity 42.5 Ci/mmol (1.57TBq/mmol). It was purchased 
from NEN life Science Products, Inc. The concentration of the stock used was 
23.5pM. The purity of the ligand is >97% as determined by HPLC.
Unlabelled ligands
Naloxone- Naloxone hydrochloride was purchased from Sigma-Aldrich (Dorset, U.K)
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Nociceptin was purchased from BACHEM.
NECA was purchased from Sigma-Aldrich (Dorset, U.K)
4.2.3 p-, Ô - , K-mediated antinociception
4.23.1 Models for the study o f nociception
The warm water tail immersion model (Janssen et al, 1963) was the main nociception 
model used in this study. A thermal stimulus was applied by the immersion of the tail 
(up to 3cm from base) in a thermostatically controlled water bath. Water temperature 
of 55°C was employed in the studies examining morphine-mediated antinociception, 
whereas 52°C was used for deltorphin-I and CI-977-mediated antinociception. 
Response time was measured using a hand held stopwatch. The response time end 
point was designated as the withdrawal of the tail from the water. A cut-off time for 
the exposure to the thermal stimulus was set at 10 sec in order to avoid possible tissue 
damage. During the application of the stimulus, the animals were confined in a 
restraining cage.
Basal nociceptive responses of wild type and A2 A receptor knockout mice were also 
evaluated by the application of a mechanical stimulus on the mice tails (3 cm from the 
base) with the use of a modified Analgesymeter, Ugo Basile, Milan (Kitchen, 1984). 
Withdrawal of the tail or flinch responses were accepted as indication of nociception. 
The preselected cut-off point was 250g, which was designed to prevent tissue damage.
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4.23.2 Preparation and route o f administration o f drugs
Morphine sulphate and CI-977 were dissolved in 0.9% saline (Phoenix Pharma Ltd, 
Glousester, U.K) whereas deltorphin-I was dissolved in saline, acidified with glacial 
acetic acid (1% v/v) and buffered with 75 mM sodium hydroxide solution to adjust 
the pH to 7. All drugs and saline were injected intraperitoneally (i.p). A range of drug 
solutions was prepared such that the dose required could be administered in a volume 
not more than 0.1 ml.
4.2.3.3 Dose-response relationship and time-course determinations
Published data and pilot experiments were used as a guide to the appropriate dose 
range and time-course that was chosen for each drug (Crook, 1993; Kitchen et al, 
1994; Kitchen et al, 1995; Kelly, 1996; Matthes et al, 1998). Control latencies were 
determined by measuring the time required for the mouse to flick or withdraw its tail 
from the water 20 min before drug or vehicle administration. Each naïve wild type or 
knockout mouse was administered vehicle or a single dose of an opioid agonist 
intraperitoneally. The dose ranges used were 1.0-20.0 mg/kg for morphine sulphate, 
0.01-0.2 mg/kg for deltorphin-I and 0.01-1.0 mg/kg for CI-977. Each mouse was 
tested for antinociceptive responses 5, 15, 30, 45 and 60 min after the administration 
of morphine or vehicle, 5, 10, 15, 30 and 45 min after the administration of 
deltorphin-I or vehicle and 5, 10, 20, 30, 45, 60 and 120 min after the administration 
of CI-977 or vehicle.
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4.23.4 Data analysis
Dose-response curves for each agonist were plotted from non-transformed data at 
times when the analgesic response to the opioid agonists was maximum. Comparison 
of dose-response curves of +/+ and -/- animals for every dose for each agonist was 
carried out using repeated measures two-way ANOVA (for factors dose and 
genotype) followed by Scheffe’s post-hoc analysis. Comparison of basal control 
latencies (both to thermal and mechanical stimuli) from +/+ and -/- animals was 
carried out using Student’s t test. Comparison of tail immersion latencies of +/+ and - 
/- vehicle-treated animals was carried out using repeated measures two-way ANOVA 
(for factors time and genotype).
4.2.3.5 Ligands
Morphine sulphate was purchased from Sigma-Aldrich (Dorset, UK), deltorphin-I 
from Bachem (Essex, UK) and CI-977 was a gift from Pfizer (Ann Arbor, Michigan).
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4.3 Results
4.3.1 Opioid receptor autoradiography
4.3.1.1 Brains
The qualitative and quantitative distribution of p , ô, k  and ORLl opioid receptors 
labelled with [^H]DAMGO (4 nM), [^H]deltorphin-I (7 nM), [^H]CI-977 (2.5 nM) and 
[^HJnociceptin (0,4nM) in coronal sections of brain of wild-type mice (Figures 4.2, 
4.3) was similar to previous studies reported by our group (Kitchen et al, 1997; 
Slowe et al, 1999; Clarke et al, 2001). The pattern of distribution of all receptor 
types studied in homozygous A2A adenosine receptor knockout mice brains was 
identical to wild type. Although there were some small regional changes in receptor 
expression (Tables 4.2-4.5), no significant differences in the levels of p , 6, k  and 
ORLl opioid receptor expression was observed between genotypes (P>0.05). The 
interanimal variation as reflected by the standard error of the mean (S.E.M) values, 
for each individual region of each genotype was less than 10% for the majority of 
values.
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Figure 4.2. The distribution of p, ô, k  and ORLl opioid receptors in wild type (+/+) and
homozygous (-/-) knockout mice brains at the level of the caudate
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Figure 4.2. Computer enhanced autoradiograms of coronal brain sections from wild- 
type (+/+) and homozygous (-/-) A2 A adenosine receptor knockout mice. All the 
sections shown are from the level of the caudate (Bregma 1.10mm). p receptors were 
labelled with [^HJDAMGO (4 nM), 5 receptors with [^H]deltorphin-I (7nM), k  
receptors with [^H]CI-977 (2.5 nM), ORLl receptors with [^HJnociceptin (0.4 nM) 
and A2A receptors with [^H]CGS216800 (10 nM). Non-specific binding (NSB), shown 
in the far right column, was determined in the presence of naloxone (1 pM for p and k  
and 10 pM for Ô), unlabelled nociceptin (100 pM for ORLl) or NECA (20 pM for 
A2A). The colour bar shows pseudo-colour interpretation of relative density of black 
and white film image calibrated in finol/mg tissue. Sections from +/+ and -/- brains 
were processed in parallel.
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Figure 4.3. The distribution of p, ô, k  and ORLl opioid receptors in wild type (+/+) and
homozygous (-/-) knockout mice brains at the level of the hippocampus
s
K
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Figure 4.3. Computer enhanced autoradiograms of coronal brain sections from wild- 
type (+/+) and homozygous (-/-) A2 A adenosine receptor knockout mice. All the 
sections shown are from the level of the hippocampus (Bregma -1.70mm). p 
receptors were labelled with [^HJDAMGO (4 nM), ô  receptors with [^H]deltorphin-I 
(7nM), K receptors with CI-977 (2.5 nM) and ORLl receptors with 
[^H]nociceptin (0.4 nM). Non-specific binding (NSB), shown in the far right column, 
was determined in the presence of naloxone (1 pM for p and k  and 10 pM for ô )  or 
unlabelled nociceptin (100 pM for ORLl). The colour bar shows pseudo-colour 
interpretation of relative density of black and white film image calibrated in finol/mg 
tissue. Sections from +/+ and -/- brains were processed in parallel.
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Table. 4.2. Quantitative autoradiography of p - opioid receptors in the brains of wild type
(+/+) and homozygous (-/-) A2A adenosine receptor knock-out mice
Region Bregma
co-ordinates
[ HjDAMGO Specific % Change 
Binding (fmol/mg) in binding
Wild-type Homozygous (-/-)
(+/+) (-/-)
Olfactory bulb 4.28mm
Ext. plexiform layer 31.4±3.4 29.6±2.2 -5.7
Granule layer 26.9±2.9 25.3±3.0 -5.9
Cortex
Motor 2.46mm
Superficial layers 22.2±1.6 21.2±2.5 -4.5
Deep layers 44.8±3.3 44.0±4.1 -1.8
Orbital 2.46mm
Superficial layers 33.7±2.5 27.9±2.8 -17.2
Deep layers 31.5±2.5 29.2±2.4 -7.3
Rostral somatosensory 1.10mm
Superficial layers 23.4±1.3 23.4±1.4 0
Deep layers 25.5±2.4 21.8±0.7 -14.5
Cingulate 1.10mm
Superficial layers 30.8±2.5 27.9±2.6 -9.4
Deep layers 30.0±1.7 30.4±2.0 1.3
Auditory -2.80mm
Superficial layers 32.6±4.7 32.4±4.5 -0.6
Deep layers 40.1±5.9 33.2±5.7 -17.2
Visual -2.80mm
Superficial layers 23.2±3.0 21.2±3.1 -8.6
Deep layers 24.7±1.8 24.2±3.7 -2.0
Retrosplenial -2.80mm
Superficial layers 19.4±0.9 17.6±0.9 -9.2
Deep layers 18.3±1.1 19.5±2.8 6.6
Nucleus accumbens 1.34mm
Shell 76.7±9.1 83.3±9.6 8.6
Core 103±14.5 106±12.7 2.9
Caudate-putamen 1.10mm 52.9±5.5 50.2±5.7 -5.1
Endopiriform nucleus 1.10mm 93.4±6.1 92.4±8.9 -1.1
Septum 0.86mm
Medial 51.4±8.9 50.3±9.7 -2.1
Lateral 33.0±5.8 30.2±6.4 -R5
Vertical limb of 0.86mm 52.7±8.3 56.1±10.6 6.5
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Table.4.2. Continued
Bed nucleus of stria -0.22mm 92.5±12.4 92.6±18.2 0.1
terminalis 
Pre optic area -0.22mm 62.6±9.0 52.8±9.5 -15.7
Medial habenula nucleu -1.70mm 132±16.2 126±16.7 -4.5
Thalamus -1.70mm 50.1±7.4 49.6±7.2 -1.0
Reuniens thalamic -1.70mm 95.8±9.8 83.3±12.8 -13.0
nucleus
Paraventricular thalamic -1.70mm 151±32.9 140±41.8 -7.3
nucleus
Intermediodorsal -1.70mm 132±13.5 114±24.6 -13.6
thalamic nucleus 
Zona incerta -1.70mm 41.7±7.7 41.0±8.6 -1.7
Amygdala
Basolateral
-1.70mm
108±18.3 109±13.0 0.9
Basomedial 50.0±7.7 52.4±5.8 4.8
Medial 85.4±19.8 83.9±15.6 -1.8
Hypothalamus -1.70mm 60.8±6.5 56.0±11.7 -7.9
Hippocampus -2.46mm 17.9±3.3 17.3±2.7 -3.4
Periaqueductal grey -3.40mm 65.1±14.1 69.7±11.5 7.1
Substantia nigra -3.40mm 56.7±11.6 47.3±6.2 -16.6
Superficial grey layer -3.40mm 103±9.0 93.3±16.2 -9.4
of superior colliculus 
Intermediate grey layer -3.40mm 80.0±9.0 74.6±14.8 -6.8
of superior colliculus
Table 4.2. The mean specific binding (n=4) ± S.E.M. of [^HJDAMGO (finol/mg) in 
brain regions of wild-type (+/+) and homozygous (-/-) A%A receptor knockout mice. 
Measures in the regions were carried out at the Bregma co-ordinates taken from the 
mouse atlas of Franklin and Paxinos (1997). Regional determinates were made from 
both left and right sides of the sections, which were cut 300 pm apart. The labelling 
was carried out on sections from +/+ and -/- mice in a completely paired protocol. 
Specific binding was >90% in all regions. There was no significant difference 
between genotypes (P>0.05, ANOVA). The percentage (%) change in binding 
represents the change in binding levels in -/- brains compared to +/+. A minus sign 
indicates a percentage decrease in binding levels.
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Table. 4.3. Quantitative autoradiography of ô -  opioid receptors in the brains of wild
type (+/+) and homozygous (-/-) A%A adenosine receptor knockout mice
Region Bregma [ H]deltorphin-l Specific %  Change
co-ordinates Binding (fmol/mg) in binding
Wild-type Homozygous (-/-)
(+/+) (-/-)
Olfactory bulb 4.28mm
Ext. plexiform layer 64.2±4.6 68.34=6.3 6.4
Int. granular layer 148±20.3 160.0±20.1 8.1
Cortex
Motor 2.46mm
Superficial layers 52.04=2.9 46.24=4.1 -11.2
Deep layers 64.74=4.3 56.54=4.5 -12.7
Rostral somatosensory 1.10mm
Superficial layers 47.64=4.0 44.24=3.6 -7.1
Deep layers 50.44=5.5 48.74=6.1 -3.4
Cingulate 1.10mm
Superficial layers 57.04=3.7 57.04=4.9 0
Deep layers 52.84=5.7 57.14=5.5 8.1
Caudal somatosensory 1.10mm
Superficial layers 46.74=2.5 45.84=6.3 -1.9
Deep layers 57.04=4.1 52.64=3.2 -7.7
Auditory -2.80mm
Superficial layers 53.54=5.5 47.84=3.1 -10.7
Deep layers 66.34=7.7 58.0=1=3.7 -12.5
Visual -2.80mm
Superficial layers 59.44=5.3 47.24=4.0 -20.5
Deep layers 62.74=3.8 53.7=1=4.0 -14.4
Retrosplenial -2.80mm
Superficial layers 38.14=4.8 36.5=1=3.8 -4.2
Deep layers 45.44=4.7 43.54=3.6 -4.2
Perirhinal -3.64mm 66.94=5.3 61.84=5.1 -7.6
Entorhinal -4.04mm 40.84=7.6 32.54=2.9 -20.3
Nucleus accumbens 1.34mm
Shell 57.94=6.3 64.24=3.9 10.9
Core 56.34=4.8 60.44:4.5 7.3
Caudate-putamen 1.10mm 82.24=6.2 93.54=2.9 13.7
Olfactory tubercle 1.10mm 80.04=6.4 68.84=7.5 -14.0
Septum 0.86mm
Medial 23.54:3.3 21.64=2.3 -8.1
Lateral 9.7=tl.4 8.24=1.7 -15.5
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Table. 4.3. Continued
Vertical limb of 0.86mm 28.94=3.3 26.74=2.7 -7.6
diagonal band
Lateral globus pallidus -0.10mm 19.34=2.6 20.84=2.3 7.8
Pre optic area -0.22mm 13.24:1.8 11.34=1.1 -14.4
Thalamus -1.70mm 25.54=1.8 244=1.1 -5.9
Amygdala -1.70mm
Basolateral 74.14=5.0 75.04=8.6 1.2
Basomedial 41.3=1=2.3 37.74=3.1 -R7
Medial 33.24:2.2 30.94=2.4 -6.9
Hypothalamus -1.70mm 17.04=1.8 16.34=0.8 -4.1
Hippocampus -2.46mm 27.64=1.6 27.14=2.8 -1.8
Presubiculum -4.04mm 61.64=6.3 50.84=3.1 -17.5
Table 4.3. The mean specific binding (n=4) ± S.E.M of [^H]deltorphin-I (fmol/mg) in 
brain regions of wild-type (+/+) and homozygous (-/-) A2 A receptor knockout mice. 
Measures in the regions were carried out at the Bregma co-ordinates taken from the 
mouse atlas of Franklin and Paxinos (1997). Regional determinates were made from 
both left and right sides of the sections, which were cut 300 pm apart. The labelling 
was carried out on sections from +/+ and -/- mice in a completely paired protocol. 
Specific binding was >85% in all regions. There was no significant difference 
between genotypes (P>0.05, ANOVA). The percent (%) change in binding represents 
the change in binding levels in -/- brains compared to +/+. A minus sign indicates a 
percentage decrease in binding levels.
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Table. 4.4. Quantitative autoradiography of K-opioid receptors in the brains of
wild type (+/+) and homozygous (-/-) adenosine receptor knock-out mice
Region Bregma
co-ordinates
rH]CI-977 Specific 
Binding (fmol/mg)
% Change
in binding
Wild-type Homozygous (-/-)
(+/+) (-/-)
Olfactory bulb 4.28mm
Ext. plexiform layer 4.74=1.3 5.74=1.4 21.3
Claustrum 1.94mm 1144=10.2 1194=14.5 4.4
Nucleus accumbens shell 1.34mm 35.64=4.4 39.44=3.6 10.7
Nucleus accumbens core 1.34mm 35.04=4.7 28.94=2.5 -17.4
Caudate-putamen 1.10mm 14.94=1.7 15.24=1.9 2
Olfactory tubercle 1.10mm 29.24=3.5 35.24=2.8 20.5
Dorsal endopiriform 1.10mm 1264=7.6 1364=15.4 8
nucleus
Medial septum 0.86mm 16.3=t3.8 12.34=3:6 -24.5
Lateral septum 0.86mm 13.7=1=3.6 16.34=6.5 19.0
Vertical limb of 0.86mm 24.64=4.3 16.64=4.7 -32.5
diagonal band
Ventral pallidum 0.14mm 47.74=2.4 46.04=6.2 -3.6
Lateral globus pallidus 0.14mm 13.54=2.4 14.84=3.5 9.6
Stria terminalis -0.22mm 24.14=6.7 18.34=7.1 -24.1
Pre optic area -0.22mm 39.84=2.7 36.04=8.5 -9.5
Amygdala -1.70mm
Basolateral 37.84=5.6 38.6 2.1
Basomedial 15.04=4.0 17.54=2.0 16.7
Medial 14.24=4.4 16.24=3.0 14.1
Thalamus -1.70mm 0 0 0
Hypothalamus -1.70mm 35.94=4.4 32.64=1.1 -9.1
Hippocampus -1.70mm 0 0 0
Substantia nigra -3.40mm 37.74=2.3 31.84=2.5 -15.6
Superficial gray of the -3.40mm 7.3=tl.8 8.84=3.2 20.5
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Table 4.4. The mean specific binding (n=4)± S.E.M of [^ H]CI-977 (finoEmg) in brain 
regions of wild-type (+/+) and homozygous (-/-) A2A receptor knockout mice. 
Measures in the regions were carried out at the Bregma co-ordinates taken from the 
mouse atlas of Franklin and Paxinos (1997). Regional determinates were made from 
both left and right sides of the sections, which were cut 300 pm apart. The labelling 
was carried out on sections from +/+ and -/- mice in a completely paired protocol. 
Specific binding was >50% in all regions. There was no significant difference 
between genotypes (P>0.05, ANOVA). The percentage (%) change in binding 
represents the change in binding levels in -/- brains compared to +/+. A minus sign 
indicates a percentage decrease in binding levels.
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Table. 4.5 Quantitative autoradiography of opioid receptor like-one (ORLl) in the brains
of wild type (+/+) and homozygous (-/-) A2A adenosine receptor knock-out mice
Region Bregma
co-ordinates
[ H]nociceptin Specific
Binding (fmol/mg)
% Change
in binding
Wild-type
(+/+)
Homozygous
(-/-)
(-/-)
2.46mm
2.46mm
2.46mm
1.10mm
1.10mm
Olfactory bulb 4.28mm
Ext. plexiform layer
Int. Granule layer 
Cortex
Motor 
Superficial layers 
Deep layers
Pre-Limbic 
Superficial layers 
Deep layers
Orbital 
Superficial layers 
Deep layers
Insular
Rostral somatosensory 
Superficial layers 
Intemediate 
Deep layers
Cingulate 1.10mm
Superficial layers 
Deep layers
Caudal somatosensory -2.80mm 
Superficial layers 
Intemediate 
Deep layers
Auditory -2.80mm
Superficial layers 
Intemediate 
Deep layers
Visual -2.80mm
Superficial layers 
Intemediate 
Deep layers
Reterosplenial -2.80mm
Superficial layers 
Deep layers
Entorhinal -4.04mm
16.04=0.3
24.5±1.5
63.14=3.9
94.24=7.4
82.14=8.0
91.94=7.6
81.54=8.6
92.74=5.1
1104=5.8
59.64=4.4
69.34=4.3
52.5=t3.1
8 6 .7 4 =5 . 7
87.54=5.9
72.44=4.6
81.24=2.8
63.74=3.4
80.14=6.6
92.14=6.2
70.84=5.4
71.34=6.1
85.34=9.2
63.44=7.0
58.94=4.8
57.74=4.3
1264=5.0
17.84=0.7
26.14=1.6
63.34=1.9
98.34=5.7
88.64=8.6
99.04=5.7
71.64=10.1
84.44=5.7
1144=9.2
54.24=5.4
70.24=3.5
48.54=4.4
90.34=4.1
87.24=5.4
61.74=6.4
74.64=6.9
61.34=3.4
76.24=8.9
90.14=7.9
69.34=7.3
70.74=5.2
78.04=10.2
58.94=6.2
56.54=4.2
56.94=5.9
1304=14.6
11.3
6.5
0.3
4.4
7.9
7.7
- 12.1
-9.0
3.6
-9.1
1.3
-7.6
4.2 
-0.3
-14.8
- 8.1
-3j:
-4.9
- 2.2
- 2.1
- 0.8
-R 6
-7.1
-4.1
-1.4
3.2
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Table. 4.5 Continued
Olfactory bulb 3.08mm 88.24=6.4 83.94=5.6 -4.9
Anterior
Nucleus accumbens 1.34mm 55.44=2.2 55.14=3.1 -0.5
Caudate-putamen 1.10mm 34.04=2.0 30.24=2.7 -11.2
Olfactory tubercle 1.10mm 46.04=3.4 46.74=3.7 1.5
Lateral septum 0.86mm 67.74=1.0 62.6=t=2.8 -7.5
Bed nucleus of stria -0.22mm 29.84=2.7 33.24=2.1 11.4
terminalis
Lateral globulus pallidus -0.22mm 12.74=2.2 11.24=1.5 -11.8
Medial habenula nucleus -1.70mm 46.14=3.5 38.94=5.0 -15.6
Thalamus -1.70mm 39.54=1.4 37.14=1.4 -6.1
Paraventricular thalamic -1.70 mm 127±17 1134=6 -11.5
nucleus
Hypothalamus 34.04=2.0 ' 37.24=0.6 9.4
Ventromedial -1.70mm 53.84=4.1 58.34=3.7 8.3
hypothalamic nucleus 
Zona incerta -1.70mm 42.34=4.8 38.94=5.5 -8.0
Amygdala -1.70mm 1114=8.0 1054=7.9 -5.4
Hippocampus -2.46mm 60.04=3.6 52.84=2.0 -12.0
Dentate gyrus -2.46mm 27.54=0.7 22.64=1.7 -17.8
Medial geniculate -3.28mm 27.44=3.2 26.24=2.0 -4.4
nucleus
Periaqueductal grey -3.40mm 48.64=3.5 48.64=5.8 0
Substantia nigra -3.40mm 25.74=2.0 25.6=b2.1 -0.4
Superficial grey layer ' -3.40mm 78.24=6.1 78.44=1.9 0.3
of superior colliculus 
Intermediate grey layer -3.40mm 46.44=2.0 47.24=2.0 1.7
of superior colliculus 
Interpeduncular nucleus -3.40mm 48.34=0.4 44.04=3.0 -&9
Edinger-Westphal -3.40mm 47.74=3.1 50.64=3.7 6.1
nucleus
Presubiculum -3.40mm 75.84=1.6 69.44=3.1 -8.4
Pontine nucleus -3.40mm 50.84=0.9 40.54=4.5 -20.3
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Table 4.5. The mean specific binding (n=4) ± S.E.M of [^H]nociceptin (fmol/mg). in 
brain regions of wild-type (+/+) and homozygous (-/-) A2A receptor knockout mice. 
Measures in the regions were carried out at the Bregma co-ordinates taken from the 
mouse atlas of Franklin and Paxinos (1997). Regional determinates were made from 
both left and right sides of the sections, which were cut 300pm apart. The labelling 
was carried out on sections from +/+ and -/- mice in a completely paired protocol. 
Specific binding was >85% in all regions. There was no significant difference 
between genotypes (P>0.05, ANOVA). The percentage (%) change in binding 
represents the change in binding levels in -/- brains compared to +/+. A minus sign 
indicates a percent decrease in binding levels.
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4.3. L 2 Spinal cords
The levels of [^HJDAMGO, [^H]deltorphin-I and [^H]CI-977 specific binding to the 
regions of wild type (+/+) cervical spinal cord analysed were very similar to those of 
thoracic and sacral spinal cord. This suggests that the pattern of distribution of p , ô  
and K receptors in the spinal cord is homogeneous throughout (Figures 4.4-4.6). The 
highest levels of [^HJDAMGO, [^H]deltorphin-I and CI-977 binding was detected 
in the superficial layers (laminae I&II) of the spinal cord. Much lower levels were 
detected in laminae III-VI, lamina X and in the ventral horns of the spinal cord. No 
binding was observed in the white matter of the spinal cord. In contrast with the p , ô  
and K receptors, the levels of ORLl specific binding of the regions of wild type (+/+) 
sacral spinal cord analysed were slightly higher than those of the respective regions of 
thoracic and cervical spinal cord (Figures 4.4-4.6). The highest levels of 
[^HJnociceptin binding were detected in the superficial layers and in lamina X of the 
spinal cord (>50finol/mg tissue). Slightly lower levels of binding were observed in 
laminae III-VII and in the dorsal horn of the spinal cord. The lowest levels of binding 
were found in laminae VIII and IX (<25finol/mg tissue). No [^Hjnociceptin binding 
was detected in the white matter of the spinal cord. The relative densities of opioid 
receptors in the superficial layers of the spinal cord was p>0RLl>5>K.
The pattern of distribution of p , ô ,  k  and ORLl receptor in the spinal cord was 
identical in homozygous A2A receptor knockout mice compared to wild type (Tables 
4.6-4.9). In contrast with the brain, a significant quantitative difference in the levels of 
[^H]deltorphin-I binding between genotypes was observed in the spinal cord (P<0.01), 
and three quarters of the regions analysed in A2A knockout mice showed a
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downregulation of ô  receptor expression. The largest loss of ô  sites (up to 19%) was 
found in the superficial layers of the spinal cord (Table 4.7), There was also a 
significant quantitative increase in the levels of [^H]CI-977 binding between in -/- 
mice compared to +/+ (P<0.05) and the greatest overall upregulation was detected in 
the dorsal horns of the spinal cord (up to 31%) (Table 4.8). In contrast to ô  and k  
binding, there were no significant differences in the levels of p or ORLl receptor 
expression between genotypes in the spinal cord (P>0.05) (Tables 4.6, 4.9). The 
interanimal variation as reflected in the standard error of the mean (S.E.M) values, for 
each individual region of each genotype was less than 10% for the majority of values.
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KFigure 4.4. The distribution of p, 8, K, ORLl and Aja receptors in wild type (+/+) and
homozygous (-/-) Aja knockout mice in cervical sections of the spinal cord
fmol/mg -4-/-I- _ /_
ORLl
'2A
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Figure 4.4 Computer enhanced autoradiograms of coronal cervical, thoracic and 
sacral spinal cord sections from wild-type (+/+) and homozygous (-/-) A2A receptor 
knockout mice. The sections taken were segment C6 according to the rat atlas of 
Paxinos and Watson (1986). p receptors were labelled with [^H]DAMGO (4nM), ô 
receptors with [^H]deltorphin-I (7nM), k  receptors with [^H]CI-977 (2.5nM), ORLl 
receptors with [^HJnociceptin (0.4nM) and A2A receptors with [^H]CGS21680 
(lOnM). Non-specific binding (NSB), shown in the far right column, was determined 
in the presence of naloxone (IpM for p and k  and 10 pM for ô), unlabelled nociceptin 
(lOOpM for ORLl) or NECA (20pM for A2A). The colour bar shows pseudo-colour 
interpretation of relative density of black and white film image calibrated in finol/mg 
tissue. Sections from +/+ and -/- spinal cords were processed in parallel.
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Figure 4.5. The distribution of p , ô, k, ORLl and receptors in wild type (+/+) and
homozygous (-/-) Aja knockout mice in thoracic sections of the spinal cord
fmol/mg
s
K
ORLl
'2A
+/+ NSB
■
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Figures 4.5. Computer enhanced autoradiograms of coronal cervical, thoracic and 
sacral spinal cord sections from wild type (+/+) and homozygous (-/-) A2A receptor 
knockout mice. The sections taken were segment T3 according to the rat atlas of 
Paxinos and Watson (1986). p receptors were labelled with [^HJDAMGG (4nM), 6 
receptors with [^H]deltorphin-I (7nM), k  receptors with [^H]CI-977 (2.5nM), ORLl 
receptors with [^H]nociceptin (0.4nM) and A2 A receptors with [^H]CGS21680 
(lOnM). Non-specific binding (NSB), shown in the far right column, was determined 
in the presence of naloxone (IpM for p and k  and 10 pM for 8 ) ,  unlabelled nociceptin 
(lOOpM for ORLl) or NECA (20pM for A2A). The colour bar shows pseudo-colour 
interpretation of relative density of black and white film image calibrated in finol/mg 
tissue. Sections from +/+ and -/- spinal cords were processed in parallel.
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sK
Figure 4.6. The distribution of p, 5, k, ORLl and A2A receptors in wild type (+/+) and
homozygous (-/-) A2A knockout mice in sacral sections of the spinal cord
fmol/mg -4-/-1- _ /_  -N  S B
ORLl
2A
I
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Figures 4.6. Computer enhanced autoradiograms of coronal cervical, thoracic and 
sacral spinal cord sections from wild-type (+/+) and homozygous (-/-) A%A receptor 
knockout mice. The sections taken were segment S4 according to the rat atlas of 
Paxinos and Watson (1986). p receptors were labelled with [^HJDAMGO (4nM), ô  
receptors with [^H]deltorphin-I (7nM), k  receptors with [^H]CI-977 (2.5nM), ORLl 
receptors with [^HJnociceptin (0.4nM) and A2A receptors with [^H]CGS21680 
(lOnM). Non-specific binding (NSB), shown in the far right column, was determined 
in the presence of naloxone (IpM for p and k  and 10 pM for ô ) ,  unlabelled nociceptin 
(lOOpM for ORLl) or NECA (20pM for A2 a)- The colour bar shows pseudo-colour 
interpretation of relative density of black and white film image calibrated in fmol/mg 
tissue. Sections from +/+ and -/- spinal cords were processed in parallel.
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Table. 4.6. Quantitative autoradiography of p- opioid receptors in the spinal cords of
wild type (+/+) and homozygous (-/-) A2A adenosine receptor knock-out mice
Region Segments [ HjDAMGO Specific Binding % Change in 
from rat atlas (fmol/mg) binding
Wild-type Homozygous (-/-)
(+/+) (-/-)
Cervical C1&C6
Superficial layers 96.24=4.1 95.94=3.0 -0.3
(laminae I&II)
Laminae IH-VI 31.24=2.2 30.24=2.2
Lamina X 27.24=1.7 28.94=2.4 6.3
Ventral horn 18.94=1.8 19.U2.1 1.1
(laminae VII-IX)
Dorsal horn 43.04=1.7 41.34=3.1 -4.0
(laminae I-VI)
Thoracic T3&T6
Superficial layers 99.54=4.6 91.54=3.6 -8.0
(laminae I&II)
Laminae III-VI 30.54=2.7 34.54=3.0 13.1
Lamina X 22.64=2.4 18.84=1.6 -16.8
Ventral horn 17.44=3.0 20.5=t2.0 17.8
(laminae VII-IX)
Dorsal horn 48.94=2.6 48.84=2.4 -0.2
(laminae I-VI)
Sacral S4
Superficial layers 91.54=8.6 92.44=4.9 1.0
(laminae I&H)
Laminae m-VI 31.64=3.1 31.14=2.6 -1.6
Lamina X 29.74=4.5 29.44=6.7 -1.0
Ventral horn 23.74=1.7 19.74=2.9 -16.9
(laminae Vfi-IX)
Dorsal horn 47.54=4.2 44.6=1=4.7 -6.1
(laminae I-VI)
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Table 4.6. Quantitative autoradiography of p-receptor binding in wild-type (+/+) and 
homozygous (-/-) A2A receptor mutant mice. The mean specific binding (n=4) ± 
S.E.M of [^HJDAMGO (finol/mg) in spinal cord regions of wild-type (+/+) and 
homozygous (-/-) A2 A receptor knockout mice. Measures in the regions were carried 
out at the Bregma co-ordinates taken from the rat atlas of Paxinos and Watson (1986). 
Regional determinates were made from both left and right sides of the sections, which 
were cut 300 pm apart. The labelling was carried out on sections from +/+ and -/- 
mice in a completely paired protocol. Specific binding was >90% in all regions. There 
was no significant difference between genotypes (P>0.05, ANOVA). The percentage 
(%) change in binding represents the change in binding levels in -/- spinal cords 
compared to +/+. A minus sign indicates a percentage decrease in binding levels.
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Table. 4.7. Quantitative autoradiography of 8-  opioid receptors in the spinal cords of
wild type (+/+) and homozygous (-/-) A2A adenosine receptor knock-out mice
Region Segments [^H]deltorphin-I Specific Binding % Change in 
from rat atlas (fmol/mg) binding
Wild-type Homozygous (-/-)
(+/+) (-/-)
Cervical C1&C6
Superficial layers 30.03=2.6 25.43=2.6 -15.3
(laminae I&II)
Laminae HI-VI 15.53=1.0 13.73=0.8 -11.6
Lamina X 18.33=2.0 18.03=0.9 -1.6
Ventral horn 13.73=0.9 12.43=0.7 -9 j
(laminae VII-IX)
Dorsal horn 18.73=1.3 15.43=0.9 -17.6
(laminae I-VI)
Thoracic T3&T6
Superficial layers 27.73=1.8 24.93=2.2 -10.1
(laminae I&II)
Laminae HI-VI 15.73=1.0 15.43=1.6 -1.9
Lamina X 16.73=1.2 15.83=1.5 -5.4
Ventral horn 14.93=0.9 14.43=1.1 -3.4
(laminae Vn-IX)
Dorsal horn 19.33=0.8 18.83=2.0 -2.6
(laminae I-VI)
Sacral S4
Superficial layers 21.23=1.3 17.23=1.5 -18.9
(laminae I&II)
Laminae DI-VI 11.23=0.9 12.03=0.9 7.1
Lamina X 11.23=0.8 11.63=0.5 3.6
Ventral horn 1 0 .9 3 =1 . 0 11.73=0.4 7.3
(laminae VII-IX)
Dorsal horn 14.23=1.2 13.53=0.7 -4.9
(laminae I-VI)
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Table 4.7. Quantitative autoradiography of ô receptor binding in wild-type (+/+) and 
homozygous (-/-) A%A receptor mutant mice. The mean specific binding (n=4) ± 
S.E.M of [^H]deltorphin-I (finol/mg) in spinal cord regions of wild-type (+/+) and 
homozygous (-/-) A2A receptor knockout mice. Measures in the regions were carried 
out at the Bregma co-ordinates taken fi-om the rat atlas of Paxinos and Watson (1986). 
Regional determinates were made fi*om both left and right sides of the sections, which 
were cut 300 pm apart. The labelling was carried out on sections jftom +/+ and -/- 
mice in a completely paired protocol. Specific binding was >80% in all regions. There 
was a significant difference between genotypes (P<0.01, ANOVA). The percentage 
(%) change in binding represents the change in binding levels in -/- spinal cords 
compared to +/+. A minus sign indicates a percentage decrease in binding levels.
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Table. 4.8. Quantitative autoradiography of k -  opioid receptors in the spinal cords of
wild type (+/+) and homozygous (-/-) A2A adenosine receptor knock-out mice
Region Segments [^H]CI-977 Specific Binding % Change in 
from rat atlas (fmol/mg) binding
Wild-type Homozygous (-/-)
(+/+) (-/-)
Cervical C1&C6
Superficial layers 15.93=1.7 15.73=1.3 -1.3
(laminae I&D)
Laminae III-VI 4.8±0.9 4.53=1.0 -6J
Lamina X 9.83:1.2 11.43=1.1 16.3
Ventral horn 2.5=1=0.7 2 .4 3 =0 . 6 -4.0
(laminae VII-IX)
Dorsal horn 7.43:1.4 8.03=1.1 8.1
(laminae I-VI)
Thoracic T3&T6
Superficial layers 16.93=2.1 20.13=1.4 18.9
(laminae I&II)
Laminae III-VI 7.03=1.3 9.23=1.0 31.4
Lamina X 1 1 .7 3 =0 . 9 11.83=1.0 0.9
Ventral horn 5.13=1.1 6.13=1.0 19.6
(laminae VII-IX)
Dorsal horn 9.93=1.4 12.73=1.2 283
(laminae I-VI)
Sacral S4
Superficial layers 17.23=1.6 2L8±2.8 26.7
(laminae I&II)
Laminae HI-VI 8.43=1.0 7.03:2.4 -16.7
Lamina X 11.23=1.1 13.43=3.4 19.6
Ventral horn 4 .7 3 =0 . 8 2.43=1.0 -48.9
(laminae Vn-IX)
Dorsal horn 12.03=1.1 13.73=2.7 14.2
(laminae I-VI)
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Table 4.8. Quantitative autoradiography of K-receptor binding in wild-type (+/+) and 
homozygous (-/-) A2A receptor mutant mice. The mean specific binding (n=4) ± 
S.E.M of [^H]CI-977 (fmol/mg) in spinal cord regions of wild type (+/+) and 
homozygous (-/-) A2A receptor knockout mice. Measures in the regions were carried 
out at the Bregma co-ordinates taken from the rat atlas of Paxinos and Watson (1986). 
Regional determinates were made from both left and right sides of the sections, which 
were cut 300 pm apart. The labelling was carried out on sections from +/+ and -/- 
mice in a completely paired protocol. Specific binding was >45% in all regions. There 
was a significant difference between genotypes (P<0.05, ANOVA). The percentage 
(%) change in binding represents the change in binding levels in -/- spinal cords 
compared to +/+. A minus sign indicates a percentage decrease in binding levels.
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Table. 4.9. Quantitative autoradiography of ORL-1 receptors in the spinal cords of
wild type (+/+) and homozygous (-/-) Aja adenosine receptor knock-out mice
Region Segments 
from rat atlas
[■^ HJnociceptin Specific
Binding (fmol/mg)
% Change in 
binding
Wild-type Homozygous (-/-)
(+/+) (-/-)
Cervical C1&C6
Superficial layers 52.93=3.6 55.83=6.3 5.5
(laminae I&II)
Laminae HI-VII 36.93=1.7 36.53=1.9 -1.1
Laminae X 46.83=3.7 50.53=2.8 7.9
Laminae Vm&IX 20.43=1.4 19.03=2.1 -6.9
Dorsal horn 40.83=2.1 42.03=2.7 2.9
(laminae I-VI)
Thoracic T3&T6
Superficial layers 54.63=3.6 67.83:8.5 24.2
(laminae I&H)
Laminae IE-VII 45.93=2.5 48.83=2.6 6.3
Laminae X 54.03=2.8 57.73=2.6 6.9
Laminae VIII&IX 23.7=tl.O 23.13=1 -2.5
Dorsal horn 48.33=3.3 54.43=4.6 12.6
(laminae I-VI)
Sacral S4
Superficial layers 66.33=3.6 75.63=11.2 14.0
(laminae I&II)
Laminae HI-VII 50.53=1.8 51.43=2.6 1.8
Laminae X 73.63=6.6 82.13=7.2 11.5
Laminae Vm&IX 24.03=1.7 22.43=1.3 -6.7
Dorsal horn 56.23=2.3 59.23=5.6 5.3
(laminae I-VI)
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Table 4.9. Quantitative autoradiography of ORLl receptor binding in wild-type (+/+) 
and homozygous (-/-) A2A receptor mutant mice. The mean specific binding (n=4) ± 
S.E.M. of [^H]nociceptin (fmol/mg) in spinal cord regions of wild-type (+/+) and 
homozygous (-/-) A2A receptor knockout mice. Measures in the regions were carried 
out at the Bregma co-ordinates taken from the rat atlas of Paxinos and Watson (1986). 
Regional determinates were made from both left and right sides of the sections, which 
were cut 300 pm apart. The labelling was carried out on sections from +/+ and -/- 
mice in a completely paired protocol. Specific binding was >90% in all regions. There 
was no significant difference between genotypes (P>0.05, ANOVA). The percentage 
(%) change in binding represents the change in binding levels in -/- spinal cords 
compared to +/+. A minus sign indicates a percentage decrease in binding levels.
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4.3.1.3 Confirmation o f genotype
Binding of A2 A adenosine receptors with [^H]CGS21680 showed a complete absence 
of A2A-sites in the brains of homozygous mice, which confirmed the genotype of the 
A2A adenosine receptor knockout mice, used in this study (Figure 4.2). Finally no 
[^H]CGS21680 binding was detected in wild type or knockout spinal cords (Figures 
4.4-4.Ô).
4.3.2 Opioid-mediated antinociception
Antinociceptive time-course and dose-response relationships were established for the 
[i agonist morphine (Figure 4.7), the 8 agonist deltorphin-I (Figure 4.8) and the k  
agonist CI-977 (Figure 4.9). The antinociceptive effect was at a maximum at 45, 15 
and 10 min post-injection for morphine, deltorphin-I and CI-977 respectively in both 
wild type and knockout mice. Although all three drugs produced a dose-related 
antinociception, in the case of deltorphin-I, the curve was bell-shaped (Figure 4.8). 
Comparison of antinociceptive dose-response relationships between +/+ and -/- mice 
showed that there was a significant decrease in 8-mediated antinociception (P<0.05) 
and a significant increase in K-mediated antinociception in -/- mice (P<0.01) but no 
change in p-mediated antinociception (P>0.05).
Comparison of basal reactivity to thermal stimuli of 55°C (as used for morphine- 
mediated antinociception studies) between knockout and wild type animals showed 
that there was a significant increase in latency in knockout animals (P<0.05) (Figure 
4.10a). However, when the animals were exposed to a stimulus of 52°C (as used for
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deltorphin-1 and CI-977-mediated antinociception studies), no significant difference 
in basal antinociception was found between genotypes (P>0.05) (Figure 4.10b). 
Similarly, a comparison of tail immersion latencies in vehicle-treated animals also 
demonstrated a significant increase in knockout mice when they were exposed to a 
thermal stimulus of 55°C (P<0.05) but not when they were exposed to 52°C (P>0.05) 
(Figures 4.7-4.9). Finally, no significant change in basal nociceptive threshold (135.7 
±12.6 for +/+ vs 157.9± 10.2 for -/-, n=43) was found when +/+ and -/- mice were 
tested with the tail pressure test (Figure 4.10c).
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Figure 4.7. Dose-related antinociception induced by morphine sulphate in 12-
week-old wild-type (+/+) and A%A receptcir knockout (-/-) mice, 
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Figure 4.7. (a) shows the time course of morphine-induced antinociception in the +/+ 
mice and (b) shows the time course of morphine-induced antinociception in the -/- 
mice measured as tail immersion latency at 55°C. (O) represents saline control 
values, ( • )  Img/kg, (□ ) 5 mg/kg, (■) lOmg/kg and (A) 20mg/kg morphine sulphate. 
Doses (0.1 ml volume i.p) were administered at 0 min. Pre: pretest responses 20 
minutes before injection, (c) shows the dose response relationship for morphine 
sulphate at peak antinociception (45 minutes post injection) in wild-type (O) and A2A 
receptor knockout ( • )  mice.
Values are means ±  S.E.M of five determinations (n=5). Differences in dose-response 
curves between genotypes were not statistically significant (P>0.05, ANOVA). The 
difference in tail immersion latencies between +/+ and -/- saline-treated animals was 
statistically significant (P<0.05, ANOVA).
212
Figure 4.8. Dose-related antinociception induced by deltorphin-I in 12 week old 
wild-type (+/+) and A%A receptor knockout (-/-) mice.
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Figure 4.8. (a) shows the time course of deltorphin-I induced antinociception in the 
+/+ mice and (b) shows the time course of deltorphin-I induced antinociception in the 
-/- mice measured as tail immersion latency at 52®C. (O) represents vehicle control 
values, ( • )  O.Olmg/kg, (□) 0.03mg/kg, (■) O.lmg/kg and (A) 0.2mg/kg deltorphin-I. 
Doses (0.1 ml volume i.p) are administered at 0 min. Pre; pretest responses 20 
minutes before injection.(c) shows the dose response relationship for deltorphin-I at 
peak antinociception (15 minutes post injection) in wild-type (O) and A2A receptor 
knockout (#) mice.
Values are means ± S.E.M of five determinations (n=5). Differences in dose response 
curves between genotypes were statistically significant (P<0.05, ANOVA). The 
difference in tail immersion latency between +/+ and -/- vehicle treated animals was 
not statistically significant (P>0.05, ANOVA). * ?<0.05 (Scheffe’s post hoc analysis).
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Figure 4.9. Dose-related antinociception induced by CI-977 in 12 week old wild-
type (+/+) and A2A receptor knockout (-/-) mice
WJ (J
S
§
%ofi(U
a
10 . 0-1
7 . 5 -  
5 .0 -
2 .5 -
0. 0 -
Pretest I
—1-------- 1---------1---------1---------1---------r
20  40  60  80  100 120
Time (min)
inj
b
10.0 -,
7. 5 -  
5 .0 -
2 .5 -
0 . 0 -
Ji
Pretest ^
—r-
20 40 60 80
Time (min)
—r- —I---------- r
100 120
iiy
10.0 -,
7 .5 -
uo
5 .0 -
2 .5 -
0.0
0.01 0.03 0.1 0.3 1 . 0
CI-977 (mg/kg)
215
Figure 4.9. (a) shows the time course of CI-977 induced antinociception in the +/+ 
mice and (b) shows the time course of CI-977 induced antinociception in the -/- mice 
measured as tail immersion latency at 52°C. (O) represents saline control values, ( • )  
O.Olmg/kg, (□ ) 0.03mg/kg, (■) O.lmg/kg, (A) 0.3mg/kg and (A) Img/kg CI-977. 
Doses (0.1 ml volume i.p) are administered at 0 min. Pre: pretest responses 20 
minutes before injection, (c) shows the dose-response relationship for CI-977 at peak 
antinociception (10 minutes post injection) in wild-type (O) and A2A receptor 
knockout (#) mice.
Values are means ± S.E.M of five determinations (n=5). Differences in dose response 
curves between genotypes was statistically significant (P<0.05, ANOVA). 
Differences in tail immersion latency between +/+ and -/- saline-treated animals were 
not statistically significant (P>0.05, ANOVA). * P<0.05 (Scheffe’s post hoc analysis).
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Figure 4.10. Basal nociceptive threshold in 12 week old wild type (+/+) and A2A
receptor knockout (-/-) mice
a p<0.05
Figure 4.10. (a) shows the basal reactivity to a thermal stimulus of 55°C for wild type 
(+/+) mice (n=25) and A2A receptor knockout (-/-) mice (n=20). (b) shows the basal 
reactivity to a thermal stimulus of 52°C for wild type (+/+) mice (n=55) and A2A 
receptor knockout (-/-) mice (n=40). (c) shows the basal reactivity to a tail pressure 
stimulus for wild type (+/+) mice (n=43) and A2A receptor knockout (-/-) mice (n=43). 
Error bars represent S.E.M. ns, not significant. P<0.05, significant difference between 
genotypes (Students’ t test).
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4.4 Discussion
Although complete quantitative mapping in all four opioid receptors has been carried 
out in the mouse brain (Clarke et al, 2001), it has not been carried out in the mouse 
spinal cord in great detail and this study was the first complete quantitative 
autoradiography using highly selective ligands in this species. In wild-type mice the 
qualitative pattern of p, Ô, k  and ORLl receptors in the spinal cord was similar to the 
studies that have been reported by other groups in the rat (Besse et al, 1990; Besse et 
al, 1991; Neal et al, 1999) and mouse (Narita et al, 1999; Mogil et al, 2000), 
showing high densities of these receptors in the superficial layers of the dorsal horn 
which are believed to be the main sites of spinal pain transmission (Besson & 
Chaouch, 1987).
The lack of change in p, 8, k  or ORLl receptor binding in the brains of -/- mice 
clearly suggests that a direct A%A receptor interaction with any opioid receptor subtype 
is not relevant in the mouse brain. This is in agreement with a study that failed to find 
changes in A2A receptor binding in the striatum of chronically morphine-treated mice 
(Kaplan et al, 1994) in contrast with the rat where A2A receptors are downregulated 
(De Montis, 1992). Moreover, the decrease in proenkephalin mRNA observed in A2A 
receptor knockout mice striatum (Ledent et al, 1997) does not appear to trigger any 
changes in opioid receptor numbers. It is possible however that the decrease in 
proenkephalin mRNA in -/- mice does not result in a decrease in the levels of the 
peptide transmitter itself. Indeed, enkephalin immunoreactivity has been shown to be 
unaltered in another strain of A2A knockout mice (Chen et a l, 1999). The lack of
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change in nociceptin mRNA (Dassesse et al, 2000) in the striatum of -/- mice 
supports the lack of changes in ORLl binding observed here in -/- mice brains of the 
same strain.
In contrast to the brain, significant changes in ô  and k  receptors were observed in the 
spinal cord of -/- mice with no change in p and ORLl binding. In order to investigate 
whether the small changes in binding had any behavioural relevance, p-, 8 -  and k -  
mediated antinociception assays were carried out. Deltorphin-I and CI-977 were used 
not only because of their high affinity and selectivity for 8  and k  receptors 
respectively but also to enable direct correlation with the results from the binding 
studies. Morphine was used as a prototypic p agonist and since p receptor gene 
knockout mice show complete loss of analgesic responses to morphine, this receptor 
is viewed as its primary target (Matthes et al, 1996). Tail immersion was used as an 
analgesic test in order to investigate changes in spinal rather than supraspinal opioid- 
induced antinociception as antinociception revealed with the tail immersion assay is 
classically considered to reflect the actions of drugs on pain transmission at spinal 
sites (DeLander et al, 1992). 55°C was employed for testing morphine-mediated 
antinociception not only because it is the standard temperature used in the literature 
for this drug in this assay, but also because it has been shown that no supraspinal 
circuits are involved at that temperature (Ossipov et al, 1995). 52°C was employed to 
test deltorphin-I and CI-977 mediated antinociception in common with previous 
studies (Millan, 1989; Crook et al, 1993; Kitchen et al, 1994; Kitchen et al, 1995; 
Matthes et a l, 1998) and because these drugs have no or limited antinociceptive 
activity at higher intensity thermal stimuli.
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The decrease and increase in 8- and K-mediated antinociception respectively and the 
lack of change in p-mediated antinociception in A2 A receptor knockout mice is in 
complete accordance with the autoradiographic receptor binding data in the spinal 
cord. This strongly suggests that even relatively small changes in receptor density in - 
/- mice do result in significant changes in the antinociceptive responses.
The possibility that the changes in 8  and k  receptors are due to lack of spinal A 2A 
receptors in -/- mice can be ruled out, as no A2A receptors were detected in the spinal 
cord of wild-type mice. The absence of A2A receptors in spinal cord was also observed 
previously in another strain of mice (C57BL/6) (chapter 2, section 2.3.2.2). This is at 
odds with DeLander and Keifs observation that antinociception induced by 
intrathecal co-administration of the selective A2A receptor agonist, CGS21680 and 
p, 8 or K selective opioid receptor agonists in mice showed additive, synergistic or 
multiplicative interactions between them (DeLander et al, 1994). However, the issue 
of whether CGS21680 actually induce antinociception in this study by acting on A2A 
receptors is debatable as significantly greater doses of CGS21680, as compared to the 
selective A% receptor agonist N^- cyclopentyl-adenosine (CPA) were required to 
induce antinociception. Thus it is likely that opioid-A2A receptor agonist interactions 
observed in that study were due to interactions at A% receptors at which CGS21680 
has lower potency (DeLander et al, 1994). However, expression of the A2 A receptor 
gene has been reported in the dorsal root ganglia in the mouse (Kaelin-Lang et al, 
1998) and A2A receptors are present on sensory nerve terminals in the periphery 
(Taiwo & Levine, 1991; Khasar et al, 1995). That suggests that A2A receptors are 
transported to peripheral sites rather than central ones.
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It has been shown that A2A receptors play a role in peripheral regulation of pain. Local 
administration of a selective A2A receptor agonist, CGS21680, has been reported to 
produce mechanical hyperalgesia (Khasar et al, 1995) and to enhance pain responses 
in the low concentration formalin model in rat (Doak & Sawynok, 1995). That action 
has been proposed to result from the stimulation of adenylate cyclase (through the 
activation of the Gg coupled A2A receptor) resulting in an increase in cAMP levels in 
the sensory nerve terminal (Taiwo et a l, 1991; Khasar et a l, 1995). As a result, the 
higher nociceptive threshold observed in A2A receptor knockout mice has been 
suggested to be due to the peripheral lack of A2A receptors (Ledent et al, 1997). 
Accordingly, the changes in ô  and k  opioid receptor-mediated antinociception and 
binding in the superficial layers of the spinal cord of -/- mice might be the result of the 
lack of A2A receptors in the sensory nerve terminals. Activation of p, 6  and k  opioid 
receptors located on the synaptic terminals of primary afferent fibres has been 
proposed as the basis for the depressive effects of opioid agonists on pronociceptive 
information coming from the peripheral nerve terminals (Besson et a l, 1987). Thus it 
seems possible that the changes in ô  and k  opioid-mediated antinociception and 
binding in A2A knockout mice are due to changes occurring in peripheral pain 
transmission as a consequence of lack of A2A adenosine receptors at sensory 
terminals. As A2A adenosine receptors are strictly localised solely in the striatum of 
mouse brain (see also sections 2.3.1.3, 2.3.3.2), and are not expressed in any major 
pain circuitries, it is highly unlikely that the lack of supraspinal A2A receptors could 
be the cause of the changes in the spinal opioid receptors and opioid-mediated 
antinociception in -/- animals. Why the changes in ô  and k  are in opposition and why 
no change in p receptor-mediated antinociception and binding was observed in -/- 
mice is not clear. However, it implies the presence of different spinal mechanisms of
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opioid receptor subtypes in modulating peripheral pain. Nonetheless, this study 
strongly suggests an interaction between peripheral A 2A receptors and spinal ô  and k  
receptors but not p receptors in regulating peripheral pain.
In order to check whether the changes observed in the opioid-mediated 
antinociception experiments were actually due to opioid-mediated antinociception and 
not due to changes in basal pain sensitivity in -/- mice, a comparison of basal tail 
withdrawal latencies was carried out between genotypes. The significant increase in 
tail withdrawal latency in -/- mice when they are exposed to 55°C water, the 
temperature used for morphine-mediated antinociception, is in complete agreement 
with the findings of Ledent et al. (1997). However, one ought to consider that blood 
flow influences nociceptive thresholds. A2A receptor knockout mice have been shown 
to have high blood pressure (Ledent et al, 1997) due to the lack of vasodilatory tone, 
reducing the skin temperature of the tail (Coupar & Tran, 2002), which could lead to 
apparent antinociception (Hole & Tjolsen, 1993). Indeed, no significant change in 
basal nociceptive threshold was observed when +/+ and -/- mice were tested with the 
tail pressure test, a nociceptive response which would not be influenced by blood 
flow. In any case, the differences in ô and K-mediated antinociception shown in this 
study could not be attributed to differences in blood flow or tail temperature as there 
was no significant difference in basal tail immersion between genotypes when tested 
at 52°C. The lack of significant difference in nociceptive threshold between genotypes 
in the response to a 52°C stimulus could be due to reduced importance of peripheral 
A2A receptors at the lower temperature, or to the involvement of supraspinal circuits, 
which are absent when the stimuli is 55°C (Ossipov et a l, 1995).
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In conclusion, deletion of the A2A receptor gene causes changes in ô and k  receptor- 
mediated antinociception and binding in the spinal cord but not in the brain of mutant 
mice, supporting a functional interaction between the spinal opioid and the peripheral 
adenosine system in the control of pain pathways.
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CHAPTER 5
Morphine withdrawal in À2a adenosine 
receptor knockout mice
225
5.1 INTRODUCTION
Chronic administration of morphine leads to tolerance and dependence, during which 
adaptive intracellular changes give rise to an altered pharmacological state. 
Abstinence from chronic opioid exposure or administration of an opioid antagonist 
after chronic exposure to morphine, results in a variety of physiological withdrawal 
symptoms based on these neuronal adaptations. The withdrawal symptoms in humans 
and/or experimental animals are similar: lacrimation, yawning, rhinorrhea, elevation 
of temperature and blood pressure, alterations of pulse rate, restlessness, diarrhoea, 
weight loss, anxiety, depression, tremors and craving (Blasig et al, 1973; Jaffe, 1991; 
Spanagel et al, 1998).
The molecular mechanisms involved in the expression of opioid withdrawal are not 
understood in detail, however it is widely agreed that over-excitability of the locus 
coeruleus is an important aspect of opioid withdrawal (Nestler et a l, 1999). The 
upregulation of the cAMP system and the activation of the transcription factor cAMP 
response binding element (CREB) after chronic opioid exposure are the intracellular 
mechanisms observed to be involved in opioid dependence (Guitart et al, 1992; 
Nestler et al, 1999; Nestler, 2001).
There is evidence to support a role for adenosine during withdrawal. As already 
stated, most studies agree that Ai and A2A adenosine receptor-selective agonists 
attenuate and antagonists exacerbate morphine withdrawal signs in the CNS of mice 
(Kaplan & Sears, 1996; Zarrindast et al, 1999) and rats (Salem & Hope, 1997). 
Moreover, a significant increase of hypoxanthine and inosine, which are break down
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products of adenosine, has been observed in the nucleus accumbens dialysate of 
morphine-withdrawn rats, suggesting that endogenous adenosine might be involved in 
the expression of morphine withdrawal (Salem & Hope, 1999). These observations 
suggest that endogenous adenosine is released during morphine withdrawal and acts at 
its receptors to produce an ongoing inhibitory “tone” which, when blocked, results in 
the enhancement of withdrawal behaviour (Salem et al, 1999). Furthermore, the bi­
directional cross-withdrawal responses observed in rats treated with adenosine 
agonists and morphine further illustrate the close interaction between adenosine and 
opioid systems during withdrawal (Coupar & Tran, 2001). Finally, chronic opioid 
treatment has been shown to regulate adenosine receptor and NBTI-sensitive 
adenosine transporter numbers. Chronic opioid treatment produced a decrease in 
striatal A2A receptor numbers and fonction in rat (De Montis, 1992) but not in mice 
(Kaplan et al, 1994) and an increase in A% receptors and NBTI-sensitive adenosine 
transporters in the brains of mice (Ahlijanian & Takemori, 1986; Kaplan et al, 1994; 
Kaplan & Leite-Morris, 1997).
Moreover, adenosine receptor activation has been shown to inhibit dopaminergic 
transmission in striatal and limbic brain regions (Ferre et a l, 1991; Ferre et a l, 1994; 
Ferre et al, 1996). Since opioid withdrawal has been shown to produce long lasting 
reductions in dopaminergic function in mesolimbic and striatal pathways (Di Chiara, 
1995), it has been suggested that adenosine-dopamine interactions could be relevant 
in this condition. Mesolimbic dopaminergic neuronal firing is inhibited during opioid 
withdrawal (Diana et al, 1995) and striatal dopamine levels are reduced during 
morphine withdrawal (Desole et al, 1996). Adenosine A, and A2A receptor activation 
has been shown to inhibit evoked dopamine release in the striatum (Jin et al, 1993).
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Adenosine Ai receptor activation inhibits dopaminergic function by uncoupling 
striatal Di dopamine receptors from their associated G-protein (Ferre et a l, 1994) and 
by reducing dopamine binding to limbic Di receptors. Adenosine A2 A receptor 
activation inhibits dopaminergic function by reducing dopamine binding to D2 
receptors in the striatum (Ferre et al, 1991).
In this study, the role of A2A adenosine receptors in the expression of morphine 
withdrawal has been evaluated. For this purpose, A2A receptor knockout mice 
generated by Ledent’s group (1997) have been used. The behavioural phenotype of 
these mice has been described elsewhere (section 4.1). Naloxone-precipitated 
morphine withdrawal signs in wild type (+/+) and A2A receptor knockout (-/-) mice 
were evaluated. To further, investigate if the opioid system is altered in the absence of 
the A2A receptor gene under conditions of morphine withdrawal, quantitative 
autoradiography of p opioid receptors and p opioid receptor-stimulated guanylyl 5’- 
[y-[^^S]thio]-triphosphate ([^^SJGTPyS) autoradiography were carried out in brain 
sections of morphine-withdrawn wild type and A2 A receptor knockout mice. 
Moreover, to investigate the involvement of D2 dopamine receptors in modulating 
A2A receptor effects, quantitative autoradiography of D2 dopamine receptors was 
carried out in brain sections of morphine-withdrawn wild type and A2A receptor 
knockout mice.
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5.2 MATERIALS AND METHODS
5.2.1 Animals
The generation of mice deficient in the À2a receptor gene used in this study has been 
described in chapter 4 (section 4.2.1).
8-10 week old male wild type and A2A receptor knockout mice were used in this 
study. Mice were housed in groups in a temperature-controlled room with 12 h 
light/dark schedule. Food and water were available ad libitum. For naloxone- 
precipitated morphine withdrawal studies, animals were tested in the same building in 
which they were housed. All studies were carried out in accordance with protocols 
approved by the Home Office (Animal Act 1986) UK.
5.2.2 Naloxone-precipitated morphine withdrawal
5.2.2A Minipump preparation and implantation
After an adjustment period in the University of Surrey animal unit, osmotic 
minipumps (Alzet, model 1007D) were implanted subcutaneously in the dorsal mid­
line position of wild type (+/+) and A2A receptor knockout (-/-) mice under isoflurane 
(Schering-Plough Animal health, Welwyn Garden city, USA) anaesthesia. Prior to 
surgical implantation, the minipumps were filled either with sterile 0.9 % saline 
(Phoenix Pharma Ltd, Gloucester, UK) or with 85-90 mg/ml morphine sulphate 
(Sigma-Aldrich, Dorset, U.K) in sterile 0.9 % saline. Their contents were delivered at
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a constant rate of 0.5 pl/h resulting in a dose of morphine sulphate of approximately 
24 mg/kg/day.
Mice were anaesthetised by placing them in an isofluorane chamber for 3 min. A 10 
mm incision was made along the dorsal midline and a subcutaneous pocket was 
formed with surgical scissors. The minipumps were implanted in such a way that the 
drug ejection end was always pointing towards the tail. Michelle clips (11x2.5 mm) 
were used to suture the opening and the mice were immediately placed into new cages 
to recover. Seven days after the pumps were implanted, preweighed mice were 
injected with naloxone HCl (10 mg/kg, i.p) (Sigma-Aldrich, Dorset, U.K) to 
precipitate opioid withdrawal, and were immediately placed in an observation box 
(20x27 cm in width, 30 cm in height) for a period of 30 mins. The Perspex 
observation box was lined with preweighed paper towelling to allow collection of wet 
and dry faecal matter.
5.2.2.2 Assessment o f  withdrawal signs
Both objective and subjective measures of withdrawal behaviour were scored for a 
period of 30 min after the injection of naloxone. The number of wet dog shakes, 
jumping, paw tremors, body writhes and face washes were counted. Ptosis and 
diarrhoea were also evaluated over 30 min giving a value between 0 and 3. No ptosis 
or diarrhoea signs were assigned a score of 0, 1 refers to mild ptosis and diarrhoea, 2 
refers to moderate ptosis and diarrhoea and 3 refers to severe ptosis and diarrhoea. 
Finally, for the period of 30 min after the injection of naloxone the percent weight
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loss and weight of faecal matter from the paper at the base of the box were also 
determined for each mouse.
5.2.23 Data Analysis
Each objective measure of withdrawal (number of wet dog shakes, jumps, paw 
tremors, body writhes, face washes) was analysed parametrically whereas subjective 
measures (diarrhoea, ptosis) were analysed by non parametric statistics. Comparison 
of the intensity of each objective withdrawal sign between individual groups 
(genotype: between wild type and A2A receptor knockout mice; and treatment: 
between chronic saline and morphine-treated mice) was carried out using analysis of 
variance (ANOVA) followed by Dunnett’s post-hoc test. For each of the diarrhoea 
and ptosis comparisons between groups (genotype: between wild type and A2A 
receptor knockout mice; and treatment: between chronic saline and morphine-treated 
mice), Kruskal-Wallis test (non parametric test) followed by post-hoc Bonferroni tests 
were used as these data were not normally distributed.
5.2.3 Receptor autoradiography
5.2.3.1 Tissue preparation and sectioning
Immediately after the 30 min observation of the withdrawal signs following injection 
of naloxone, morphine-withdrawn wild type and A2A receptor knockout mice were 
killed by cervical dislocation and intact brains were removed, frozen at -20°C in 
isopentane and stored at -80°C for up to one month before sectioning. 20 pm (for p or
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Ü2 receptor autoradiography) or 10 pm (for p receptor-stimulated GTPyS 
autoradiography) sections taken from the level of the nucleus accumbens (Bregma 
1.34 mm) of the brain and through to the caudate (Bregma 1.10 mm) were cut. The 
sections were thaw mounted on to pre-cleaned and gelatin subbed ice-cold microscope 
slides. Adjacent sections were cut for the determination of total and non specific 
binding of p and D2 receptor binding. For p receptor-stimulated [^^SjGTPyS binding, 
adjacent sections were cut for the determination of basal [^^SJGTPyS binding, for 
DAMGO (3 pM and 10 pM)-stimulated [^^SJGTPyS binding, naloxone reversal of 
DAMGO (3 pM)-stimulated [^^SJGTPyS binding and non-specific binding. Finally, 
the sections were dried using anhydrous calcium sulphate (Drierite, BDH Chemicals, 
Poole, UK) at 4 °C for 2 h, to prevent the formation of crystals, before storage at -20 
°C for one week.
5.23.2 p  opioid receptor autoradiography
Binding of p opioid receptors with [^HJDAMGO, autoradiographic film preparation, 
development and analysis were carried out on the sections of naloxone-precipitated 
morphine-withdrawn wild type and A2A receptor knockout mice as described in 
chapter 2 (sections 2.2.5-2.2.9). The mean and standard error of the mean of 
[^HJDAMGO binding (fmol of radioligand bound/mg of tissue) were calculated in 
each region for each genotype. The percentage change in binding levels from 
withdrawn wild type to A2 A receptor knockout mice brains was determined. Data of p 
receptor binding in brain regions of naïve wild type and A2A receptor knockout mice 
were obtained from section 4.3.1.1. Comparison of quantitative measures of 
autoradiographic binding between individual groups (genotype: between wild type
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and A2A receptor knockout mice, and treatment: naïve and morphine withdrawn mice) 
in each region analysed was carried out using one-way ANOVA followed by 
multiway Bonferroni post-hoc test for each region analyzed.
5.2.33 D2 dopamine receptor autoradiography
Sections from the brains of each morphine-withdrawn wild type and A2A receptor 
knockout mice were processed for binding using identical stock solutions. All slides 
were allowed to defrost for not less than 30 min prior to binding. [^HJraclopride (D2 
dopamine receptor antagonist) was used for binding to D2 dopamine receptors. The 
radioligand was made up in incubation buffer of 50 mM Tris-HCl, 120 mM NaCl, 5 
mM KCl, 2 mM CaCL and 1 mM MgCL (pH 7.4 at 25 °C) at 4 nM concentration for 
determination of total and non-specific binding. The concentration chosen was 
approximately three to four times the IQ of the ligand. 10 pM (-)-sulpiride (D2 
receptor antagonist) was added to the incubation buffer containing the radioligand for 
the determination of non-specific binding.
Slides used for [^HJraclopride binding were pre-incubated for 20 min in 50 mM Tris- 
HCl, 120 mM NaCl, 5 mM KCl, 2 mM CaCL and 1 mM MgCl2 (pH 7.4 at 25 °C). All 
slides were then placed in binding trays and 1 ml of either total or non-specific 
binding solutions was pipetted on to the sections (1 ml per slide). Incubation was 
carried out at room temperature for 60 min. Following the incubation period, the 
slides were washed six times for one minute in ice cold rinse buffer containing 50 mM 
Tris-HCl (pH 7.4 at 0 °C) followed by a dip into ice-cold distilled water. Slides were
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then dried for two hours in a cold air stream. Drying was continued for a further 7 
days using anhydrous calcium sulphate (Drierite, BDH Chemicals, Poole, UK).
The determination of scrape binding, the autoradiographic film preparation, 
development and analysis were carried out as described earlier (sections 2.2.5.3- 
2.2.9). The exposure time of sections bound with [^HJraclopride to films was 9 weeks. 
Image analysis of autoradiography films of brain sections was carried out as described 
earlier (section 2.2.8). The mean and standard error of the mean of each ligand 
binding (fmol of radioligand bound/mg of tissue) was calculated in each region for 
each genotype. The percentage changes in binding levels from morphine-withdrawn 
wild type to homozygous brains were determined. Comparison of quantitative 
measures of autoradiographic binding in each brain region analysed from +/+ and -/- 
animals was carried out using one-way ANOVA.
5.23.4 p  receptor-stimulated f^SJGTPyS binding autoradiography
Sections from the brains of each naloxone-precipitated morphine-withdrawn wild type 
and A2A receptor knockout mice were processed for binding using identical stock 
solutions. All slides were allowed to defrost for not less than 30 min prior to binding.
Sections were pre-incubated in assay buffer (50 mM Tris-HCl, 3 mM MgCl2.6H20, 
0.2 mM ethylene glycol-bis(P-aminoethylether)-N,N,N,N’-tetraacetic acid (EGTA), 
100 mM NaCl, pH 7.4 at 25 °C) for 10 min. Sections were then incubated in guanylyl- 
diphosphate (GDP) assay buffer (ImM GDP, 50 mM Tris, 3 mM MgCl2.6H20, 0.2 
mM EGTA, 100 mM NaCl, pH 7.4 at 25 °C) for 15 min and rinsed in fresh assay
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buffer. |x receptor agonist-stimulated activity was determined by incubating the 
sections in [^^S]GTPyS (0.04 nM) with the selective p opioid receptor agonist 
DAMGO (3 pM or 10 pM) for 2 h. The incubation buffer consisted of 1 mM GDP, 
50 mM Tris-HCl, 3 mM MgC^.bHzO, 0.2 mM EGTA, 100 mM NaCl, pH 7.4 at 25 
°C (GDP assay buffer). Basal G protein activity was determined by incubating the 
sections in [^^S]GTPyS (0.04 nM in GDP assay buffer) in the absence of the agonist. 
Non-specific binding was assessed by incubating sections in [^^S]GTPyS (0.04 nM) in 
assay buffer (in the absence of GDP) in the presence of 10 pM unlabelled GTPyS. 
Reversal of DAMGO-stimulated activity on [^ S^] GTPyS binding was determined by 
incubating sections in [^^S]GTPyS (0.04 nM in GDP assay buffer) in the presence of 
DAMGO (3 pM) and naloxone (1 pM). After incubation for 2 hours, slides were 
rinsed twice for 3 min in ice-cold buffer (50 mM Tris-HCl, pH 7.4 at 0 °C) followed 
by one rinse in de-ionised water. Slides were then dried for two hours in a cold air 
stream. Drying was continued for a further 2 days using anhydrous calcium sulphate 
(Drierite-BDH chemicals, Poole, UK).
Sections from the brains of morphine-withdrawn wild type and A2A receptor knockout 
mice were apposed to Hyperfilm pmax (Amersham international pic, 
Buckinghamshire, UK) for four days. The Hyperfilm was laid, emulsion side down, 
directly onto the tissue sections, which were securely placed inside hypercassettes. 
The hypercassettes were sealed with opaque tape, to prevent light exposure, and were 
stored flat until development. The above procedure was carried out in a dark room 
under safe light conditions (red filter).
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Films were developed using an aqueous solution of 50% v/v Kodak D19 developer 
(Sigma-Aldrich, Dorset, U.K) for four minutes. The reaction was stopped by placing 
films in a solution of distilled water and glacial acetic acid for 30 seconds. Fixation of 
images was carried out in Kodak rapid fix solution for 5 minutes. The above 
procedure was carried out under safe light condition (red filter) in a dark room. Films 
were then rinsed in fresh distilled running water for 30 minutes and dried overnight in 
a fume cupboard.
Autoradiographic images were analysed by video-based computerised densitometry 
using an MCID image analyser (Imaging Research, Canada). Image analysis of the 
brain autoradiography films was carried out as described earlier (section 2.2.8). 
DAMGO-stimulated activity in mice brain sections was calculated by subtracting the 
optical density in basal sections from that of DAMGO-stimulated sections. The net 
percentage stimulation of [^^S]GTPyS binding was calculated by the following 
equation:
Net percent stimulation of binding= (O.DagonisrO.Dbasai/O.Dbasai-O.DNSB) x 100 %, 
where O.D is relative optical density.
Data were expressed as the % mean ± S.E.M of each experimental group. Comparison 
of percentage (%) p receptor stimulation of [^^S]GTPyS activity between morphine- 
withdrawn wild type and AzA receptor knockout mice for each brain region analysed, 
was carried out using Student’s t-test. Comparison of percentage (%) DAMGO (3 
pM) stimulated [^ S^] GTPyS binding and percentage (%) DAMGO (3 pM) stimulated
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[^ ^S]GTPyS binding in the presence of naloxone, was carried out using Student’s t 
test.
5.2.3.5 Ligands
[^HJraclopride Specific activity 78.4 Ci/mmol (2.9 TBq/mmol). It was purchased 
from NEN Life Science Products (Boston, USA). The purity of the ligand is >97% as 
determined by HPLC.
[^ H] DAMGO- Specific activity 56.0 Ci/mmol (2.07 TBq/mmol). It was purchased 
from Amersham International pic (Buckinghamshire, U.K.). The concentration of the 
stock used was 17.9 pM. The purity of the ligand is >99% as determined by HPLC.
[35s]GTPyS specific activity 1250 Ci/mmol (4.62 TBq/mmol). It was purchased from 
Perkin Elmer Life Sciences (Boston, USA). The purity of the ligand is >95% as 
determined by HPLC.
(-)-Sulpiride was obtained from Tocris (Bristol, UK).
Morphine Sulphate was purchased from Sigma-Aldrich (Dorset, U.K).
Naloxone- Naloxone hydrochloride was purchased from Sigma-Aldrich (Dorset, 
U.K).
DAMGO was purchased from Tocris (Bristol, UK).
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GTPyS was purchased from Sigma-Aldrich (Dorset, U.K).
GDP was purchased from Sigma-Aldrich (Dorset, U.K).
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5.3 RESULTS
5.3.1 Naloxone-precipitated morphine withdrawal in wild type (+/+) and Aza
receptor knockout (-/-) mice
During the behavioural observation performed before the administration of naloxone, 
no somatic signs of withdrawal were observed in either chronic saline or morphine- 
treated wild type or Aza receptor knockout mice. After the injection of naloxone, the 
morphine withdrawal syndrome was manifested by the presence of a variety of 
somatic signs in both chronic morphine-treated wild type and Aza receptor knockout 
mice (Figure 5.1). No somatic signs of withdrawal were observed in naloxone- 
injected chronic saline-treated wild type or Aza receptor knockout mice. Indeed, there 
was a significant treatment effect between chronic saline versus chronic morphine- 
treated mice for the majority of the withdrawal signs measured (Figure 5.1). There 
was a significant increase in the number of jumps (P<0.01), paw tremors (P<0.01) and 
writhes (P<0.05) in morphine-withdrawn Aza receptor knockout mice compared to 
wild type (Figure 5.1). In contrast, the intensity of withdrawal signs were identical 
(P>0.05) in chronic morphine-treated wild type and Aza receptor knockout mice for 
six physical signs: weight loss, amount of urine and faecal matter, diarrhoea, number 
of wet dog shakes, number of face washes and ptosis (Figure5.1).
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Figure 5.1. Quantification of withdrawal signs of chronic saline or morphine-treated 
wild type and A2A receptor knockout (-/-) mice for a period of 30 min after naloxone 
injection. Values represent mean ± S.E.M values (n=4 for saline-treated animals and 
n=12 for morphine-treated). All values apart from diarrhoea and ptosis score were 
analysed by ANOVA followed by post hoc Dunnett’s test. For diarrhoea and ptosis 
score comparisons Kruskal-Wallis test followed by Bonferonni post-hoc test were 
used. * P<0.05, ** P<0.01 versus chronic saline-treated animals of the same 
genotype; # P<0.05, ## P<0.01 versus morphine-withdrawn wild type mice. Closed 
columns represent wild type and open columns represent A2A receptor knockout (-/-) 
mice.
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5.3.2 jn opioid receptor autoradiography
The qualitative and quantitative distribution of p opioid receptors labelled with 
[^HJDAMGO (4 nM) in coronal sections of brains of morphine-withdrawn wild type 
mice (Figure 5.2) was similar to that obtained in coronal sections of brains of naïve 
wild type mice (chapter 4, section 4.3.1.1). The pattern of distribution of p opioid 
receptor studies in morphine-withdrawn homozygous A2A receptor knockout mouse 
brains was identical to morphine-withdrawn wild type. Although there were some 
regional upregulation in p receptor expression (13-20% in nucleus accumbens and 
caudate putamen), no significant differences (P>0.05) in the levels of p opioid 
receptor expression was observed in any of the brain regions of morphine-withdrawn 
A2A receptor knockout mice compared to wild type (Table 5.1). There was no 
significant difference (P>0.05) in p receptor expression between naïve wild type and 
A2A receptor knockout animals and morphine-withdrawn wild type and A2A receptor 
knockout mice. Finally, as described previously (section 4.3.1.1), there was no 
significant difference in the levels of p opioid receptor expression in any of the brain 
regions of naïve A2A receptor knockout mice compared to wild type (P>0.05).
242
(UÆ
t+HO
<u
I I
cQ
! / 3c
2
d)U
-C
e-0 
S
1
(U
•Ic
I I
8
2
’O
[o
"5,o
"o
.1
3
X)
V3
’5
g
ri
2
&
O
o
o
8
<CA
3
OCU3
O
So
X
73
§
(U 73
ê  I
■'^ î: V
s.
a T )
CJ
>
• PM & a
(Q k CJ
o k
H
243
Figure 5.2. Computer enhanced autoradiograms of coronal brain sections from naïve 
and morphine-withdrawn wild-type (+/+) and homozygous (-/-) A2A adenosine 
receptor knockout mice. All the sections shown are from the level of the caudate 
(Bregma 1.10 mm), p receptors were labelled with [^HJDAMGO (4 nM). Non­
specific binding (NSB), shown in the far right column, was determined in the 
presence of naloxone (1 pM). The colour bar shows pseudo-colour interpretation of 
relative density of black and white film image calibrated in finol/mg tissue. Sections 
from +/+ and -/- brains were processed in parallel.
244
Ins
•I
&
I
aCQ
I
*o
II
li
1
I Î
(M 13
0  03
4 - f
1 J
i ti i  
1 1  
I I  
V ê
I Ï
CN O CN
(N
Tf CN
o  vd
CN CN
0\ m 
o  vd
(N CN
VO 00<n
VO ON
00 CN »?
I
t
o
a
CO
O
o
S
O nCN
O
CO
CO
CO
245
Table 5.1. The mean specific binding (n=4-6) of [^H]DAMGO (finol/mg) ± S.E.M. in 
brain regions of naïve (taken from section 4.3.1) and morphine-withdrawn wild-type 
(+/+) and homozygous (-/-) A2A receptor knockout mice. Measures in the regions 
were carried out at the Bregma co-ordinates taken from the mouse atlas of Franklin 
and Paxinos (1997). The labelling was carried out on sections from +/+ and -/- mice in 
a completely paired protocol. Specific binding was >90% in all regions. Comparison 
of genotypes (wild type versus knockout mice) or treatment (naïve versus morphine- 
withdrawn) was not significantly different for any of the regions analysed (P>0.05, 
one-way ANOVA followed by Bonferroni post hoc test). The percentage (%) change 
in binding represents the change in binding levels in -/- brains compared to +/+. A 
minus sign indicates a percentage decrease in binding levels.
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5.3.3 D% dopamine receptor autoradiography
Quantitative autoradiography of D2 dopamine receptors from coronal sections of the 
caudate showed a very restricted localisation (Figure 5.3). [^HJraclopride binding was 
restricted to the nucleus accumbens, the caudate putamen, where the highest level of 
binding was detected, and the olfactory tubercle. Binding was low to undetectable in 
all other brain regions and was therefore not quantified. The pattern of distribution of 
D2 dopamine receptors in morphine-withdrawn homozygous A2 A receptor knockout 
mice brains was identical to wild type (Figure 5.3). No significant difference (P>0.05) 
in the levels of D2 dopamine receptor expression was observed between genotypes in 
any of the regions analysed (Table 5.2).
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Table. 5.2. Quantitative autoradiography of dopamine Dj receptors
in the brains of morphine-withdrawn wild type (+/+) and homozygous (-/-)
Aja receptor knock-out mice
Region Bregma [^H]Raclopride Specific
_________________ co-ordinates______Binding (fmol/mg)
Wild-type Homozygous
(+/+) (-/-) (-/-)
Nucleus accumbens 1.34mm
Shell 36.4±3.1 37.74=7.3 3.6
Core 39.0±2.8 37.14=2.1 4.9
Olfactory tubercule 43.44=2.3 38.34=2.2 11.8
Caudate-putamen 1.10mm 69.44:3.8 66.74=2.9 -3.9
Table 5.2. The mean specific binding (n=6) of [^H]raclopride (fmol/mg) ± S.E.M. in 
brain regions of morphine withdrawn wild-type (+/+) and homozygous (-/-) A%A 
receptor knockout mice. Measures in the regions were carried out at the Bregma co­
ordinates taken from the mouse atlas of Franklin and Paxinos (1997). The labelling 
was carried out on sections from +/+ and -/- mice in a completely paired protocol. 
Specific binding was >90 % in all regions. Comparison of genotypes was not 
significantly different for any of the regions analysed (P>0.05, one-way ANOVA). 
The percentage (%) change in binding represents the change in binding levels in -/- 
brains compared to +/+. A minus sign indicates a percentage decrease in binding 
levels.
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5.3.4 p opioid receptor-stimulated [^^S]GTPyS autoradiography
In vitro [^^S]GTPyS autoradiography was performed in coronal brain sections of 
naloxone-precipitated morphine-withdrawn wild type and A2A receptor knockout mice 
to investigate if there was a difference in DAMGO-stimulated [^^S]GTPyS activity 
between genotypes. Representative brain sections are illustrated in Figure 5.4, in 
which the basal [^ S^] GTPyS binding, DAMGO-stimulated [^^S]GTPyS binding and 
non-specific binding are shown in both morphine-withdrawn wild type and A2A 
receptor knockout mice. DAMGO stimulated [^^S]GTPyS binding (20-25 % of basal) 
in the nucleus accumbens and the caudate putamen of withdrawn wild type animals. 
No stimulation was observed in the somatosensory cortex of the same animals (Figure
5.5). In morphine-withdrawn A2A receptor knockout mice, DAMGO produced a more 
marked stimulation of [^^S]GTPyS binding (70 % of basal) in the nucleus accumbens 
and a moderate stimulation (25 % of basal) in the caudate putamen and the 
somatosensory cortex of the same animals (Figure 5.5). The receptor specificity of 
DAMGO-stimulated [^ S^] GTPyS binding was verified by incubation of sections with 
DAMGO in the presence of naloxone. The levels of [^^S]GTPyS binding in the 
presence of agonist and antagonist were comparable to basal activity (Figure 5.5). 
Comparison of DAMGO-stimulated [^^SJGTPyS binding in brain regions of 
morphine-withdrawn wild type and A2A receptor knockout mice revealed that 
stimulation was significantly higher (P<0.05, Student’s t test) in the nucleus 
accumbens of A2A receptor knockout mice, whereas no differences (P>0.05, Student’s 
t test) were observed in the caudate putamen and the somatosensory cortex (Figure
5.5).
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Figure 5.4. Sections were pre-incubated with 1 mM GDP and then with [^^S]GTPyS 
(0.04 nM) and 1 mM GDP for 2 h under basal conditions, in the presence of DAMGO 
(3 pM and 10 pM) and in the presence of 10 pM unlabelled GTPyS (non specific 
binding-NSB). The colour bar shows the pseudocolour interpretation of relative 
density of black and white film image. Sections from +/+ and -/- were processed in 
parallel. R.O.D: relative optical density
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Figure 5.5. DAMGO-stimulated [^^S]GTPyS binding and inhibition of DAMGO 
stimulated [^^SJGTPyS binding in brain regions of naloxone-precipitated morphine 
withdrawn wild type (+/+) and A2A receptor knockout mice (-/-)
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Figure 5.5. [^^SJGTPyS binding was stimulated by DAMGO (3 pM or 10 pM). 
Inhibition of DAMGO (3 pM) stimulated [^^S]GTPyS binding was carried out in the 
presence of naloxone (1 pM). The data represent the mean (3-4) ± S.EM of 
percentage (%) [^^SJGTPyS stimulation above basal in brain regions of naloxone- 
precipitated morphine-withdrawn wild type (+/+) and homozygous (-/-) A2A receptor 
knockout mice. ** P<0.01 compared with DAMGO (3 pM) stimulated [^^SJGTPyS 
binding (Student’t t test). # P<0.05 compared with withdrawn wild type DAMGO (3 
pM) stimulated [^^S]GTPyS binding (Student’s t test).
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5.4 DISCUSSION
The aim of this study was to investigate the behavioural responses related to morphine 
withdrawal in A2A receptor knockout mice and to try to find a possible molecular 
explanation for these responses.
Although the intensity of some of the opioid withdrawal signs measured in A2A 
receptor knockout mice was similar to wild type, a significant enhancement of 
withdrawal jumping, paw tremor and writhing was apparent in A2 A receptor knockout 
mice. This is in agreement with studies demonstrating that A2 A receptor-selective 
agonists attenuate and antagonists exacerbate opioid withdrawal signs in the CNS of 
mice and rats (Kaplan et al, 1996; Salem et al, 1997; Zarrindast et a l, 1999; Coupar 
et al, 2001). More specifically, the reduction of naloxone-induced withdrawal 
jumping and paw shakes observed after the administration of the A2 receptor agonist 
5’-(A-cyclopropyl)-carboxamidoadenosine (CPCA) and CGS21680 respectively 
(Kaplan et al, 1996) and the enhancement of withdrawal jumping after the 
administration of A2 receptor antagonist DMPX in morphine-dependent animals 
(Salem et al, 1997), correlate with the enhancement of withdrawal jumping and paw 
shakes in mice lacking A2A receptors. However, the lack of change in withdrawal 
diarrhoea, amount of faecal mass, number of wet dog shakes and weight loss observed 
in A2A receptor knockout mice is in contrast with studies showing a reduction in the 
amount of faecal matter, wet dog shakes and withdrawal diarrhoea after the 
administration of A2A receptor selective agonists, and an increase in withdrawal 
diarrhoea after the administration of an A2A receptor selective antagonist in morphine- 
withdrawn animals (Salem et al, 1997; Zarrindast et al, 1999). However, the
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pharmacokinetics, pharmacodynamics, receptor selectivity as well as the secondary 
locomotor effects of the drugs used in these studies may be called into question. 
DMPX, an antagonist in the study just described above, has a small degree of 
selectivity (10 fold) for A2 A adenosine receptors over A% (Choi et a l, 1988), therefore 
it may be possible that some of its effect is through blocking Ai receptors rather than 
A2A. Furthermore, the lack of motor coordination observed after the administration of 
a certain dose of A2A receptor agonists and the increase in basal locomotor activity 
after the administration of A2A receptor antagonists could also account for the 
behavioural effects of adenosine receptor ligands on the morphine-withdrawn animals 
described earlier (Salem et al, 1997; Zarrindast et al, 1999). On the other hand, the 
knockout methodology is known to be 100% selective for the elimination of A2A 
receptors, which gives us greater confidence in suggesting that changes in withdrawal 
signs observed in A2 A receptor knockout mice are due directly or indirectly to the 
absence of A ja receptors.
As the increase in the behavioural signs of opioid withdrawal observed in A2A 
receptor knockout mice involved movement, which is a centrally controlled 
mechanism (Bianchetti et al, 1986; Maldonado et al, 1992), it could be suggested 
that endogenous adenosine acts as a modulator, via activation of A2A receptors, for the 
expression of some somatic opioid withdrawal behaviours linked to locomotion. On 
the other hand, A2A receptors do not appear to be involved in gastrointestinal motility 
and fluid secretion in withdrawn mice, which would account for increased diarrhoea 
and weight loss in withdrawn A ia receptor knockout mice. Indeed, withdrawal 
diarrhoea is mediated via a direct effect on gastrointestinal motility and fluid secretion 
(Bianchetti et al, 1986; Brown et al, 1988). As a result, changes at the level of the
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central nervous system may not necessarily result in changes in the peripheral 
component of the abstinence syndrome. Besides, it has been suggested that peripheral 
Ai rather than A2A receptors play an important role in defecation (Tomaru et al, 
1994).
An attempt to understand part of the molecular basis of the induction of some 
withdrawal signs in A2A receptor knockout mice was made, p opioid receptor, D2 
dopamine receptor and p receptor-stimulated [^^S]GTPyS autoradiography of sections 
of the striatum (divided into caudate putamen, nucleus accumbens and olfactory 
tubercle) of morphine-withdrawn wild type and A2A receptor knockout mice was 
carried out in order to investigate possible alterations of the opioid and dopaminergic 
systems in the absence of A2A receptors under conditions of morphine withdrawal. 
The striatum was selected not only because of the high levels of p, D2  and A2A 
receptors present in this brain structure (Ferre et al, 1992) (see also chapter 2 3 and 4) 
but also because its function has been associated (especially the nucleus accumbens) 
with somatic symptoms and reward processing of opioid withdrawal (Harris & Aston- 
Jones, 1994; Shaw-Lutchman et al, 2002). As a result, it would be more likely to 
visualise an opioid-adenosine-dopamine interaction in the striatum.
No significant changes in D2 dopamine receptors were observed in any of the brain 
regions of th morphine-withdrawn A2 A receptor knockout mice analysed. This is in 
agreement with a study that failed to observe any change in D2 receptor density in 
striatal binding sites between naïve wild type and A2A receptor knockout mice 
(Dassesse et al, 2001). Thus, the data indicate that D2 receptors in the striatum might 
not be involved in the modulation of the manifestation of somatic signs of opioid
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withdrawal in A2A receptor knockout mice. The involvement of D2 dopamine 
receptors in the regulation of the manifestation of somatic signs of opioid withdrawal 
is an issue of controversy. It has been demonstrated that activation of D2 receptors 
within the nucleus accumbens prevents the manifestation of somatic signs of 
naloxone-induced opioid withdrawal, and blockade of D2 receptors in the nucleus 
accumbens of opioid-dependent animals elicits somatic withdrawal symptoms (Harris 
et al, 1994). On the other hand, the behavioural expression of morphine withdrawal 
was found to be unchanged in mice deficient in D2 receptors (Maldonado et al, 1997). 
Not only might D2 receptors not be involved in the manifestation of withdrawal signs, 
but their regulation by A2A receptor activation or blockade seems not to be relevant as 
far as opioid withdrawal is concerned. This is unexpected as the reduction of 
dopamine binding to D2  receptors by adenosine A2A receptor activation is a widely 
established phenomenon of the A2A-D2 interaction (Ferre et al, 1997).
However, it has to be stressed that the lack of involvement of D2 receptors in the 
manifestation of somatic withdrawal signs in A2A receptor knockout mice does not 
necessarily mean the lack of dopaminergic involvement. In vivo microdialysis 
experiments in the striatum revealed a 45 % decrease in extracellular dopamine in 
mice lacking adenosine A2A receptors and that has been linked to their decreased 
locomotor activity (Dassesse et al, 2001). The decrease in basal levels of dopamine is 
probably related to the defect in A2 A receptor-stimulated dopamine release, which 
takes place in the striatum (Sebastiao & Ribeiro, 1996). Moreover, naloxone 
administration to morphine-dependent animals has been shown to reduce extracellular 
dopamine concentration and dopamine activation in the nucleus accumbens (Pothos et 
al, 1991; Rossetti et al, 1992). As a consequence, it is likely that morphine-
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withdrawn A2A receptor knockout mice will have even lower dopamine levels than 
withdrawn wild type mice and naïve A2A receptor knockout mice. That possible 
change in dopamine concentration and neurotransmission could explain the induction 
of somatic locomotor withdrawal signs observed in A2A receptor knockout mice. 
Indeed, a decrease in somatic withdrawal signs has been observed in a mouse model 
of hyperdopaminergic transmission such as dopamine transporter knockout mice 
(Spielewoy et al, 2000).
In addition to D2 receptor binding, no change in p opioid receptor binding was 
observed in any of the regions of the striatum of naloxone-precipitated withdrawn A2A 
receptor knockout mice compared to wild type. A lack of change in p receptor 
binding was also observed between naïve wild type and A2A receptor knockout 
animals (chapter 4). Moreover, morphine withdrawal did not trigger any changes in p 
receptor density in either wild type or A2A receptor knockout mice as no change in 
[^HJDAMGO binding was observed in any regions of the striatum of morphine- 
withdrawn animals compared to naïve mice. This is in accordance with a wide range 
of studies that failed to identify any changes in p receptor density in brain regions of 
morphine-withdrawn or dependent animals (Way, 1979; Robson et a l, 1983; De 
Vries et al, 1993; Polastron et al, 1994; Reddy et al, 1994; Buzas et a l, 1996; Tao 
et al, 2000). As a result one could conclude that the induction of morphine 
withdrawal signs in A2A receptor knockout annimals cannot be explained by altered 
expression of p receptors, an important target for morphine withdrawal action.
As intracellular mechanisms such as upregulation of cAMP system (Nestler et al, 
1999), rather than changes in p opioid receptor density and affinity, are well
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recognised to be involved in withdrawal responses, G-protein activity in response to p 
opioid receptor stimulation was investigated in morphine-withdrawn wild type and 
A2A receptor knockout mice brains. DAMGO-stimulated [^^SJGTPyS autoradiography 
was used because it can detect activation of G-protein coupled receptors upon agonist 
binding and, at the same time, allows visualisation of the location of activated 
receptors (Sovago et a l, 2001). A significant increase in the levels of DAMGO- 
stimulated [^^S]GTPyS binding was observed in the nucleus accumbens of morphine- 
withdrawn A2A receptor knockout mice compared to wild type. Interestingly, a lack of 
significant change in DAMGO-stimulated [^^SJGTPyS binding was detected in the 
accumbens of rats undergoing morphine withdrawal (Sim et al, 1996; Kirschke et al, 
2002). As a result, it seems that although change in p receptor G-protein function is 
not a mechanism involved in the expression of morphine withdrawal when the A2 A 
receptors are present and intact, it does however, seem to be involved when A2A 
receptors are not present.
The increase in p receptor-stimulated G-protein activity in withdrawn A2 A receptor 
knockout mice might be due to the lack of tonic inhibition that A2A receptor activation 
might have upon p receptor stimulation. Indeed, activation of the Gg coupled A2A 
receptors might have an inhibitory effect on p receptor Gi coupled activity. The 
molecular mechanism of how the increase in p receptor stimulated G-protein activity 
in A2A receptor knockout mice might cause an induction in some withdrawal signs is 
not clear but only speculations can be made. The activation of p opioid receptors has 
been shown to increase dopamine release and transmission in the nucleus accumbens 
(Nestler et al, 1993; Di Chiara, 1995). Thus, the increase of p receptor G protein 
activity in the nucleus accumbens might be a compensatory mechanism undertaken by
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the brain to increase levels of extracellular dopamine, which are expected to be 
extremely low (as discussed previously) in the brain of withdrawn A%A receptor 
knockout mice.
Finally, it is not clear that the increase in DAMGO-stimulated GTPyS activity in the 
nucleus accumbens of withdrawn A2A receptor knockout mice is a phenomenon 
observed only during withdrawal conditions. Further p receptor-stimulated 
[^^SJGTPyS experiments should be carried out on naïve wild type and A2A receptor 
knockout mice in order to investigate whether the increase is observed in naïve 
animals as well.
In conclusion, deletion of the A2A receptor gene under naloxone-precipitated 
morphine withdrawal conditions causes an elevation in some withdrawal signs 
associated with locomotion. Although no change in p or D2 receptor binding was 
observed in withdrawn A2 A receptor knockout mice, an elevation of p receptor- 
stimulated [^^SJGTPyS activity was evident in the nucleus accumbens of these mice. 
The data indicate that adenosine, via its action on A2A receptors, exerts an important 
control on the expression of opioid withdrawal. Several mechanisms may be involved 
in the adenosinergic control of morphine withdrawal including possible inhibitory 
effects of A2A receptor stimulation on p receptor-stimulated G-protein activation. 
Although D2 receptors might not be involved in the A2A receptor-mediated 
adenosinergic control of morphine withdrawal, dopamine release and transmission 
might be implicated.
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CHAPTER 6
GENERAL DISCUSSION
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6. General Discussion
There is a large body of evidence indicating that the antinociceptive effect of opioids 
is mediated by adenosine. In addition to its involvement in the expression of opioid- 
mediated antinociception, a role of adenosine in the development of opioid tolerance, 
dependence and withdrawal has also been suggested. Both in vivo and in vitro studies 
have been carried out attempting to investigate the nature and mechanism of this 
opioid-adenosine interaction. However, the most important problem arising from 
these studies is the poor knowledge of selectivity of ligands in vivo and the poor 
selectivity of some ligands in vitro (especially adenosine receptor ligands) leading to 
the generation of undesirable secondary effects of some compounds. Using the 
technique of homologous recombination, knockout mice deficient in opioid peptides 
and receptors, and mice deficient in adenosine receptors have been generated. These 
animals, apart from being highly selective tools for the analysis of the contribution of 
individual peptides or receptors to physiological function, provide important insights 
into interactions with other neurotransmitter systems. In this thesis, knockout mouse 
technology was used in order to address the issue of interactions of the opioid and 
adenosine systems.
6.1. A2a receptors play an important role in the expression of naloxone- 
precipitated morphine withdrawal signs
Previous studies which have examined adenosine agonists and antagonists effects on 
opioid withdrawal have yielded a mixture of findings (Brailowsky et al, 1981; Tucker 
et al, 1984; Ahlijanian & Takemori, 1985; Contreras, 1990; Germany et al, 1990;
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Dionyssopoulos et al, 1992; Kaplan & Sears, 1996; Salem & Hope, 1997; Zarrindast 
et al, 1999; Coupar & Tran, 2001). The inconsistency of those studies lies on the 
questionable pharmacokinetics, pharmacodynamics, receptor selectivity and 
secondary locomotor effects of the drugs used. On the other hand, the use of A2A 
receptor knockout mice in this study eliminates all the problems acquired by the use 
of drugs as it provides 100% selectivity for the elimination of A2A receptors. Thus, the 
significant enhancement of withdrawal jumping, paw tremor and writhing in 
morphine-withdrawn A2A receptor knockout mice is associated directly or indirectly 
with the absence of A2A receptors. Moreover, one could suggest that adenosine, via its 
action on A2A receptors, regulates the expression of morphine withdrawal signs. This 
study also points to the potential role of adenosine agonists in the treatment of opioid 
withdrawal. Clonidine and methadone, which itself is addictive, are the two main 
drugs available for the treatment of opioid withdrawal. The inhibitory effect of A2A 
receptors on opioid withdrawal expression should be investigated further in clinical 
trials as it might lead to the potential development of a novel drug for the treatment of 
withdrawal.
The exact mechanism of how A%A receptors might regulate opioid withdrawal remains 
to be elucidated. An inhibitory effect of A2A receptors on p receptor stimulated G- 
protein activation is suggested from this study. Even though no change in D2 receptor 
binding was observed in withdrawn A2A receptor knockout mice, that does not 
necessarily exclude dopaminergic involvement. Dopaminergic involvement has been 
largely implicated both in morphine withdrawal and in regulation of A2A receptors 
(Pothos et a l, 1991; Rossetti et al, 1992; Sebastiao & Ribeiro, 1996; Ferre et al, 
1997; Dassesse et al, 2001). Consequently, the possible involvement of dopamine in
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the expression of morphine withdrawal in A2A receptor knockout mice should be 
further investigated.
6 .2 .  Peripheral A%A receptors play an important role in regulating 8 -  and k -  
mediated antinociception
Many studies have implied a role for spinal A2 A receptors in regulating nociceptive 
responses (Choca et a l, 1987; Sawynok & Sweeney, 1989; DeLander & Keil, 1994; 
Lee & Yaksh, 1996; Suh et a l, 1997; Poon & Sawynok, 1998). Although in some of 
these studies highly selective A2A receptor agonists (e.g. CGS21680) were used, high 
doses of the drugs were utilised. The studies from this thesis clearly argue against any 
kind of involvement of spinal A2A receptors in regulating antinociception as they were 
undetectable in the spinal cord of two different species of mice. As a result, the 
studies suggesting a role for spinal A2 A receptors in regulating nociceptive responses 
could be explained by interactions of the A2A receptor agonist at A% receptors at which 
the drug has lower potency.
In contrast with the spinal A2 A receptors, A2A receptors located in the periphery are 
suggested from this thesis to play an important role in regulating 8- and K-mediated 
antinociception. Local administration of CGS21680 has been reported to be 
pronociceptive (Doak & Sawynok, 1995; Khasar et al, 1995) and the changes in ô- 
and K-mediated antinociception and binding in the superficial layers of the spinal cord 
of A2A receptor knockout mice might be the result of the lack of A2A receptors located 
in the sensory nerve terminals. Local administration of an A2 A receptor antagonists
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combined maybe with an opioid agonist could potentially be used for the treatment of 
peripheral pain.
Although peripheral A2A receptors seem to be important, supraspinal A2A receptors 
might not play a role in regulating opioid-mediated antinociception. No changes in 
supraspinal p, 5, k  and ORLl receptor binding were observed in A2A receptor 
knockout mice and no changes in A2A receptor binding was observed in the brains of 
p knockout, enkephalin knockout and naltrexone-treated mice. Indeed, A2A receptors 
are not expressed in any major pain circuitries and there is no evidence in the 
literature for supraspinal A2 A receptor involvement in pain regulation.
6.3. p opioid-Ai adenosine receptor interaction in the CNS
Many studies have demonstrated that manipulation of the opioid system by chronic 
morphine treatment lead to changes in A% receptor expression in the brain and spinal 
cord of animals (Ahlijanian & Takemori, 1986; Tao & Liu, 1992; Kaplan et a l, 1994; 
Tao et al, 1995; White et al, 1995; Kaplan & Leite-Morris, 1997). Two models of 
manipulation of the opioid system were used in studies described in this thesis: 1) 
Two models of p receptor upregulation (enkephalin knockout and naltrexone-treated 
mice) and 2) a model of the lack of p receptor expression. The autoradiographic 
mapping shows clearly that there no major overall changes in cerebral Ai receptors in 
any of the models used. However, some regions showed between 20 and 40% change 
in the direction of p receptor change and from this observation one cannot exclude the 
possibility that subtle changes have occurred in the A% receptor populations in the 
animal models used. Whether the small changes in receptor expression translate to
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biological relevant effects remains to be determined, but it should be noted that 
changes in Ô- and K-mediated antinociception in A2A receptor knockout mice 
correlated with changes of receptor expression which were less than 20%. There was 
a significant correlation between changes in Ai receptors in regions of the brains of 
both models and the level of p receptor expression in control animals, suggesting that 
in regions where p receptors are in abundance there is some modulation of Ai 
expression. Whether the specificity of the structures involved in marked changes in A% 
receptor expression would cause regional-specific behavioural changes is not known. 
It is a possibility, however, as the large upregulation of opioid receptors in limbic 
areas of enkephalin knockout mice was shown to be consistent with the increased 
emotional and aggressive behaviours observed in the enkephalin knockout mice.
6.4. p opioid-NBTI-sensitive adenosine transporter interaction in the CNS
Kaplan and Leite-Morris (1997) demonstrated an upregulation of NBTI-sensitive 
adenosine transporters in the brains of chronic morphine-treated animals. The 
significant downregulation of these transporters in the brains of p receptor knockout 
mice and the significant upregulation of these transporters in the brains of enkephalin 
and chronic naltrexone-treated mice, where p receptors are upregulated, further 
suggest the presence of an interaction between p receptors and NBTI-sensitive 
adenosine transporters. The nature of this interaction is, however, not known and 
requires further investigation.
267
6.5. Concluding remarks
In summary, the studies in this thesis have provided further evidence for the presence 
of interactions between the opioid and adenosine systems in the CNS and the 
periphery. Despite its limitations, the knockout mouse technology used in these 
studies has proved to be an important new tool for the study of the pharmacology of 
the interactions between the opioid and adenosine systems. Finally, these studies have 
prompted new questions concerning the nature and mechanism of these interactions 
which remain to be answered.
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